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ABSTRACT 
Anna E. Bauer: Variations in carbon monoxide, nitric oxide, and detoxification genes, 
interactions with maternal smoking, and associations with preeclampsia: a mother-child dyad 
analysis 
(Under the direction of Stephanie M. Engel) 
 
 Preeclampsia is a serious pregnancy complication with limited treatment. Etiology is 
hypothesized to originate during placentation, and may have both maternal and fetal 
contributions. There is a well-established enigmatic inverse relationship between maternal 
smoking and preeclampsia. A plausible biological explanation for this relationship is through 
response to cigarette smoke components, via vasodilation or activation of smoking 
detoxification pathways. Examining genes in these pathways and their modification by smoking, 
while incorporating maternal and child genetic contributions, could provide support for a genetic 
or related biological mechanism. 
 We conducted a nested case-control study within the Norwegian Mother and Child Birth 
Cohort of 1,545 case-pairs and 995 control-pairs from 2,540 validated dyads (2,011 complete 
pairs, 529 missing mother or child genotype). For aim 1, we selected 1,518 single nucleotide 
polymorphisms (SNPs) in nitric oxide and carbon monoxide signaling pathways. For aim 2, we 
analyzed these and 397 additional SNPs in smoking detoxification pathways for their 
modification by maternal smoking during placentation. We used log-linear Poisson regression 
models and likelihood ratio tests to assess maternal and child effects and included a SNP by 
smoking interaction term to assess maternal and child genotype-smoking interactions. 
The child variant, rs12547243 in adenylate cyclase 8 (ADCY8), was associated with an 
increased risk (RR=1.42 [95% CI: 1.20, 1.69] for AG vs GG, RR=2.14 [1.47, 3.11] for AA vs GG, 
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Q=0.03). We also found suggestive associations of SNPs in PDE1C for preeclampsia sub-
phenotypes. We found limited evidence for multiplicative SNP by smoking interaction after 
correction for multiple comparisons.  
 This study uses a novel approach to disentangle maternal and child genotypic effects of 
smoking-related genes on preeclampsia. Our findings do not provide strong support that the 
inverse smoking-preeclampsia relationship is due to a genetic effect in these pathways, 
although our power was limited due to the low prevalence of smoking in this population. Dyad 
methods and gene-environment interaction analysis may be useful for the study of pregnancy 
outcomes, particularly preeclampsia. Larger populations, such as multi-cohort consortia 
combined with these evolving methods may be necessary to dissect this enigmatic association. 
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CHAPTER I. INTRODUCTION AND SPECIFIC AIMS 
 
A. Introduction 
Preeclampsia, characterized by gestational hypertension and proteinuria, occurs in 2-8% 
of pregnancies.1 It is a serious complication of pregnancy, and resulting sequelae can be 
harmful to both the mother and child. Preeclampsia can progress to eclampsia, which is defined 
by seizures and is a potentially life threatening condition.2 Low-dose aspirin may help prevent 
preeclampsia in high-risk women,3 but treatment is often limited to delivery,4 which may pose 
serious risks to the infant if preterm.  
Preeclampsia is of unknown etiology, but is hypothesized in part to originate from 
processes occurring during formation of the placenta.2,4 During normal placentation, fetal 
cytotrophoblasts invade the maternal decidua and penetrate the walls of adjacent maternal 
spiral arteries. Here, the arteries lose smooth muscle, greatly increasing vascular dilation. This 
process does not completely occur with preeclampsia, reducing vascular capacity.5  
There is a well-established enigmatic inverse association with smoking and 
preeclampsia.6 One hypothesis for this association is through the powerful, vasodilatory action 
of carbon monoxide (CO) and nitric oxide (NO),7,8  which are produced by combustion of 
cigarettes9,10 as well as endogenously in the body.11–16  We aimed to determine if genetic 
variants in pathways related to CO and NO signaling are associated with preeclampsia, which 
may occur through changes in endogenous production of these compounds. Three canonical 
pathways are particularly relevant to CO and NO activity: 1) endothelial nitric oxide synthase 
(eNOS) signaling, 2) heme degradation, and 3) hypoxia-inducible factor 1-alpha (HIF1A) 
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signaling. The eNOS signaling pathway primarily describes the endogenous synthesis of NO 
from L-arginine, heme degradation describes the breakdown of hemoglobin into CO and 
bilirubin, and HIF1A signaling describes regulation of oxygen homeostasis and response to 
hypoxia important for both CO and NO activity. Genetic polymorphisms in all of these pathways 
exist,17,18 and several are associated with cardiovascular diseases that share features with 
preeclampsia.12,17,19–21 Inconsistent associations with preeclampsia have been found for three 
genes in these pathways (HMOX1, eNOS, iNOS).22–24 However, sample sizes in these studies 
were small, however, and none investigated entire pathways, gene by environment interactions, 
or the combination of maternal and child DNA. 
We also aim to determine if associations of SNPs involved in response to smoking 
components with preeclampsia are modified by an exogenous exposure (maternal smoking). 
For this aim, we included additional smoking detoxification genes, particularly those encoding 
the CYP and GST enzymes and involved in the pathways: 1) xenobiotic metabolism 2) aryl 
hydrocarbon receptor signaling, 3) glutathione-mediated detoxification, 4) nicotine degradation II 
and, 5) nicotine degradation III. 
This study is a nested case-control study ancillary to the Norwegian Mother and Child 
Cohort Study (Den norske mor og barn-undersøkelsen (MoBa)). MoBa is a longitudinal study 
following women and their children from pregnancy through childhood.  
The study uses a mother-child dyad design including 1564 validated preeclampsia cases 
and 999 validated non-preeclampsia controls, and 2563 total mother-child pairs. Because the 
placenta is of fetal origin and because mothers and their offspring share half of their genetic 
material, fetal genetics may play a role in the development of preeclampsia. Dyad designs are 
most appropriate in circumstances like this, where both maternal and child genetics have 
independent associations with the outcome, but the association of child genetics is inherently 
confounded by maternal genetics. Disentangling these features allows us to ascertain whether 
associations are primarily due to a maternal or fetal genetic component.  
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B. Specific Aims 
Specific Aim 1 
Determine the association of genetic variants within genes in nitric oxide and carbon monoxide 
signaling pathways with risk of preeclampsia. Pathways include endothelial nitric oxide synthase 
signaling (eNOS), heme degradation, and hypoxia-inducible factors 1-alpha (HIF1A). 
Aim 1a: Evaluate the association between maternal and child single nucleotide 
polymorphisms in these pathways and risk of preeclampsia. 
Aim 1b: Evaluate the associations between variants in these pathways on risk of 
preeclampsia stratified by preeclampsia subtype: early-onset preeclampsia, severe 
preeclampsia, preeclampsia with delivery <34 weeks, and preeclampsia accompanied by small 
for gestational age (SGA). 
 
Specific Aim 2 
Assess gene by environment interaction of maternal smoking and genetic variants in carbon 
monoxide and nitric oxide signaling pathways, as well as smoking detoxification pathways in 
their association with preeclampsia. 
Aim 2a: Determine if maternal active smoking at the time of spiral artery remodeling 
modifies the effects of carbon monoxide and nitric oxide genes described in Aim 1. 
Aim 2b: Determine if maternal active smoking at the time of spiral artery remodeling 
modifies the effects of other smoking detoxification genes. Pathways include xenobiotic 
metabolism, aryl hydrocarbon receptor signaling, glutathione-mediated detoxification, and 
nicotine degradation. 
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Hypotheses 
Hypothesis 1: Variants in the eNOS, heme degradation, and HIF1A signaling pathways 
are associated with a change in risk of preeclampsia; direction of change varies by SNP 
function. 
Hypothesis 2: These effects may have both a maternal and fetal component. 
Hypothesis 3: Stronger associations may also be found in more severe preeclampsia 
phenotypes, such as early-onset preeclampsia (<34 weeks’ gestation), severe preeclampsia, 
preeclampsia with early delivery, or preeclampsia complicated by SGA. 
Hypothesis 4: We expect differential effects of some of the variant associations in carbon 
monoxide, nitric oxide, and smoking detoxification pathways among mothers who smoked 
during pregnancy as compared to those who did not. 
Hypothesis 5: We further expect stronger smoking by gene interactions among mothers 
who smoked throughout the entire pregnancy rather than only during early pregnancy. 
 
 Currently, there are few effective therapeutic interventions for the treatment of 
preeclampsia,2,4 though low-dose aspirin supplementation has been recommended for 
prevention in high-risk women.25 A better understanding of the biological processes leading to or 
protecting from preeclampsia may reveal new therapeutic targets, with the goal of reducing 
maternal and infant morbidity and mortality. 
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CHAPTER II. REVIEW OF THE LITERATURE 
 
A. Preeclampsia 
The symptoms of preeclampsia and eclampsia have been recognized for ages, since the 
time of Hippocrates.26 These symptoms later became recognized as eclamptic hypertension and 
named preeclampsia in 1897, and in 1906, magnesium sulfate was used as medical 
management for preeclampsia and eclampsia.26  Despite the long-existing knowledge of this 
condition, treatment has changed very little in the last century; magnesium sulfate is still used 
for management of severe preeclampsia/eclampsia during and after labor, and low-dose aspirin 
use for high-risk women is the only widespread preventive intervention that has been shown to 
be successful.3,25,27 Although preeclampsia is well-studied, it remains perplexing and not well-
understood. 
 
Definition 
Preeclampsia is characterized by de novo gestational hypertension and proteinuria after 
20 weeks of pregnancy. In this proposed study, preeclampsia will be defined by the 2002 
American College of Obstetricians and Gynecologists (ACOG) diagnostic criteria,27 which 
include: 
1) Systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at 
least 90 mm Hg, occurring after 20 completed weeks of gestation in a woman 
with previously normal blood pressure, and 
2) Proteinuria, defined as at least +1 on urine dipstick measurement. 
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There is substantial heterogeneity in the severity, clinical characteristics, and timing of 
symptom onset in preeclampsia. Severe preeclampsia meets the general criteria described 
above and at least one of the following additional requirements27: 
1) Systolic blood pressure of at least 160 mm Hg or diastolic blood pressure of 110 mm 
Hg on at least two occasions, measured 6 hours apart and while the patient is at 
rest, 
2) Urinary protein excretion of at least 5g/day in a 24-hr urine specimen or at least 3+ 
urine dipstick protein measurement on two samples collected 4 hours apart, 
3) Oliguria or less than 500 ml of urine in 24 hours, 
4) Cerebral or visual disturbances, 
5) Pulmonary edema or cyanosis, 
6) Epigastric or right upper quadrant pain, 
7) Impaired liver function, 
8) Thrombocytopenia, or 
9) Fetal growth restriction, which will be defined as estimated fetal weight or birthweight 
below the 10th percentile at a given gestational week in our study, however, can also 
include femur length and blood flow as determined by ultrasound.28 
Early-onset preeclampsia is considered that which is diagnosed prior to 34 weeks’ gestation. 
 The ACOG Task Force on Hypertension in Pregnancy recommended new diagnostic 
guidelines in November 2013.25 Of greatest importance, the task force eliminated the 
requirement of proteinuria as a diagnostic criterion due to the “syndromic nature” of 
preeclampsia. In the absence of proteinuria, preeclampsia is diagnosed as hypertension 
combined with 1) thrombocytopenia, 2) impaired liver function, 3) new development of renal 
insufficiency, 4) pulmonary edema, or 5) new-onset cerebral or visual disturbances. These 
indications are considered severe features of preeclampsia, however, high urinary protein and 
fetal growth restriction have been removed as indications of severe preeclampsia.25 The older 
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guidelines were used as they were in place at the time of enrollment in the MoBa cohort and are 
the guidelines that have been most widely used in other studies. However, it is necessary to 
consider definitional changes while comparing associations with preeclampsia across studies. In 
recent years, multiple changes in disease criteria is a significant challenge to the synthesis of 
the etiological literature. 
 
Burden 
Preeclampsia occurs in 2-8% of pregnancies worldwide.1 Incidence of preeclampsia has 
increased in the US29 and in Norway in recent decades.30,31 It is one of the most common 
serious pregnancy complications. In the mother, preeclampsia can quickly become severe and 
lead to eclampsia which can cause placental abruption, cerebral hemorrhage, hepatic rupture, 
renal failure, pulmonary edema, seizure, brain damage, and death.2,27,32–34 It is one of the most 
common contributors of maternal morbidity and mortality worldwide.2 Approximately 10-15% of 
maternal deaths in both industrialized and developing countries are attributed to preeclampsia 
and eclampsia, however, most of the maternal mortality due to these conditions occurs in low-
income countries.35,36 Women with preeclampsia are at risk for future poor health outcomes 
including preeclampsia in a subsequent pregnancy,37,38  diabetes,39 and cardiovascular 
disease.40,41 Preeclampsia can also lead to poor pregnancy outcomes that can affect the fetus, 
such as reduced amniotic fluid and abnormal oxygenation and poor fetal outcomes such as 
encephalopathy, fetal growth restriction, preterm birth, and perinatal death.2,42,43 Preeclampsia is 
also a common reason for medically-indicated preterm delivery.5 In the US, approximately 42% 
of medically-indicated preterm births and 15% of all preterm births may be attributed to 
preeclampsia.44 Long-term consequences of preeclampsia in the child can include later 
cardiovascular disease, hypertension, stroke, and venous thromboembolism40 as well as 
outcomes associated with preterm birth, such as visual, motor, and cognitive deficits.45 
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Despite advances in perinatal care and extensive research on causes of preeclampsia, 
the incidence of this serious condition has not declined,34,46,47  and prediction and prevention of 
the disease has not improved.46–48 Salt restriction, zinc, magnesium, fish oil, vitamin C and E 
supplementation, diuretics, calcium supplementation, and aspirin have been studied as potential 
preventive strategies;46,49,50  low-dose aspirin is suggested to be the most promising,3 and it has 
been one of the few therapies now recommended for women at risk of preeclampsia.2,25,46  
The only definitive treatment of preeclampsia is delivery of the fetus to prevent development of 
maternal or fetal complications.43 The use of antihypertensive drugs to control elevated blood 
pressure has not been found to alter the course of the disease,43 however, may reduce the 
occurrence of comorbid pregnancy complications such as maternal stroke and renal 
complications. Throughout labor and delivery, labetalol, hydralazine, and nifedipine can be 
given to control severe hypertension43 and magnesium sulfate can be administered for the 
prevention of seizures,51–54 but these therapies only aim to reduce the most serious outcomes 
and do nothing to prevent incidence of the disease.43 
 
Etiology 
Although the etiology of preeclampsia is unknown, the most widely accepted hypothesis 
is that it originates in part through incomplete or ineffective placentation.5 During normal 
placentation, cytotrophoblasts invade the decidua, moving into the adjacent spiral arteries and 
the myometrium. As they penetrate the walls of the spiral arteries, the arteries are remodeled, 
losing smooth muscle to become dilated and allow for more blood flow.5 Animal studies show 
that in preeclampsia, this process is incomplete and leads to a cascade of maternal 
inflammatory responses, resulting in placental ischemia and hypoxia.55–57  The hypothesis is that 
this ischemia and hypoxia then induces the release of soluble fms-like tyrosine kinase-1 (sFlt-1) 
and soluble endoglin (sEng) into maternal circulation,58,59  inhibiting production of vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF).57,60,61 Reduction in these 
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proangiogenic factors may lead to an antiangiogenic state and cause widespread maternal 
endothelial dysfunction55,56 (See Figure 1)  
 
Figure 1. Antiangiogenic state resulting from poor placentation 
 
In a longitudinal study of calcium supplementation, in which serum sFlt-1 and PlGF were 
measured over the course of pregnancy, sFlt-1 increased and PlGF decreased during the last 
two months of pregnancy even among normotensive controls, however, changes occurred 
earlier and were of greater magnitude in women who were later diagnosed with preeclampsia.60  
Additionally, these alterations were even greater in women with earlier onset preeclampsia (At 
21 to 32 weeks: sFlt-1 1672 pg/ml with early preeclampsia vs. 935 pg/ml with term 
preeclampsia, p<0.001; PlGF 297 vs. 676 pg/ml, p<0.001. At 33 to 41 weeks: sFlt-1 8150 vs 
2467 pg/ml, p<0.001; PlGF 73 vs. 370 pg/ml, p=0.05).60  In a similar analysis of serum levels of 
7,519 women of the Generation R study during early pregnancy (<18 weeks’ gestation) and 
mid-pregnancy (18-25 weeks’ gestation), low PlGF was associated with uterine artery 
resistance at both time points (β= 0.033, 95% CI:0.022-0.044 in early pregnancy and β= 0.021, 
95% CI:0.010-0.032 in mid-pregnancy).61 In women who were diagnosed with preeclampsia, 
sFlt-1 increased in the same time period (Delta sFlt-1 -0.032 ng/ml in controls vs 0.011 ng/ml in 
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cases, p<0.05) and there was a lower positive change in PlGF (21.4 pg/ml vs 14.7 pg/ml, 
p<0.05).61  
It is speculated that preeclampsia that presents earlier in pregnancy (<34 weeks’ 
gestation) and more severe forms of preeclampsia may be considered a separate phenotype 
and may have a different underlying etiology.  Risk and protective factors differ for early-onset 
and late-onset preeclampsia. African-American race, chronic hypertension, and congenital 
anomalies are more strongly associated with early-onset preeclampsia, while younger maternal 
age, nulliparity, and diabetes mellitus are more strongly associated with late-onset 
preeclampsia.62  In a study of differences in hemodynamic state, Valensise et al. found that 
patients with early preeclampsia had significantly more (15% versus 60%) bilateral notching of 
the uterine artery at 24 weeks than those with late onset,63  which illustrates that there are 
potentially differing vascular blood flow patterns with timing of preeclampsia onset. Vascular 
resistance was also increased and cardiac output decreased in early preeclampsia, while 
prepregnancy BMI was higher in late preeclampsia than early-onset.63  In a microarray study of 
gene expression within placental tissues, Nishizawa et al. identified eleven genes that were 
differentially up- or down- regulated in early-onset preeclampsia compared to late-onset 
preeclampsia.64  Most studies differentiate subtypes of preeclampsia by time of diagnosis, 
however, it is important to note that timing is not independent of severity. Early-diagnosed cases 
are typically the most severe cases of preeclampsia.65,66 
 
Risk Factors 
Known risk factors for preeclampsia include nulliparity, previous preeclampsia, family 
history of preeclampsia, multifetal pregnancy, history of subfertility, chronic hypertension, 
diabetes mellitus, autoimmune disorders, kidney disease, obesity (high prepregnancy BMI), 
African-American race, and maternal age.42,67,68 
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Both young and old maternal age are risk factors for preeclampsia as is typical for most 
pregnancy-related morbidities, though some have found no difference in risk across age 
groups.69,70 Other factors related to the pregnancy, such as parity, interpregnancy interval, and 
history of preeclampsia in a previous pregnancy are much stronger risk factors. First 
pregnancies have more than twice the risk of preeclampsia than later pregnancies.68 
Recurrence risk of preeclampsia is also high, and women who had preeclampsia in their first 
pregnancy have two to three times the risk in the general population of pregnant women.68 
Traditional risk factors for cardiovascular disease and other comorbidities such as high 
pre-pregnancy body mass index, diabetes, chronic hypertension, and autoimmune disorders are 
also risk factors for preeclampsia, however, the relationship of these risk factors to 
preeclampsia is poorly understood.1 Even when combined with pregnancy risk factors such as 
age and parity, it is difficult to predict who will be become preeclamptic.4 
 
B. Relationship of Smoking and Cigarette Smoke Components 
Epidemiology of Smoking and Preeclampsia 
One of the most consistent associations with preeclampsia is maternal smoking (Figure 
2). Maternal smoking is associated with as much as a 50% reduced risk of preeclampsia despite 
increasing risk of other poor pregnancy outcomes, which often co-occur with preeclampsia, 
including preterm birth and fetal growth restriction.71–73  
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Figure 2. Association between cigarette smoking and preeclampsia in cohort studies. From 
Conde-Agudelo et al. 1999.71 
 
Studies of smokeless tobacco (snus, used in Sweden), have not found a similar 
reduction in risk.74 One can only make limited inferences the effect of timing of smoking on 
preeclampsia and dose-response relationships between cigarette smoking and preeclampsia 
because many women who smoke prior to pregnancy do not continue to smoke throughout the 
entirety of their pregnancy, and those that do tend to reduce their quantity of smoking. Some 
evidence indicates that women who smoke more cigarettes have the lowest risk of 
preeclampsia71 and this risk may differ by timing of smoking during pregnancy.75 
 
Biological Mechanism of Carbon Monoxide and Nitric Oxide 
A biological mechanism explaining this inverse relationship between smoking and 
preeclampsia has been hypothesized but not definitively established, and appears paradoxical 
given the contradictory relationship between smoking and cardiovascular disease among non-
pregnant adults and by the contradictory relationship of smoking with fetal growth restriction 
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and/or birthweight among normotensive pregnancies. One often posited explanation involves 
carbon monoxide and nitric oxide.8,15,76 CO and NO have been shown to be associated with 
smooth muscle relaxation and blood pressure regulation12,14, and there is evidence of their role 
specifically in the placental vascular system.15,77 Because of these characteristics, CO and NO 
may be particularly relevant for preeclampsia.15 Nitric oxide production and serum metabolites 
of NO are found to be lower among women with preeclampsia than during normal 
pregnancy,16,22 and women with preeclampsia have been found to have decreased amounts of 
CO concentrations in their exhaled breath compared to those with healthy pregnancies.59,78 The 
endothelium from chorionic and umbilical vessels releases NO,79 and CO can be directly 
produced by trophoblasts.80 It has been suggested that both NO and CO are required for 
trophoblast differentiation and invasion to occur properly.8,15,77 Due to endothelial dysfunction, 
high vascular resistance and hypoxia may result from reduced endothelial-derived nitric oxide 
bioavailability,17,22,81 contributing to hypertensive disorders of pregnancy.82–86 Additionally CO 
has been shown to directly inhibit secretion of sFlt-159, resulting in an antiangiogenic state. 
Pregnant women may be exposed to CO and NO endogenously or exogenously by 
inhaling cigarette smoke or air pollutants. Pathways influencing CO and NO production are 
highly integrated, and the synthesis of these gases occur primarily through the degradation of 
heme in hemoglobin and conversion of L-arginine (Figure 3).  Catalyzed by heme oxygenase 
(HO-1, HO-2), heme breaks down into biliverdin, iron, and carbon monoxide. 11,87,88 Carbon 
monoxide then triggers nitric oxide synthase (NOS) of two types -- endothelial nitric oxide 
synthase (eNOS) and inducible nitric oxide synthase (iNOS).14 Nitric oxide synthase then 
catalyzes the production of NO in the body from L-arginine, an amino acid synthesized in the 
body and found in dietary sources. NO, in turn, increases HO-1 expression.89  
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Figure 3. Nitric oxide and carbon monoxide signaling. 
 
Animal models demonstrate that induction of HO-1 can reduce hypertension and the 
angiogenic imbalance characteristic of preeclampsia.58,90 HO-1 protein expression is 
significantly lower in preeclampsia placentae than those with normal pregnancies.14,80  
The role of carbon monoxide and nitric oxide may partially explain the enigmatic relationship 
between maternal smoking and preeclampsia.  Smokers overall have reduced plasma levels of  
the anti-angiogenic factors sFlt-1, similar to the reduction found in women with preeclampsia, 
even after controlling for pregnancy outcome (779.6 pg/ml, 95% CI:487.5-1140.8 vs 1116.5 
pg/ml, 95% CI: 793.6-1905.2).91 Studies have shown that both exogenously administered CO 
and NO inhibit platelet aggregation and relax blood vessels by activating soluble guanylate 
cyclase and increasing levels of guanosine 3’ 5’ cyclic monophosphate (cGMP) as 
endogenously produced CO and NO would.89  Smoking has the potential to modify the 
relationship between carbon monoxide signaling genes and preeclampsia, though this 
relationship could be synergistic or antagonistic. Most studies of the effect of cigarette smoke on 
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these pathways have assessed nitric oxide synthase activity in pulmonary endothelial cells and 
have found reduced eNOS and iNOS activity with cigarette smoke exposure.92,93 
  
Biological Mechanism of Smoking Detoxification 
The primary aims of the study are to investigate nitric oxide and carbon monoxide 
signaling pathways as a potential biological mechanism for the inverse association between 
smoking and preeclampsia, and to whether the effects of genes in smoking-related pathways 
are modified by exposure to smoking during pregnancy. Thus, in addition to CO and NO 
signaling pathways, we also include smoking detoxification genes and their relationship with 
preeclampsia.  
Nicotine and polycyclic aromatic hydrocarbons are both components of cigarette smoke 
that activate receptors involved in smoking detoxification. Nicotine stimulates the nicotinic 
acetylcholine receptor and there is evidence in vitro that nicotine restores proangiogenic 
functions to endothelial cells harmed by soluble fms-like tyrosine kinase and soluble endoglin 
while stimulating placental growth factor,94 all of which are associated with preeclampsia.59,61,95 
Polycyclic aromatic hydrocarbon response occurs through the aryl hydrocarbon receptor 
pathway (Figure 4), comprised of three phases (Figure 5). In phase I toxins are activated by 
enzymes such as those of the cytochrome P450 mono-oxygenase (CYP) family and epoxide 
hydrolase (EPHX). In phase II the reactive intermediate is conjugated to glutathione (GSH) by 
enzymes such as the glutathione S-transferases (GST). In phases III, these conjugates are less 
biologically active and more hydrophilic, so are then excreted via urine or bile. 
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Figure 4. Aryl hydrocarbon receptor signaling and other related detoxification pathways96 
 
 
Figure 5. Overview of Phase I, Phase II, and Phase III xenobiotic metabolism97 
 
Canonical Pathways 
Below we describe the canonical pathways that served as the basis for selection of candidate 
genes involved in smoking detoxification and CO/NO signaling. 
 
Three canonical pathways describe carbon monoxide and nitric oxide activity, and genes 
were grouped within these canonical pathways for analysis of aim 1. These pathways include 
endothelial nitric oxide synthase (eNOS) signaling, heme degradation, and hypoxia inducible 
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factor – 1 alpha (HIF1α) signaling. Five additional pathways were also included in aim 2 and 
these are xenobiotic metabolism, aryl hydrocarbon receptor signaling, glutathione-mediated 
detoxification, and nicotine degradation II, and nicotine degradation III. 	
eNOS Signaling 
 Nitric oxide is endogenously synthesized from L-arginine by nitric oxide synthases. 
Endothelial nitric oxide synthase is the isoform found in the endothelium and platelets, and is 
most relevant to preeclampsia for its role in vasodilation of the endothelium.98 Other related 
isoforms are inducible nitric oxide synthase and neuronal nitric oxide synthase. Lower levels of 
eNOS expression have been found in syncytiotrophoblasts from the placentae of women with 
preeclampsia compared to those in placentae of women without preeclampsia despite no 
significant differences in levels of asymmetric dimethylarginine, which is an endogenous 
inhibitor of eNOS.99 
 
Heme Degradation 
 Carbon monoxide is endogenously synthesized in heme catabolism. Heme, originating 
primarily from hemoglobin, is cleaved by heme oxygenases to form biliverdin, then bilirubin and 
carbon monoxide. Heme oxygenase occurs as 2 isozymes, inducible heme oxygenase 
(HMOX1) and constitutive heme oxygenase (HMOX2).100 In studies of placental vascular 
formation in mice as determined by micro-computerized tomography, mice with a partial 
deficiency in HMOX1 were found to have malformations of the fetomaternal interface and 
insufficient spiral artery remodeling.101 
 
HIF1α Signaling 
 Hypoxia inducible factor 1 is a transcription factor that regulates oxygen homeostasis.102–
104 It regulates response to hypoxia by activating transcription of genes whose protein products 
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increase oxygen delivery or facilitate adaptation to hypoxic conditions,102 and is important in 
embryonic and placental vascularization and pathophysiology of ischemic disease, such as 
preeclampsia.102 Because of the role in oxygen adaptation and delivery, HIF1A and related 
genes are heavily involved in both carbon monoxide and nitric oxide signaling.  HIF1A is 
overexpressed in placentas from women with preeclampsia,105 and cell free plasma expression 
of HIF1A is greater in pregnancies complicated by hypoxia and/or intrauterine growth restriction 
than in uncomplicated pregnancies.106 Additionally, in a placental expression study of 57 women 
terminating pregnancies at 6-8 weeks’ gestation, expression of HIF1A in active smokers was 
found to be significantly higher than non-smokers (estimate not provided, p=0.003)107 indicating 
the potential importance of the effect of smoking on the placenta during early pregnancy, 
particularly as it relates to preeclampsia. 
 
Xenobiotic Metabolism  
Xenobiotics, such as those that are contained in cigarettes trigger cellular stress 
response, leading to cell proliferation, differentiation, apoptosis or necrosis.108 The xenobiotic 
metabolism pathway induces expression of enzymes to protect the body from these harmful 
responses. These enzymes include phase I enzymes (CYP, ALDH, FMO) that usually create a 
polar group, phase II enzymes (UGT, GST, SULT) that produce hydrophilic products, and phase 
III enzymes (MDR1, OATP2, MRP) which are transporters that export xenobiotics and their 
products out of the cell.108 The xenobiotic metabolism pathway is highly integrated with the aryl 
hydrocarbon receptor signaling and nicotine degradation pathways. Gene by environment 
interactions have been studied among some of the genes in these pathways and these 
associations are summarized in the section of SNPs in genes involved in smoking detoxification. 
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 Aryl Hydrocarbon Receptor Signaling 
Halogenated and polycyclic aromatic hydrocarbons are contained in cigarette smoke.108 
Figure 5 describes the aryl hydrocarbon receptor signaling pathway, in which the aryl 
hydrocarbon receptor (AhR) mediates xenobiotic metabolism, dioxin and polycyclic aromatic 
hydrocarbon toxicity, and vascular development.109 AhR is highly expressed in the placenta110 
and higher in preeclamptic pregnancy placentas than normal pregnancy placentas.111  AhR has 
been shown to increase invasion of cancer cells in several types of cancer, and it is 
hypothesized that AhR may increase invasion of fetal cytotrophoblast cells as well, protecting 
against preeclampsia.111 
 
Glutathione-mediated Detoxification 
Figure 5 describes the general detoxification pathway, where the first step can be 
catalyzed by many different enzymes, collectively known as glutathione transferases, or GSTs. 
In the first reaction, R may be an aliphatic, aromatic or heterocyclic group, and X may be a 
sulfate, nitrile or halide group. General Background Thiols play several major roles in the cell; 
they help maintain the redox balance, keeping a reduced environment (see the pathway 
glutathione redox reactions II), they fight reactive oxygen and nitrogen species (ROS and NOS, 
respectively), and they are involved in the detoxification of many other toxins and stress-
inducing factors. In most organisms the major thiol is the tripeptide glutathione (γ-Glu-Cys-Gly, 
known as GSH). GSH is active against toxins by a process that involves multiple enzymes, and 
in the case of eukaryotes, occurs across multiple organs. 
 
 Nicotine Degradation II and III 
Nicotine is the principal alkaloid in the leaves of tobacco and is available in both 
smokeless and smoking tobacco. In cigarette smoke, it is carried into the body on particulate 
matter. It binds to the nicotinic cholinergic receptors and activates dopaminergic reward system 
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in the brain. It is primarily metabolized in the liver and most is metabolized to cotinine. It is 
metabolized primarily through signaling of the CYP enzymes as with other xenobiotics.112 
 
Analogy with Air Pollution 
Some have suggested that the mechanism for smoking and preeclampsia should mirror 
associations seen with other tobacco or combustible exposures, but studies of air pollution or 
environmental tobacco smoke and preeclampsia have not shown consistent results and 
generally do not find the similar reduction in risk found with smoking studies. Most studies of air 
pollution have measured particulate matter, nitrogen oxides, carbon monoxide and ozone at air 
monitors of closest proximity to study participants.113–121 Four studies specifically analyzed either 
CO or NO; of these, three found an increased risk of preeclampsia for both CO and NO117–119 
and one found a decreased risk of preeclampsia with carbon monoxide exposure.115  
Though one may expect a similar inverse relationship between air pollution and 
preeclampsia because of the gaseous composition, differential results of smoking studies and 
air pollution studies may exist for several reasons. Exposure from the ambient environment may 
have a different effect than personal exposure to cigarettes. In particular, there has been no 
relationship found between second-hand smoke from partner smoking and preeclampsia or 
pregnancy induced hypertension122 which may indicate differences in delivery or dose of the 
exposure. Additionally, the studies of air pollution described above have all used registry data 
for risk estimates, which have a greater potential of outcome misclassification and likely 
encompass a large number of women with pregnancy induced hypertension rather than 
preeclampsia. 
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C. Genetics of Preeclampsia 
Familial Associations 
 Numerous studies have suggested a familial predisposition for preeclampsia risk in first-
degree relatives of women with preeclampsia 123. In studies of familial aggregation of 
preeclampsia, genetic factors may contribute more than 50% of heritability 124–126, which is 
supported by both large-scale registry-based epidemiologic studies127,128 and studies of 
transgenic mice.123,129 A number of candidate regions have been identified through linkage 
studies124, and approximately a dozen genes show altered placental expression in preeclampsia 
in at least two independent studies.123 
  
Early Linkage and Candidate Gene Studies 
A search was done on PubMed as well as the Preeclampsia SNP Database 
(PESNPdb)130 and The Genetic Association Database131 for previously found associations of 
SNPs with preeclampsia (Table 1).  Although there have been hundreds of genetic studies of 
preeclampsia, including placental expression, linkage analyses, candidate SNP, and genome 
wide association studies, findings have been inconsistent. 
Some of the most replicated relationships in the genetic preeclampsia literature are 
among linkage analyses detecting potential susceptibility loci. Genome wide scans have 
detected associations with preeclampsia of variants on chromosome 2 (on 2p11-14 and 2q22-
23) in Icelandic (LOD score=4.70)132, Australian and New Zealand (LOD score=2.58)133, and 
Finnish populations (NPL score=3.77, p=0.000761)134.  Roten et al. did a scan of 71 SNPs in 
these regions of chromosome 2 in Norwegian women and found four significant SNPs in 
ACVR2A using a false discovery rate of 5%.135 A genome wide association study found two 
variants meeting modified Bonferroni significance (rs7579169, p=3.58 x 10-7 and rs12711941, 
p=4.26 x 10-7) in an intergenic region near INHBB on 2q14.2.136 Laivuori et al. found an 
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additional susceptibility locus in 9p13 in the same Finnish population, but this has not been 
replicated in other studies.134 
Among the more recent and larger candidate gene studies (those with at least 150 cases 
(Table 1)), few variants have been consistently associated with preeclampsia. This is partially 
due the selection of different markers; for some there has been no attempt at replication apart 
from through GWA studies. However, among the better powered candidate gene studies, some 
replication has been found for variants within TNFA137–139 and IL10,124,138,139 although there are 
also studies that have found no associations.140,141 
Buurma et al. conducted a recent meta-analysis of genetic variants and preeclampsia, 
finding 542 genetic associations of preeclampsia with 22 replicated genetic variants.142 Of these 
22, only seven variants were significantly associated with preeclampsia following meta-analysis. 
These are: FV rs6025, FV rs6020, F2 rs179963, SERPINE1 rs1799889, ACE rs4646994, 
CTLA4 rs231775, and LPL rs268.142 The majority of the studies considered, however, are quite 
small (range=7 to 665 cases, median=102, mean=119) which is a possible reason for 
unreplicated findings and lack of associations after meta-analysis. For example, for variants in 
TNFA and IL10, which were those associations most replicated in studies with at least 150 
preeclampsia cases, the number of cases were small: 1075 cases among 8 studies for IL10 and 
1592 and 390 cases for two variants of TNFA, respectively.142  
In addition to the lack of overlap in typed markers and small study sample sizes, several 
other factors may influence the inconsistent findings in candidate gene studies of preeclampsia. 
It is plausible there is truly no effect of any variants on preeclampsia aside from those described 
in the meta-analysis. However, it is also plausible that substantial heterogeneity among these 
studies make comparisons across studies difficult. Differences in study design are described 
below. 
Although all of the studies used preeclampsia as an outcome, there were a variety of 
definitions used. For example, some of the studies only included women with severe 
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preeclampsia.143–147 In older studies, a change in blood pressure rather than a set cutpoint was 
often used as a criterion for preeclampsia.148–151 Because risk factors differ for various subtypes 
of preeclampsia,62 and different presentations of preeclampsia may have a different underlying 
etiology, the inclusion or exclusion of various subtypes could yield conflicting results.  
The method of case ascertainment may affect validity and replicability. Nearly all of the 
candidate gene studies are case-control studies, and study participants were generally recruited 
or selected from hospitals or obstetric clinics. Preeclampsia diagnosis was almost always 
determined from clinical records and hospital chart review, which can reduce the likelihood of 
misclassification, though misclassification may still occur due to lack of multiple blood pressure 
and urinary measurements over time and differential practices of health care providers. 
Misclassification of the outcome would not likely bias results if non-differential,152 however, could 
increase noise and reduce power to detect an effect. 
Lastly, the study populations of all the preeclampsia genetic studies are extremely 
diverse, with populations from countries including India153, Korea99, United States154, Brazil83, 
and Colombia155, among others. Some of the individual studies are done in places like the 
United States, in which the population is ethnically heterogeneous, which opens up the potential 
for population stratification bias within the study.156 When making comparisons across studies, 
populations of different ancestry may show different associations. There is variation in LD 
among populations of different origins,157 which can lead to different SNP selection, haplotypes, 
and associations for different populations. 
 
Genome Wide Association Studies  
PubMed as well as the National Human Genome Research Institute Catalog of 
Published Genome Wide Association Studies was searched for GWA studies of preeclampsia. 
To date, there are only three GWAS of preeclampsia, and none have found any associations 
meeting Bonferroni significance.136,158,159 The first genotyped 648,175 SNPs in 538 women with 
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preeclampsia and 540 with normal pregnancies of Caucasian ancestry in Australia. Two SNPs 
in an intergenic region near INHBB on chromosome 2 met their modified significance threshold 
(rs7579169, p=3.58 x 10-7 and rs12711941, p=4.26 x 10-7).136 Another genome-wide scan of 
705,969 SNPs in 177 preeclampsia cases and 116 normotensive controls was conducted 
among mothers who gave birth in Iowa from Aug 2002 to May 2005 as part of the SOPHIA 
study. The top four SNP associations had genotypic p-values between 10-5 and 10-6.158 The third 
preeclampsia GWAS is another study by Zhao and colleagues, a subset of the Hyperglycemia 
and Adverse Pregnancy Outcome study cohort of a diverse group of mothers from Barbados; 
Brisbane and Newcastle, Australia; Toronto, Canada; Belfast, United Kingdom; Bellflower, 
California; and Bangkok, Thailand. This study analyzed approximately 979,693 SNPs and the 
study population consisted of Afro-Caribbean women (21 cases, 1010 controls), Hispanic 
women (62 cases, 658 controls), and European ancestry women (50 cases, 1202 controls).159 
As in the other cohorts, none of the variants were Bonferroni significant, though the top SNP for 
each ethnic group had p-values between 10-6 and 10-7.159 None of the top SNPs were replicated 
in other studies. The closest replication of variants were those from the HAPO study that were 
“suggestively replicated” in the SOPHIA study; two variants in an intronic region of INVS among 
women of Caucasian ancestry.159 
Although the GWA studies are generally larger than the candidate gene studies, they all 
still face the challenge of being underpowered when considering multiple comparisons for the 
number of SNPs analyzed. In particular, the Iowan study of 705,969 SNPs in 177 preeclampsia 
cases and 116 controls158 is far too small to detect any reasonable effects. This study by Zhao 
and colleagues also leaves the greatest potential for outcome misclassification of the three 
GWA studies. Potential cases were first identified through electronic birth certificates that were 
“check box positive” for either pregnancy induced hypertension or eclampsia.158 It is quite 
possible that a woman could not have had the box checked and still met the clinical criteria for 
preeclampsia.  In an effort to ensure the validity of cases and controls, cases were confirmed by 
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telephone interviews with study participants and the medical record, however, evidence has 
shown that validity of self-reported preeclampsia is moderately poor. In a validation study as a 
part of the Generation R cohort study in The Netherlands, 50% of women who self-reported 
preeclampsia (72/152) were determined not to meet the clinical criteria for disease.160 
Of these studies, the one by Johnson et al. seems the strongest. It has the largest 
number of cases by approximately three-fold (n cases = 538), a fairly homogeneous population 
of Australian women of Caucasian ancestry (PCA revealed minimal population structure), and 
case ascertainment determined from new-onset hypertension and protein levels confirmed by 
medical records.136 This study, however, is still likely to be underpowered at all but the most 
common allele frequencies. 
These three GWA studies have not found any significant associations at genome-wide 
significance levels, however, even the top hits that may be suggestive of association are 
different in each study. This may be, in part, due to the problem that these three studies are not 
necessarily good comparisons for one another. Although each of them have the greatest 
number of women of European ancestry compared to other ancestral groups within each study 
and all were assessed for population stratification using principal components analysis, the 
HAPO population is quite heterogeneous. Although it has the largest sample size (though not 
the largest number of cases), the sample is divided among three different ancestry groups (Afro-
Caribbean: 21 cases, 1010 controls; European ancestry: 50 cases, 1202 controls; Hispanic: 62 
cases, 658 controls).159 These three studies also do not use the same case definition for 
preeclampsia. Although they all consider preeclampsia to be de novo hypertension of a systolic 
blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg in the 
presence of urinary protein, the study by Johnson et al. includes a change in systolic blood 
pressure of 25mmHg and/or diastolic blood pressure of 15 mmHg as diagnostic criteria.136 Each 
of the studies also uses different criteria for proteinuria (Johnson et al. 2012: ≥0.3 g/l in a 24 hr 
specimen or 2+ dipstick reading or spot protein:creatinine ratio ≥0.3 g/mmol136; Zhao et al. 2012: 
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1+ dipstick reading from two or more specimens collected at least 4 hours apart, one or more 
dipstick values of 2+ near end of pregnancy, one or more catheterized dipstick values of 1+ 
during delivery hospitalization, or 24 hr urine collection with protein >300mg158; Zhao et al. 2013: 
dipstick protein value ≥1+ or 24 hr urine collection with protein ≥300 mg159). These differences in 
population and case definition decrease the ability to replicate findings, particularly in 
underpowered studies.  
Because of the lack of replicable findings among GWAS of preeclampsia, some 
researchers are beginning to use methods that may account for a potential polygenic effect 
rather than a single SNP effect. Smith et al. use genome wide data to investigate genetic risk 
scores for essential hypertension and their association with preeclampsia.161 They found that 
genetic risk scores for hypertension were not associated with a risk of preeclampsia, suggesting 
that a different underlying genetic etiology of preeclampsia and essential hypertension. 
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Single Nucleotide Polymorphisms in Genes Involved in CO and NO Activity 
Genetic factors play a role in how carbon monoxide and nitric oxide are processed and 
synthesized in the body, and these genes have reported associations with hypertensive 
disorders. Each of the enzymes involved in production of NO and CO described earlier are the 
product of a specific gene: HMOX1 codes for heme oxygenase 1, NOS1 codes for neuronal 
nitric oxide synthase, NOS2 codes for inducible nitric oxide synthase, and NOS3 codes for 
endothelial nitric oxide synthase. Nitric oxide is not stored after synthesis and has a short half-
life in tissue, so production is partially regulated through alterations in expression or activity of 
eNOS.162 The Glu298Asp163, intron 4 17, and -786T>C 17 polymorphisms of NOS3 are associated 
with reduced basal NO production and low plasma NO levels and are also the most widely 
studied in relation to preeclampsia, as they are considered clinically relevant.164 In mice, 
expression of HO-1 can be induced by the signaling molecule adenosine 3',5'-cyclic 
monophosphate (cAMP), which then stimulates formation of CO and NO.165 
Several genes involved in our pathways have demonstrated associations with 
cardiovascular disease and hypertension. NOS3 knockout mice are hypertensive.166 A meta-
analysis of human studies found NOS3 polymorphisms to be associated with coronary heart 
disease (OR 1.17; 95% CI 1.07-1.28).17 Similarly, SNPs of NOS1 were associated with stroke 
susceptibility.167 However, GWA studies have not found cardiovascular disease associations 
with any of the NOS genes.  
Variants in HMOX1 have also been associated with hypertension in several 
populations19,168, though no associations of HMOX1 have also been found in GWA studies of 
hypertension. Although NOS and HMOX genes are the most commonly studied, variants of 
seven other genes in our pathways have reported associations with cardiovascular disease 
phenotypes in GWA studies. These include CAV1169,170, ESR1171, GUCY1A3172–174, 
GUCY1B3172–174, and PRKCA175 in the nitric oxide synthase pathway and EDN1176 and EPO177 
in the HIF1A signaling pathway. 
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In preeclampsia specifically, as with other variants, those within NOS3 have been widely 
studied but associations remain inconsistent (Figure 6), which as with genetic studies of 
preeclampsia overall, may be partly attributable to small sample sizes, heterogeneity in 
race/ethnicity of population, and differences in case definition. In a linkage study of 42 women 
with pregnancy induced hypertension in 50 families in Scotland and Iceland, Arngrimsson et al. 
found evidence of linkage of region 7q36 (LOD score=3.36), where NOS3 is located, and a 
transmission disequilibrium test provided evidence of association for a marker in intron 13 of 
NOS3 within this region (-2LL difference = 6.43, p=0.005).178 Linkage to this region in other 
genome-wide scans, however, has not been confirmed in other populations.133,134  
 
 
Figure 6. Forest plot of NOS3 rs1799983 associations from Buurma et al. meta-analysis, 
supplementary data.142 Figure references.23,83,85,99,149,153–155,179–185 
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There have been numerous candidate gene studies of NOS3 and preeclampsia, 
reporting widely variable estimates on both sides of the null. A recent meta-analysis of the three 
most widely studied polymorphisms in NOS3 (G894T, T786C, and intron 4b/a) found that only 
the G894T polymorphism in a recessive model was associated with preeclampsia after meta-
analysis.164 The recent meta-analysis by Buurma et al. analyzed findings of the variants 27 bp-
VNTR in intron 4, rs2070744, and rs1799983 of NOS3 (Figure 6). The study included only 
genetic variants that were associated with preeclampsia and for which independent replication 
was available. After meta-analysis of 29 studies of those variants, however, the authors found 
no association between any of these variants and preeclampsia.142 
 
Single Nucleotide Polymorphisms in Genes Involved in Smoking Detoxification 
 Genes encoding interleukins (IL1A,138,186 IL1B,187 IL4136) and tumor necrosis factor 
(TNF)137,138,186,188 are the most widely studied genes within the smoking detoxification pathways 
for their association with preeclampsia. Studies have shown generally null and unreplicated 
findings. The cytochrome P450 genes, CYP1A1 and CYP19A1, have been studied primarily in 
Japanese populations; findings have been null.189,190 
Smaller candidate gene studies of CYP1A1, GSTT1, and GSTP1 have revealed 
potential interactions with exogenous exposures, for other reproductive outcomes including 
CYP1A1 and benzene with shortened gestation, GSTT1 and smoking with birthweight, and 
GSTP1 and smoking with spontaneous abortion.191 
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Summary of Limitations of Existing Genetic Studies 
There have been a large number of genetic studies of preeclampsia, however, these 
studies are limited in what we can determine about the etiology of the disease. The majority of 
genetic studies of preeclampsia are early linkage analysis studies, candidate gene studies, or 
placental expression studies. 
Linkage analyses use information from related individuals and can provide a starting 
ground in which to conduct further analyses or select potential candidate genes by identifying 
potential regions of the genome that may be associated with disease192. With regards to the 
preeclampsia literature, potential susceptibility loci determined by linkage analysis have been 
some of the most widely replicated findings. Preeclampsia is a heterogeneous phenotype, in 
which unclear case definition can lead to misclassification of affected and unaffected individuals. 
In a linkage study, some selection criteria are usually applied to the phenotype before families 
are selected.192 In preeclampsia, this makes the case definition consistent across related 
individuals, which may increase the ability to identify a potential linkage region. This, however, 
may reduce the ability to generalize the findings to the larger population.192 Because linkage 
studies are also studies of related individuals, they likely share more environmental factors. 
Although it seems plausible that are shared environment may improve the ability to replicate 
genetic effects by excluding environmental effects, a simulation study by Tiret and colleagues 
found that ignoring a GxE interaction effect among nuclear families decreases power to detect a 
gene effect and biases parameter estimates.193 Overall, linkage studies of preeclampsia can be 
a good starting place, however, they do not give the ability to find specific SNPs or determine 
anything about variant function, nor account for any environmental factors that may be important 
particularly for preeclampsia.  
The majority of preeclampsia genetic studies are candidate gene studies, and there 
have been widely variable associations found for many of the genes studied. Although genes 
are generally selected based on biologically plausible hypotheses, past experience in genetic 
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epidemiology has demonstrated that scientists generally do a poor job of selecting candidate 
genes. 
For gene expression studies of preeclampsia, placental tissue is typically used. In these 
studies, the placenta is collected after birth, therefore, it is collected and analyzed after the 
onset of disease. Although these studies can detect differences in placentas of women who had 
preeclampsia and those who have not, a temporal relationship cannot be determined. It is 
possible that expression differences may result from the consequences of preeclampsia rather 
than explain the onset of preeclampsia.  
 Of the three genome wide association studies of preeclampsia, none have found any 
genome-wide significant associations when correcting for multiple tests using the standard 
Bonferroni correction. In general, GWAS of preeclampsia are hugely underpowered to detect 
modest effects. Although the GWA studies are some of the largest preeclampsia studies, 
sample sizes have hovered in the hundreds of cases and controls rather than the thousands or 
tens of thousands necessary to be truly powered to detect an effect.  Additionally, because 
preeclampsia is a heterogeneous phenotype, in which all subtypes of preeclampsia may not be 
associated with a single variant, small numbers within subtypes may make it even more 
challenging to detect an effect. With other phenotypes such as cardiovascular disease or 
cancer, in which the GWAS literature is more advanced, consortia are created to pool large 
cohorts of data to improve power. A consortium for preeclampsia has recently been established, 
InterPregGen, although no findings from this study have yet been published. 
 Small sample size and low power are both a problem in the smaller candidate gene 
studies and larger GWA studies of preeclampsia. To my knowledge, even among the 500+ 
studies of preeclampsia, only those in Table 1 have at least 150 cases of preeclampsia in the 
study population. The populations studied are highly diverse, representing ethnicity of over 20 
countries. Reduction in power due to additional random noise in the population is also an 
important consideration that may reduce the ability to detect a genetic effect. Misclassification of 
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the outcome is also a potential problem in both the candidate gene studies and GWAS. 
Preeclampsia diagnosis is based on both blood pressure and protein measurements, as well as 
syndromic clinical and symptomatic criteria, which can vary in severity over time. Information 
may be recorded on a prenatal record, through the place of delivery, or in registry data. 
Because of this, some cases may be missed. In addition, although most of the studies use a 
similar definition of preeclampsia, some define the phenotype differently, such as including 
pregnancy induced hypertension without proteinuria or using change in blood pressure rather 
than an absolute measure as a diagnostic criterion.  
 One final limitation of the current genetic preeclampsia studies is that very few include 
child (fetal) DNA in analysis. Although preeclampsia is a maternal disease, it likely originates in 
the placenta, tissue of fetal origin. Only a few studies (see Table 1) have included fetal DNA, but 
fetal contribution may explain some of the missing heritability of preeclampsia. In a study by Hill 
and colleagues, they found only a fetal effect of the variants studied.194 In another study by 
Petry and colleagues, in which they solely studied known imprinted genes, they found both 
maternally and paternally transmitted fetal genes associated with maternal mean arterial blood 
pressure.195 Since maternal and fetal genotype are correlated, there may be confounding of the 
fetal association with preeclampsia by maternal genotype; thus, it is important to include both 
maternal and fetal genotype in the analysis.  
 This study contributes to the current state of the genetic preeclampsia research by 
taking a somewhat hybrid approach. The study is hypothesis driven, as with the candidate gene 
studies, however, it assesses genes within larger pathways based on biological plausibility of 
the role of an entire pathway. This reduces the number of SNPs from a GWAS to improve 
power while still looking at a broader set of variants. In addition, we use evidence of reported 
associations from phenotypes that are likely related to preeclampsia, such as general 
hypertension and cardiovascular disease, areas in which the state of the genetic literature is 
much more advanced. Wan and colleagues did this successfully in two recent papers – 
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selected two variants that were associated with hypertension in GWAS, and found they were 
also associated with preeclampsia.196,197 By prioritizing the variants with known associations, 
they could reduce the need for correcting for multiple testing, greatly improving power. At the 
same time, we account for the contribution of both maternal and child genetics by implementing 
a dyad analysis design. 
 
 
D. Knowledge Gaps 
Inconsistent genetic findings and novel genes 
This dissertation investigates new genes and their association with preeclampsia while 
building on those associations already suggested. Many of our genes had been studied in 
relation to cardiovascular disease broadly, but never investigated with preeclampsia. To date, 
only two specific genes in nitric oxide and carbon monoxide pathways (NOS2, NOS3) have 
been reported on for the study of preeclampsia.17,82,198,199 Most studies of preeclampsia seeking 
to look at several genes have used microarray technology to assess differential gene 
expression patterns in placentae.123 However, with the exception of genes coding for leptin 
(LEP) and fms-related tyrosine kinase 1 (FLT1), these studies have found inconsistent results of 
differentially expressed genes in preeclampsia.64,200–210 There have been over five hundred 
papers of candidate gene studies in preeclampsia, but most have investigated a single 
polymorphism in a single candidate gene. Although over 50 candidate genes have been studied 
and reported, eight genes account for approximately 70% of the published research about 
candidate genes for preeclampsia.123 NOS3 is one of the more widely studied genes that we 
investigate155,188, but the other genes are novel for this question. Aside from NOS2 and NOS3, 
genes involved in carbon monoxide and nitric oxide signaling have not been extensively 
investigated for their relationships with preeclampsia.  
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Sample size and measurement of preeclampsia 
This study uses a large sample of validated cases and validated controls to undertake a 
mother-child dyad approach. Most of the genetic studies of preeclampsia to date have used 
relatively small sample sizes. These studies may be underpowered, particularly to address 
heterogeneity of disease. Another difficulty in the genetic study of preeclampsia is inconsistency 
in case definition. Although preeclampsia is generally defined as gestational hypertension plus 
proteinuria, the cut-points for those criteria can sometimes vary by medical provider and have 
changed over time.211 This imprecision in phenotype definition may increase random variation in 
the outcome, decreasing power overall. 
 
Family-based methods to disentangle maternal and child genetic effects 
A unique challenge of studying the genetics of preeclampsia is that both maternal and 
fetal genes may play a role. One cannot determine the maternal and fetal genetic contribution 
with a traditional case-control design because mother and child genotypes will be correlated. 
This is a potential concern in many reproductive outcomes, and one that has not yet been 
thoroughly explored.212 Very few studies of preeclampsia have investigated the fetal 
genotype,123 and none have used both mother and child DNA to control for confounding of fetal 
genotype by maternal genotype.   
The case-parent trio design is one that is sometimes used in studies of rare outcomes 
such as cancer, because the design significantly improves power, reduces the potential of 
population stratification bias, and removes the requirement of recruiting controls. A similar 
design, a mother-child dyad design may similarly improve power with less burden of 
recruitment. Shi and Weinberg have explored some of these methods,213 and this study 
continues to apply their innovative methods that may be so relevant to reproductive 
epidemiology. 
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This study uses a mother-child dyad approach. The sample consists of 1564 validated 
preeclampsia case-pairs and 999 validated non-preeclampsia control-pairs. This innovative 
approach allows us to disentangle maternal and fetal genetic contributions to preeclampsia by 
controlling for both maternal and fetal genotype while examining genetic effects.  
 
Investigation of gene by environment interactions, an emerging area in reproductive 
epidemiology 
This study investigates gene by environment interactions, an emerging area in 
reproductive epidemiology. To my knowledge, the only other study of gene by environment 
interactions for preeclampsia is one assessing the interaction of the MTHFR gene and folate.191 
There have been a few other studies of gene by smoking interactions in the field of reproductive 
epidemiology on birth defects and preterm birth. One assesses the association of TNFα, 
smoking, and cleft lip and palate,191 and another of GSTT1, smoking, and orofacial clefts.214 
Another is assessing CYP1A1, GSTT1, and their interactions with smoking on preterm birth.215 
Although these studies provide some evidence of gene by environment interaction, they do not 
analyze the unique combination of our selected genes, exposure, and outcome.  
The large, inverse association of smoking and preeclampsia has been found repeatedly, 
but it is still unknown as to whether this association is indeed causal or rather due to some 
pervasive and uncontrolled bias (e.g. left truncation).  Identifying a gene by environment 
interaction with smoking would provide evidence that the inverse relationship may at least in 
part be due to an underlying biological mechanism. Since there is such a strong and consistent, 
yet unexplained relationship with the environmental exposure of smoking and preeclampsia, this 
study provides an opportunity to investigate this complex relationship further. 
Genetic epidemiology studies, particularly GWA studies are moving toward novel 
methods to assess gene by environment interactions such as gene by environment-wide 
interaction studies (GEWIS). Much of these are with the goal of characterization of joint effects, 
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rather than just modeling and testing significance of interaction terms, as has been typical in 
past studies, as well as discovery of new loci.216 It is possible that genetic factors that impact 
disease through environmental interaction will not be detected through traditional GWAS 
analyses. 
The study of interaction of genes in pathways relating to carbon monoxide signaling, 
nitric oxide signaling, and detoxification with the environmental exposure of cigarette smoking 
offers an opportunity to explore both a potential statistical and biological interaction, as there is 
evidence that both endogenous and exogenous CO and NO and well as other cigarette smoke 
components may affect preeclampsia. Family-based designs are also an area in which G x E 
methods have just recently been developed,212,217,218 yet are a promising technique for 
improving power for G x E studies, which otherwise need large sample sizes.216 Although this 
study is a candidate gene study, it is possible that the use of maternal and fetal DNA in dyad 
methods can be expanded and included with novel methods in GEWIS for reproductive 
outcomes that likely have very important genetic and environmental risk factors, both through 
maternal and fetal pathways. 
In summary, this study uses a large and validated sample of cases and controls from 
both mothers and their offspring. The maternal-child dyad approach allows us to investigate 
contributions of maternal and fetal genetics, rarely done in reproductive epidemiology studies. 
GWA studies of preeclampsia have also only generally used maternal blood or buccal cells, and 
have not incorporated fetal genetics into analysis. Dyad analytic methods can improve efficiency 
in study design and analysis both for genetic studies and those of gene by environment 
interactions by imposing constraints inherent in the family structure of dyads. Genome wide 
association studies for preeclampsia have been conducted with inconsistent results; our 
hypothesis-driven candidate pathway study investigates genes for which there is a plausible 
biological mechanism yet have not been thoroughly investigated. We seek to provide some 
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insight into the paradoxical relationship of smoking and preeclampsia, a disease for which there 
is still no known cause or effective therapeutic treatment. 
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CHAPTER III. METHODS 
 
A. Study Design Overview 
This study is a case-control study of validated preeclampsia cases and non-
preeclampsia controls nested within the Norwegian Mother and Child Cohort Study (MoBa), 
conducted by the Norwegian Institute of Public Health.219 Preeclampsia is a rare disease, 
occurring in approximately 4% of pregnancies in our study population; therefore, a case-control 
study is the most efficient way to study this outcome. A candidate gene case-control study 
allows us to look for gene by smoking interaction. To elucidate whether any effects of genetic 
variants on risk of preeclampsia are of maternal or fetal origin, we use a mother-child dyad 
design; cord blood samples have been analyzed from each infant born to the case and control 
mothers if available. A candidate pathway case-control study best enables us to efficiently 
determine if genetic variants in the proposed pathway are associated with preeclampsia, 
whether these variants in the mother or child have a greater effect, and if they are modified by 
maternal smoking during pregnancy. 
 
B. Study Population 
Norwegian Mother and Child Cohort Study 
The Norwegian Mother and Child Cohort Study (MoBa) is a large prospective birth 
cohort of pregnant women and their offspring, recruited throughout Norway from 1999 to 2008. 
The purpose of the study is to identify causes of disease in the mother and child.220 All pregnant 
women living in Norway who gave birth at a hospital or maternity unit with more than 100 births 
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annually and could speak Norwegian were eligible; MoBa investigators applied no other 
exclusion criteria. Pregnant women were recruited by mail with addresses provided by their 
prenatal care provider prior to their routine ultrasound appointment scheduled for 17 to 20 
weeks’ of gestation. Because of the consistency and availability of care in Norway, nearly all 
pregnant women have routine ultrasounds at this time.221 Of all women invited to participate, 
38.5% enrolled in the study.219 Participants complete several questionnaires by mail. Pregnant 
women were recruited by mail prior to their routine ultrasound appointment at 17 to 20 weeks’ of 
gestation. Of all women invited to participate, 41% enrolled in the study.222 Participants 
completed two prenatal questionnaires about their health and environment. The early pregnancy 
questionnaire is completed prior to the ultrasound appointment at 13-17 weeks’ gestation. It 
asks for detailed information about previous pregnancies, medical history, medications, 
occupation, home and work exposures, mental health, and lifestyle habits. A late pregnancy 
questionnaire (~30 weeks’ gestation) asks about the pregnancy and any changes in status from 
the first questionnaire. Survey completion rate was 91% for the early pregnancy questionnaire 
(administered between weeks 13 and 17) and 83% for the late pregnancy questionnaire 
(administered at week 30).222 Biospecimens are also collected from the mother and child. For 
those enrolled, maternal blood was collected at the ultrasound appointment. Cord blood was 
collected from the child at birth unless they were unable; in those cases, blood was collected by 
heel stick during routine PKU screening 3 or 4 days after birth. Maternal blood was received 
from 89% of participants and child (cord) blood from 81% of children in the cohort.222 For both 
maternal and infant blood, DNA was extracted at the time of collection before being stored at 
the MoBa Biobank.  
A validation study of preeclampsia diagnosis was conducted within the MoBa cohort.223 
The investigators selected all pregnancies with preeclampsia in MoBa that were registered in 
the medical birth registry of Norway (MBRN) (N=4081), and a random control group without 
preeclampsia registered in the MBRN (N=2000). Delivery units were asked to provide antenatal 
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charts that contained blood pressure and urinary measurements, as well as hospital discharge 
codes. Data from 87% of eligible pregnancies was received (N=5340). The investigators 
considered a gold-standard for true preeclampsia to be blood pressure of 140 mmHg systolic 
and/or 90 mmHg diastolic after the 20th week of gestation, together with proteinuria of ³ 0.3 g 
per 24 hours (³1 + on dip-stick) noted on the antenatal chart, or presence of 
preeclampsia/eclampsia ICD-10 codes on the hospital discharge form. One antenatal visit that 
fulfilled these criteria was considered adequate to be a preeclampsia case. Of the 3500 
registered preeclampsia cases and 1840 registered to be unaffected by preeclampsia for which 
records were received, 2936 pregnancies identified as preeclampsia cases from the MBRN 
were verified to have been affected by preeclampsia, and 1745 pregnancies identified as 
unaffected by preeclampsia were found to be negative for preeclampsia. Overall positive 
predictive value considering registry data as predictive of clinical records in the validation study 
was found to be 83.9%. When extrapolated to the entire MoBa population, estimated sensitivity 
was low (43.0%) and specificity was high (99.2%), and many false negative cases in MoBa 
actually had mild forms of preeclampsia. 223  
The samples for the proposed study were selected only from the preeclampsia cases 
and non-preeclampsia controls validated within the study described above. When controls were 
determined to meet case criteria in the validation study, they were reassigned to the case group. 
 
Eligibility and Sampling 
As described above, for this proposed study, 2936 cases were selected from women 
with validated preeclampsia and 1745 controls were selected from women who were reported 
not to have preeclampsia and were validated as non-cases. Cases were oversampled relative to 
controls in order to maximize power to detect associations in subgroups of PE (e.g. early PE, 
severe PE). Because of inconsistencies with diagnosis of preeclampsia,211 all cases and 
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controls were validated through an independent validation study described above.223 Women 
with pregnancy-induced hypertension (~1% of sample) were not excluded from controls. To be 
eligible for this study, women also met the following criteria: 
1) Singleton pregnancy conceived without the use of in vitro fertilization who returned 
both the 1st and 3rd pregnancy questionnaire (which contains self-reported smoking 
information) 
2) Maternal blood sample collected during mid-pregnancy and DNA extracted and 
stored in the MoBa Biobank 
3) No evidence of hypertension prior to pregnancy 
In total, 2682 preeclampsia case samples (2236 samples from 1118 mother/child pairs and 446 
unpaired maternal samples) and 1967 non-preeclampsia control samples (1936 samples from 
968 mother/child pairs and 31 unpaired maternal samples) met inclusion criteria and were 
genotyped. There were no unpaired offspring genotyped.  
 
Study Sample for Aim 1 
Quality control measures are described in the section on exposure assessment. After 
quality control, the final analysis sample for aim 1 (n=4551 total samples) included dyads with 
both mother and child genotype data as well as incomplete dyads with only mother or child 
genotype data (Table 2). 
 
Table 2. Final analysis sample for aim 1. 
 Cases Controls Total 
 Mother Child Total Mother Child Total Mother Child Total 
Paired Dyad 1076 1076 2152 935 935 1870 2011 2011 4022 
No paired DNA 459 10 469 46 14 60 505 24 529 
Total 1535 1086 2621 981 949 1930 2516 2035 4551 
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 Study Sample for Aim 2 
The sample for aim 2 made additional exclusions for ancestry as described in paper 2. 
After quality control, the final analysis sample for aim 2 (n=4514 total samples) included dyads 
with both mother and child genotype data as well as incomplete dyads with only mother or child 
genotype data after excluding samples in which the first three principal components were 
greater than 3 standard deviations from the mean (Table 3). 
 
Table 3. Final analysis sample for aim 2. 
 Cases Controls Total 
 Mother Child Total Mother Child Total Mother Child Total 
Paired Dyad 1063 1063 2126 925 925 1850 1988 1988 3976 
No paired DNA 450 20 470 45 23 68 495 43 583 
Total 1513 1083 2596 970 948 1918 2483 2031 4514 
 
Human Subjects 
 Women provided informed consent prior to participation in the Norwegian Mother and 
Child Cohort Study. MoBa received approval from the Institutional Review Board of the 
Norwegian Institute of Public Health. The parent study in which the samples were genotyped 
was approved by the Institutional Review Boards of the Norwegian Institute for Public Health 
and the University of North Carolina at Chapel Hill. 
This dissertation uses previously collected, de-identified data and no study participants 
were contacted for additional information. Data were encrypted and password protected. The 
project was approved by the Institutional Review Board of the University of North Carolina at 
Chapel Hill on April 5, 2015. 
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C. Outcome Assessment 
Details of the validation study for preeclampsia have been previously described.223 In 
brief, preeclampsia was defined by the American College of Obstetrics and Gynecologists 
(ACOG),27 which includes the following two criteria:  
1) Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure of ≥ 90 mm Hg 
occurring after 20 weeks’ gestation in a woman whose blood pressure has been 
previously normal, and 
2) Proteinuria, with excretion of ≥ 0.3 g of protein in a 24-hour urine specimen or as 
measured by 1+ on urine dipstick. 
This 2013 revision of this definition included clinical symptoms, however, we used the 
criteria current at the time of the validation study. Diagnoses of preeclampsia with severe 
features, eclampsia, or HELLP syndrome (a variant of preeclampsia marked by hemolysis, 
elevated liver enzymes, and low platelet count) are often considered indications for induction of 
delivery. Thus, these cases often go into the hospital system immediately after diagnosis and 
information cannot be validated solely from the antenatal record. We therefore considered as 
“true cases” any case with an ICD-10 code of severe PE (O14.1) or HELLP syndrome (O14.2) 
and delivery <39 weeks. All cases with an ICD-10 code of eclampsia are routinely validated by 
the MBRN and are included as true cases.  
We also performed analyses within subtypes of preeclampsia. Although ACOG 
guidelines also include clinical symptoms for the diagnosis of severe preeclampsia, study data 
were limited to blood pressure and urinalysis values recorded on the antenatal chart, along with 
birth outcome features captured by the Medical Birth Registry. Criteria for these subtypes are as 
follows: 
Severe preeclampsia  
In this study, severe preeclampsia meets the general criteria described above and at least one 
of the following additional requirements in the antenatal record27: 
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1) Systolic blood pressure of at least 160 mm Hg or diastolic blood pressure of 110 mm 
Hg, or 
2) Urinary protein excretion of at least 5g/day in a 24-hr urine specimen or at least 3+ 
urine dipstick protein measurement. 
Additionally, cases in this study were classified as severe if they were diagnosed as 
having eclampsia or HELLP syndrome in the MBRN. 
 
Early-onset preeclampsia 
Early-onset preeclampsia is preeclampsia that meets the any criteria for preeclampsia 
diagnosed prior to 34 completed weeks of gestation.27 Estimated gestational age at time of 
preeclampsia diagnosis was recorded in the antenatal record. Cases were also considered 
early-onset if they met the criteria for preeclampsia as described above and had a delivery 
before 34 weeks’ gestation. 
Preeclampsia with delivery prior to 34 weeks’ gestation 
The subset of early-onset preeclampsia cases that also had a delivery before 34 
weeks’ gestation were also considered separately. 
 
Preeclampsia complicated by small for gestational age 
Preeclampsia complicated by small for gestational age was defined as cases meeting 
the criteria for general preeclampsia described above plus an infant born small for gestational 
age (<10th percentile). Gestational age provided from ultrasound estimation and birthweight 
were attained from the MBRN. Norwegian population-based tables for fetal term prediction and 
size assessment were provided from eSnurra Norway (http://www.nsfm.no/esnurra/0.php) to 
compare percent deviation from median birthweight for each gestational age and with the 
population percentiles to determine whether an infant falls below the 10th percentile. 
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D. Exposure Assessment 
Sample Collection and DNA Extraction 
 Maternal and child blood samples were collected for the MoBa study as described 
above. For DNA extraction, whole blood was collected in a 7-ml EDTA tube (Becton-Dickson, 
Plymouth, UK), labeled with the woman’s name and national identification number, and shipped 
overnight to the MoBa Biobank, where samples were processed on the day they were received. 
Once received at the Biobank, whole blood was aliquoted into two polypropylene deep-well 
plates (ABgene, Surrey, UK) using Tecan pipetting robots. DNA was then extracted manually 
using the FlexiGene kit (Qiagen, Hilden, Germany). Quality control was performed on all DNA 
samples using a spectrophotometer (Spectramax 190, Molecular Devices, Sunnyvale, CA) to 
test optical density. DNA needed a purity of 1.6-2.0 260/280 ratio, a concentration greater than 
20ng/μl, and an optical density at zero for the negative control to be included in each 24-sample 
batch. DNA was then aliquoted into 1.4-ml deep-well plates and stored at -20 °C, where 
connected to backup power and an alarm system. Samples were collected and processed at the 
hospital before being sent to the MoBa Biobank.221 
 
Illumina Process 
The Illumina HumanCoreExome+ assay (Illumina, Inc., San Diego, CA) has been 
described in more detail by Illumina.224 The HumanCoreExome+ BeadChip includes 
approximately 240,000 genome wide association markers and 240,000 exome markers plus 
space for additional custom markers.  
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Tag Selection for Parent Study 
 Custom selected SNPs included SNPs on the Illumina Cardio-Metabolic chip not already 
included in the HumanCoreExome+ manifest, with particular emphasis on three regions of 
interest: 1) regions associated with systolic blood pressure, diastolic blood pressure, and 
hypertension; 2) regions associated with myocardial infarction, chronic heart disease, and 
chronic kidney disease; and 3) regions associated with body mass index, lipids, and C-reactive 
protein. Additional candidate genes were selected based on the following pathways and 
sources: 1) existing associations with preeclampsia and/or commonly hypothesized genes, 2) 
inflammation, 3) angiogenesis, 4) apoptosis, 5) smoking detoxification, 6) carbon monoxide 
signaling, 7) smoking addiction, and 8) novel pathways including Vitamin D and in vitro studies. 
For each gene, the Illumina database was queried for all polymorphism design scores within our 
genes of interest, allowing for 20kb upstream and 10kb downstream margins. A scoring 
algorithm for each SNP was created, taking into account Illumina design score, Illumina error 
codes, DNA coding changes, and presence in a possible 5’ promoter site. The composite SNP 
database was then analyzed using TagZilla (http://tagzilla.nci.nih.gov) to identify haplotype 
tagging SNPs with an R2 criteria of 80%. In total, 525,125 variants were genotyped for the larger 
parent study of genetics and preeclampsia. 
 
Gene and SNP Selection 
 Gene and SNP Selection for Aim 1 
For aim 1, 66 genes involved in three canonical pathways were selected for analysis 
from the parent study. Genes were selected from the following canonical pathways relevant to 
carbon monoxide and nitric oxide activity: 1) endothelial nitric oxide synthase (eNOS) signaling, 
2) heme degradation, and 3) hypoxia-inducible factor 1-alpha (HIF1A) signaling. (Table S1). 
Particular emphasis was placed on genes in which there were prior associations with other 
cardiovascular disease or are hypothesized to be involved in reproductive processes 
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SNPs were extracted for this analysis from the overall study database after genetic 
quality control using PLINK 1.07. SNPs were extracted for each gene based on position of 10kb 
upstream and downstream margins around the transcription start and end sites for each gene. 
After QC, 1518 SNPs were selected and analyzed for aim 1. 
 
Gene and SNP Selection for Aim 2 
For aim 2, 124 genes involved in response to cigarette smoke components were 
identified from 8 canonical pathways. These included the same pathways in aim 1: 1) 
endothelial nitric oxide synthase (eNOS) signaling pathway, 2) heme degradation, 3) hypoxia-
inducible factor 1-alpha (HIF1A). They also included five additional pathways related to smoking 
detoxification: 4) xenobiotic metabolism, 5) aryl hydrocarbon receptor signaling, 6) glutathione-
mediated detoxification, 7) nicotine degradation II, and 8) nicotine degradation III. These 
pathways and their associated genes are described in Table S2. A total of 1,915 SNPs were 
selected and analyzed for aim 2, using a 10kb upstream and downstream margin around the 
transcription start and end sites of each gene. 
 
 Genotyping and Quality Control 
 SNPs were genotyped by the UNC Mammalian Genotyping Core using the 
HumanCoreExome+ chip from Illumina (Illumina, Inc., San Diego, CA). Thirty-five samples failed 
initial genotyping at the lab due to chromosomal aberration (1), DNA contamination (14) or low 
concentration, no DNA, or poor quality DNA (20). These samples were not included in the QC 
process. Genotyping of 12 samples on one plate (NPE-617) was repeated due to a defective 
chip; failed samples were dropped and repeated samples were retained for analysis. A total of 
525,125 variants were typed. 
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This study is not powered to assess extremely rare variants, and SNPs with a minor 
allele frequency of <5% were excluded. 118,391 variants had a minor allele frequency of <5% 
and were excluded from analysis. 
Hardy Weinberg Equilibrium (HWE) was examined in PLINK among non-cases stratified 
by relationship type (mother or child) (p<0.001). A QQ plot of observed versus expected Hardy-
Weinberg p-values was generated to determine an appropriate cut point for deviation. SNPs 
were determined to be outside of HWE if p<0.001. Any SNPs showing evidence of Hardy 
Weinberg disequilibrium were examined by Jason Luo of the Mammalian Genotyping Core to 
determine possible reasons and if disequilibrium was due to genotyping error. SNPs that 
showed HWE disequilibrium after review were dropped from analysis (n=9,457). 
Data were cleaned using best practices as described by the Cohorts in Heart and Aging 
Research in Genomic Epidemiology (CHARGE) consortium.225 Data were cleaned using PLINK 
1.07. (http://pngu.mgh.harvard.edu/purcell/plink). Monomorphic loci were dropped (n=153,659). 
Both subjects and SNPs where call rates were <95% were dropped. All samples had 
genotyping information for at least 95% of genotypes and none were excluded due to missing 
genotype information. 123 SNPs were missing genotype information for all individuals and were 
excluded. One additional SNP (exm2216494) was missing genotype information for >95% of 
individuals and was excluded.  In total, 124 variants were excluded due to missing information 
for at least 95% of individuals. 
Sex-specific markers were genotyped and inspected. Three individuals were excluded 
because reported sex phenotype was female and sex based on heterozygosity was determined 
to be male. Inbreeding coefficients were calculated using PLINK 1.07 (plink --file data --het) 
based on observed number of homozygous genotypes versus expected number of homozygous 
genotypes. An exclusion threshold of F £ -0.15 was used. No individuals met this threshold and 
were excluded from the analysis based on inbreeding coefficient.  
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The study sample uses data from a limited geographic area and an ethnically 
homogeneous population which presents the possibility of individuals to be related. Statistical 
analyses make the assumption of independence of samples, and residual relatedness can lead 
to an overestimation of the effect of a variant on the outcome because genotypes in families will 
be overrepresented. Heritability was examined using PLINK identity-by-descent (IBD) to confirm 
parent-child relatedness, and to discover any fugitive relatedness in the cohort. Cryptic 
associations were assessed in PLINK 1.07 using identity-by-descent analysis. PLINK provides 
an estimate of proportion IBD (pi-hat) between each pair of samples. Identical samples (or 
monozygotic twins) have an expected pi-hat=1, parent-offspring or sibling pairs have an 
expected pi-hat=0.5, second-degree relatives (aunt-niece/nephew) have an expected pi-hat 
=0.25, and third-degree relatives (first cousins) have an expected pi-hat=0.125 
Pairs with a high degree of relatedness (pi-hat>0.125) were flagged and inspected. Pairs which 
were indicated to be related in MoBa but were not confirmed to be related by IBD analysis were 
dropped. Pedigrees were examined to retain the most complete data among families. In 
instances where there were two related mothers (sisters, cousins) the mother with associated 
child data was retained. If both mothers had paired child data, then the pair with the least 
amount of missing SNP data was retained. In instances in which there were two related children 
for a single mother (siblings or half-siblings), the closest relationship was selected, and 
otherwise one sibling was randomly selected. 
One pair in which one of the samples was a mother and one was a child was 
unexpectedly found to be a duplicate. This pair of samples was dropped since one was likely a 
sample swap. Among pairs that were not labeled as being related, 55 pairs were found to be 
genetically related at a pi-hat>0.125. Some of these pairs were part of the same pedigree, so 
ultimately 42 separate samples were excluded because of relatedness. 
 IBD analysis in PLINK was also used to confirm relatedness in mother-child pairs that 
were labeled as being related. Mother-child pairs should have a pi-hat value of approximately 
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0.5. Of labeled related pairs, 9 were found to be genetically unrelated. In these cases, both 
mother and child were dropped, as there is no certainty which sample is mislabeled. 
Several measures were put in place in this study to ensure quality control of genotyping.  
Since dyad analysis is dependent on paired DNA, linked mother and child DNA were analyzed 
on the same plate to reduce the possibility of losing information from both if a problem occurs, 
but cases and controls were randomly distributed by plates to reduce systematic error.  
Blind duplicate samples were included to identify genotyping errors by the examination 
of discordant alleles between duplicate samples.  For this analysis, both study (MoBa) 
duplicates and CEPH (Centre d’Etude du Polymorphisme Humain, a known family trio) controls 
were included. In total, 186 unique samples were a part of the blind assessment. 
Fifty-one duplicate pairs were chosen randomly from the study sample to be included as 
duplicates (Table S3). Duplicate samples with high levels of discordance (>2 instances of SNP 
mismatch) were excluded. Two samples were excluded due duplicate mismatch (Table S4). 
After exclusion of discordant samples, all SNPs were highly concordant among duplicate 
samples, and no SNPs were excluded for analysis based on discordance. 
CEPH duplicates (n=208 pairs), representing five families composed of 15 individuals 
from the Coriell Institute CEPH Utah pedigrees were selected and genotyped (Table S5). 
Twenty-eight trios of 84 samples were included for quality control.  Each sample was repeated 
between 4 and 9 times over the course of the assay. Between one and seven CEPH controls 
were included on each plate (Table S6). Ten of these CEPH duplicate samples were included 
on the same plate and 74 were included on different plates, which allowed for inter- and intra- 
plate quality control (Table S7). 
Out of the 208 CEPH blinds, there were three pairs of duplicate samples that each had 
two discordant SNPs. The two discordant SNPs were the same for each duplicate pair 
(rs7719740 on chromosome 5 and rs4820872 on chromosome 22). Although the same two 
SNPs were discordant in three separate pairs, the discordance was driven by one sample that 
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was repeated in each pair; the other duplicates of this set were all 100% concordant. (Table 
S8). Therefore, these two SNPs were not dropped from the analysis. All other CEPH duplicates 
had identical genotypes. These error rates were within our pre-specified range of acceptable 
values. 
Known CEPH trios of child, mother, and father were also included for quality control by 
confirming mendelian inheritance. Five families composed of 15 individuals from the Coriell 
Institute CEPH Utah pedigrees were selected and genotyped (Table S5). Twenty-eight trios 
were included for quality control.  
PLINK version 1.07 was used to assess mendelian inheritance among the 28 trios (plink 
--bfile cephtrios --mendel). Overall genotyping was 0.999237 and 547,082 variants that passed 
initial quality control screening were included in this step. No mendelian errors were detected. 
No SNPs were excluded from analysis based on quality control assessment of CEPH trios. 
 
Quality Control Summary and Flowcharts 
Individual Samples 
Genotyping was conducted on an Illumina HumanCore ExomeChip+ platform with 4,799 
samples typed for 545,125 SNPs. The samples included women for this study, quality control 
samples, and repeated samples due to initial genotyping error.  
 
Of these 4,799 samples genotyped, the following were removed during the QC process: 
84 CEPH trio samples included for consistency of duplicates and mendelian inheritance 
QC 
22 known duplicates included for QC  
12 repeated samples due to defective chip 
3 repeated samples due to lab error 
35 that failed initial genotyping for other reasons: 
  1 due to chromosomal aberration 
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  14 due to DNA contamination 
  20 due to low concentration, no DNA, or poor quality DNA 
  
4,643 samples were assessed in PLINK for further QC.  
92 samples were excluded during this phase: 
29 blind duplicates included for QC 
2 samples discordant with blind duplicates 
3 sex discrepancies 
58 related subjects with >0.125 IBD 
 
No individuals had >5% missing genotype data or inbreeding problems (F<-0.15 inbreeding 
coefficient). 
 
In total, 248 individuals were dropped from the original genotyped samples and 4,551 were 
available for analysis. Table S9 provides IDs and reasons for all sample exclusions made during 
the quality control process. 
 
Single Nucleotide Polymorphisms 
Samples were typed on the HumanCore ExomeChip+ platform for 525,125 total SNPs. 
123 SNPs were missing genotype information for all individuals and were excluded (Table S6). 
One additional SNP (exm2216494) was missing genotype information for >5% of individuals 
and was excluded (Table S10).   
 
545,001 SNPs entered the QC process. Of these: 
153,659 were monomorphic.  
9,457 were outside of HWE p<0.001 
118,391 had a minor allele frequency of <5% 
 
  
 
60 
In total, 281,631 SNPs were dropped from the original typed variants and 243,494 SNPs were 
available for analysis.  
 
 
Figure 7. Flowchart for sample quality control process. 
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Figure 8. Flowchart for SNP quality control process. 
 
Genetic Ancestry 
As indicated the directed acyclic graphic description for aim 1, ancestry may confound 
the relationship between a genetic variant and the outcome, known as population stratification 
bias. In genetic studies that employ logistic regression, eigenstrata are generally included as 
covariates to reduce population stratification bias, however, the use of log-linear Poisson 
regression with a mating type parameter in the model should reduce the need for adjustment 
with eigenstrata. Nevertheless, because of concern that missingness may depend on 
membership in subpopulations, we assessed ancestral origin in our population. 
  
525,125	variants	genotyped
-123	missing	genotype	for	all	
individuals
525,002	have	SNP	information
525,001	pass	initial	genotyping	
>=95%
-1	missing	genotype	
information	for	>=5%	of	
individuals
525,001	pass	QC	assessment	for	
blinds	and	mendelian inheritance
371,342	polymorphic	SNPs
-153,659	monomorphic	SNPs
9,457	SNPs	outside	of	HWE
361,885	SNPs
243,494	SNPs	pass	all	QC	filters
118,391	SNPs	with	MAF	<5%
1,915	SNPs	in	124	genes	selected	for	Aim	21,518	SNPs	in	66	genes	selected	for	Aim	1
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Quantile-quantile plots and calculation of genomic control lambda226 were assessed to 
detect evidence of population stratification and indicated no systematic test statistic inflation, 
suggesting that population stratification was negligible (Figure 9).  
 
Figure 9a.     Figure 9b. 
  
Figure 9. Quality control quantile-quantile plots for maternal and child genotypic effects among 
genome-wide data of 263,494 variants to assess genomic inflation. Test results (observed -
log10p values) are plotted against the expected -log10p values for each of 263,494 SNPs in the 
sample. Figure 9a. Q-Q plot of maternal genotypic effects among maternal samples. Genomic 
inflation factor, lambda=1.01. Figure 9b. Q-Q plot of child genotypic effects among child 
samples. Genomic inflation factor, lambda=1.03. 
 
The top 3 principal components of genetic variation were plotted for the MoBa data 
together with the 1000 Genomes reference populations and visually inspected to assess 
evidence of admixture (Figure 10).  
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Figure 10. Top three axes of genetic variation based on common SNPs for our Norwegian 
Mother and Child Cohort sample (MOBA) compared to 1000 Genomes reference populations. 
Plots are show for axes 1 and 2, axes 1 and 3, and axes 2 and 3. Reference populations are: 
CEU: Utah Residents with Northern and Western Ancestry; CHB: Han Chinese in Beijing, 
China; PUR: Puerto Ricans from Puerto Rico; MXL: Mexican Ancestry from Los Angeles, USA; 
CLM: Colombians from Medellin, Colombia; YRI: Yoruban in Ibadan, Nigeria. 
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Cases and controls were also plotted along ancestral axes to examine differential case 
and control status by ancestry (Figure 11). 
 
Figure 11. Case and control status of the study sample plotted along the first two axes of 
variation for genetic ancestry. 
 
 
Samples that fell outside of the European ancestral population were excluded in a 
sensitivity analyses for Aim 1. For aim 2, we excluded all samples that fell outside 3 standard 
deviations from the mean for the top three principal components. 
 
Maternal Smoking  
Maternal smoking was included an effect measure modifier in our study to assess gene 
by environment interactions. Smoking is self-reported on the early and late pregnancy MoBa 
questionnaires through a series of questions that ask about current smoking, smoking prior to 
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pregnancy, and smoking in the intervening window between questionnaires; quantity of 
cigarettes smoked; age at smoking initiation; whether the woman stopped smoking; age or week 
of pregnancy when stopped smoking; and time of day when smoking primarily occurs. Smoking 
was examined at three time periods, as these provide different and important information. 
Smoking during the first trimester will always precede preeclampsia, while symptoms of 
preeclampsia may exist before smoking is reported on the third questionnaire. Smoking as late 
as the third trimester, however, likely indicates both a greater level of smoking and a greater 
addiction, as women are encouraged to quit as soon as they become pregnant. As with all self-
reported smoking variables, there is potential for underreporting. However, a recent validation 
study of self-reported smoking and plasma cotinine indicated that reported smoking on the 
MoBa questionnaire is a valid marker of tobacco exposure (Sensitivity=82%, 
Specificity=99%).227 Women who falsely reported non-smoking compared to women who 
correctly reported non-smoking were more often cohabiting (61% vs 42%) rather than married 
(35% vs 56%) and had lower education (55% vs 37% with education 12 years or fewer).227 Self-
reported maternal smoking in the MoBa cohort is 23% in the first trimester and 9% in the third 
trimester. Self-reported maternal smoking in the study sample was 19% in the first trimester and 
8% in the third trimester.  
We created a dichotomous time-specific smoking variable for any maternal smoking 
during the window of 11 to 20 weeks’ gestation. We used smoking during this time period for our 
primary analysis, as we considered it to be the period of greatest biological relevance to our 
hypothesis during which trophoblast invasion, spiral artery remodeling, and maternal blood flow 
perfusion into the intervillous space occur.228 If a person indicated she had never smoked, we 
considered her a non-smoker at our time point. If she indicated she did not currently smoke at 
the time of the early survey and had no other evidence of smoking at any time point, we 
considered her a non-smoker. If a woman indicated she currently smoked “sometimes” or “daily” 
in the early pregnancy questionnaire, we considered her to be a smoker. If she indicated that 
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she did not currently smoke at the time of the survey, but noted a quit week after gestational 
week 10 on either the early or late questionnaire, we considered her to be a smoker. If a woman 
was missing smoking information on the early survey, we supplemented with information from 
the late survey. If she indicated a smoking quit week on the third survey after 10 gestational 
weeks’, we considered her a smoker. If she indicated being a daily smoker in the late survey, 
we assumed she had been smoking in weeks 11 to 20. Smoking was noted as missing if we 
were missing information from both the early and late surveys, or smoking status was 
ambiguous based on the existing information.  
 
E. Additional Covariates 
Potential risk factors for preeclampsia include maternal age (both young and old), race, 
nulliparity, change in partner, long interpregnancy interval, high body mass index, prior 
preeclampsia, multi-fetal pregnancy, diabetes, and low socioeconomic status. Covariates of 
interest were obtained from the early pregnancy MoBa questionnaire and the Medical Birth 
Registry of Norway. The following covariates were considered: 
 
Maternal Age 
 Maternal age at delivery was recorded on the MoBa questionnaire and in the MBRN. 
 
Parity 
 Number of previous deliveries obtained from the MBRN. Parity was considered the 
number of deliveries stated by the mother or the number of previous deliveries reported by the 
MBRN, beginning at gestational week 16 (1967-2001) or gestational week 12 (2002 to present); 
we used whichever number reported was greater. 
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Body Mass Index 
 Pre-pregnancy body mass index was calculated from self-reported weight and height 
from early MoBa questionnaire. Implausible values were excluded (n=5). 
 
Maternal Education 
Maternal education information was obtained from the questionnaire item asking 
participants “What education do you and the baby’s father have?” Levels of education included 
9-year secondary school, 1-2 year high school, technical high school, 3-year high school for 
general studies/junior college, regional technical college/4-year university degree (Bachelor’s, 
teaching, nursing, etc.), more than 4-year university or technical college (Master’s, medical 
doctor, PhD, etc.), and other education. Participants were asked whether each level was 
completed or on-going. 
 
Birth Outcomes 
 Other birth outcome information including gestational age and birthweight were obtained 
from the MBRN. Small for gestational age was calculated using Norwegian population 
percentiles. Gestational age and birthweight were assessed as independent covariates and 
were also used to determine preeclampsia subtypes. 
 
F. Statistical Analysis 
Descriptive Statistics 
Descriptive statistics were performed for potential covariates. Continuous variables were 
examined for measures of central tendency and spread, including the mean, median, standard 
deviation, and interquartile range. Deviations from a normal distribution including presence of 
outliers, skew, and kurtosis. For categorical or binary covariates, minimum and maximum 
  
 
68 
values, and spread of data within categories were assessed. Missing covariate values were 
tabulated for all variables and analyzed for their associations with the exposure and outcome to 
determine if missing data imputation was to reduce bias due to missingness. Bivariate 
associations between exposures (smoking) and outcomes, covariates and outcomes, and 
exposures and covariates were analyzed to inform model-building. 
 
Specific Aim 1 Statistical Analysis 
Aim 1 uses log-linear Poisson regression to estimate relative risks for the main effects of 
CO and NO related genes in the eNOS signaling, heme degradation, and HIF1A signaling 
pathways on preeclampsia.  
Although preeclampsia is a maternal disease, it involves the placenta, an organ of fetal 
origin. Because of this unique connection, it is plausible that both maternal genotype and fetal 
genotype may independently or jointly play a role in the development of preeclampsia. Wilson et 
al. posit that both maternal and fetal genes related to vascular remodeling may be related to 
preeclampsia risk,229 and others have recently recognized the importance of investigating both 
maternal and fetal genotype in obstetric complications.124,230 Additionally, maternal and fetal 
genotype are correlated, as half of child alleles are transmitted from the mother, and thus, fetal 
genotype may confound the association between maternal genotype and outcome, and vice 
versa.213,231 Both of these aspects require that maternal and fetal genotype be simultaneously 
considered as predictors in a single model using either of the proposed methods. 
Logistic regression for the estimation of odds ratios is a commonly used analysis 
technique for case-control studies of candidate genes. We initially fit separate logistic models for 
maternal and fetal genotype to calculate unadjusted odds ratios to aid in determining if models 
are behaving as expected, however, other models can be used to incorporate the related 
mother-child genotype. A logistic model for the association of each SNP with preeclampsia can 
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be used including parameters for both maternal and fetal genotype.  This model is of the 
following form proposed by Shi et al.213: 
!" Pr	('|), +)1 − Pr	('|), +) = 0 + 234(563) + 274(567) + 834(963) + 874 967  
where M and C are the number of copies of the variant allele carried by the mother and child, 
respectively; 4 is an indicator function which is 1 when the expression is true and 0 otherwise; 23 
and 27 are natural logs of the mother’s risk (S1 and S2) when the mother has 1 or 2 copies of the 
variant allele, respectively; 83 and 87 are natural logs of the child’s risk (R1 and R2) when the 
mother has 1 or 2 copies of the variant allele, respectively; and 0 is the natural log of the 
underlying risk in the source population.  
 Logistic regression is a valid technique provided there is no underlying population 
substructure,231 however, it does not take advantage of particular features of mother-child dyad 
case-control data. With mother-child pairs for cases and controls, one can make certain 
assumptions and impose certain nonlinear constraints that are particular to family data (dyads 
and triads) to significantly improve power.213,231,232 This study uses log-linear Poisson regression 
with the expectation-maximization algorithm as proposed by Shi et al.213 to enforce these 
constraints and estimate risk ratios. 
 As with the logistic model, we must assume the disease is rare in the population and that 
the population is risk-homogenous and does not covary with allele prevalence across 
subpopulations.213 The parent-child relationship, however, also implies certain family based 
constraints.  Additional assumptions can also improve precision: 
1) Mendelian inheritance 
2) Parental mating symmetry for the studied locus in the source population 
3) Allelic exchangeability 
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As above, M, F, and C are 0, 1, or 2, for the number of variant alleles that the mother, 
father, or child carries, respectively.  Assuming Mendelian inheritance, the expected frequency 
of parent pairs is denoted by μmf, in which the mother has m copies of the variant allele and the 
father has f copies. Triads of mothers, fathers, and children are classified by the number of 
variant alleles carried by each of the mother, father, and child, which results in a 15-cell 
multinomial distribution.212,233,234 With mother-child dyads, this number is reduced to 7 cells by 
collapsing over the missing fathers. These frequencies are shown in Tables 4 and 5. Mendelian 
inheritance imposes the constraint that the expected counts for (1, 0) and for (1, 2) sum to the 
expected count for (1, 1).  
 
Table 4. Expected frequencies of control mother-child pairs under Mendelian transmission of 
parental alleles. 
 C = 0 C = 1 C = 2 
M = 0 μ00 + (1/2) μ01 (1/2)μ01 + μ02 0 
M = 1 (1/2)μ10 + (1/4) μ11 (1/2)[μ10 + μ11 + μ12] (1/4)μ11 + (1/2)μ12 
M = 2 0 μ20 + (1/2)μ21 μ22 + (1/2)μ21 
 
 
Table 5. Expected frequencies of case mother-child pairs under a multiplicative model for risk. 
 C = 0 C = 1 C = 2 
M = 0 B[μ00 + (1/2) μ01] BR1[(1/2)μ01 + μ02] 0 
M = 1 BS1[(1/2)μ10 + (1/4) μ11] (1/2)BR1S1[μ10 + μ11 + μ12] BR2S1[(1/4)μ11+(1/2)μ12] 
M = 2 0 BR1S2[μ20 + (1/2)μ21] BR2S2[μ22 + (1/2)μ21] 
  
 In addition to Mendelian inheritance, one can also assume parental mating symmetry, 
that is μmf = μfm at the locus under study. This assumption implies an additional constraint that 
the expected difference in the source populations (Table 4) between the count for (1,0) and 
(0,1) equals the expected difference between the count for (1,2) and (2,1); (1/4)μ11 – μ02 is the 
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same as (1/4)μ11 – μ20. This constraint reduces the number of parental “mating type” parameters 
from 9 to 6. 
 A third potential assumption is parental allelic exchangeability, which is when for a set of 
four alleles carried by a pair of parents, the alleles are randomly allocated to the two individuals; 
μ11 = 4μ02 = 4μ20. The exchangeability assumption implies the first two assumptions, and thus, 
the expected difference between the count for (1,0) and (0,1) and the expected difference 
between the count for (1,2) and (2,1) are equal to each other which are equal to zero. This 
implies a third constraint.  
 To impose these constraints, log-linear Poisson regression was employed as outlined by 
Shi et al.213 This model takes the following form: !" : ;<=> = 	?<= + @A + 23A4<63 + 27A4<67 + 83A4=63 + 87A4=67 
where : ;<=>  is the expected value of the counts of families with each of maternal genotypes, 
child genotypes, and case or control status and A is case or control status where A = 1 for a 
case and A = 0 for a control; and I(m=j) and I(c=i) are indicators for whether a mother or child has j 
(= one or two) copies of the variant allele. The ?<= parameters allow flexibility of the control-
mother distribution (avoiding the need to assume Hardy-Weinberg for the source population) 
and ensure that the parental genotype distribution is flexible as it is only constrained by the 
family-based constraints. Poisson regression provides a way to impose constraints on these 
parameters. Here, the model is based on the natural log of the expected cell count, and subject 
to non-linear constraints, as described above. Those constraints can be imposed by observing 
that the complete data (if the fathers had also been included) would follow a log-linear model 
and consequently statistical missing data methods (the EM algorithm) can be used to maximize 
the likelihood.235 In a triad analysis, one would use the 15 cells, but here, fathers’ genotypes are 
missing by design. The program uses the expectation-maximization algorithm to maximize the 
fatherless likelihood, and enables one to impose the constraints of family structure. Missingness 
must be noninformative, but since all fathers are missing, one can easily make this assumption. 
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Using log-linear Poisson regression with the EM algorithm to impose one or several constraints 
of family structure should improve power compared to the logistic model. Doing so also provides 
an opportunity to investigate imprinting or parent of origin effects. 
LEM software236 was used to fit these models. The expectation maximization algorithm 
was used to incorporate dyads with missing genotypes. Likelihood ratio tests comparing 
reduced models with maternal genotype or child genotype with the saturated model were 
performed to determine p-values for both maternal and child genetic effects, each adjusted for 
the other genotype. A 4 degree-of-freedom likelihood ratio test was used to determine joint p-
values for simultaneous tests of maternal/child genetic effects. Point estimates and 95% 
confidence intervals for relative risks were calculated for each SNP for both maternal and child 
genotype. 
Confounders were identified a priori based on existing literature. A directed acyclic graph 
(DAG) was used to identify a minimally sufficient adjustment set. DAGs for maternal genotype 
as the exposure and fetal genotype as the exposure are shown in Figure 7. There are few 
factors that directly affect our exposure (SNP), therefore, there are very few that are true 
confounders and necessary for adjustment in the models. 
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Figure 12. Directed Acyclic Graph for Aim 1 
 
Based on the DAG, aside from correlated familial genotype, ancestry is the only other 
potential confounder for the main effects of genes on preeclampsia. Population stratification 
occurs when there are differences in allele frequencies in cases and controls due to differences 
in ancestry rather than in true disease risk.156 Since all participants were required to speak 
Norwegian to participate in the study and Norway’s population is relatively homogeneous, 
population stratification bias may not be a considerable concern. However, studies of other 
Northern European populations have indicated significant heterogeneity even among small 
geographic areas.237,238 In genetic studies that employ logistic regression, eigenstrata are 
generally included as covariates to reduce population stratification bias, however, the use of log-
linear Poisson regression with a mating type parameter in the model should reduce the need for 
adjustment with eigenstrata. Nevertheless, because of concern that missingness may depend 
on membership in subpopulations, samples that fell outside of the European ancestral 
population were excluded in sensitivity analyses, as described in paper 1 methods. 
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To visually inspect results across the whole genome, we generated quantile-quantile 
plots of the observed versus expected -log10(p-values) for each SNP from the dyad models. We 
also calculated the genomic inflation factor, lambda226, for maternal and child genetic effects, 
which is based on comparing the median chi-squared value with its expectation under the null. 
Separate plots were generated for maternal and child effects. 
For Aim 1b, we examined these associations by preeclampsia subtype. We performed 
separate analyses for early-onset preeclampsia, severe preeclampsia, preeclampsia with early 
delivery, and preeclampsia accompanied by small for gestational age, all defined 
dichotomously. The criteria and sample for each subtype is described in Table 6. 
 
Table 6. Criteria and number of cases for preeclampsia subtypes 
Phenotype Criteria Case Pregnancies 
Preeclampsiaa • New onset systolic blood pressure ≥ 140 mm Hg 
or diastolic blood pressure of ≥ 90 mm Hg 
AND 
• Proteinuria ≥ 0.3 g/24-hr or ≥1+ on urine dipstick 
1545 
Severe preeclampsiaa General requirements of preeclampsia plus 
• Systolic blood pressure of ≥ 160 mm Hg or 
diastolic blood pressure of ≥ 110 mm Hg 
OR 
• Proteinuria ≥ 5g/24-hr or ≥3+ on urine dipstick 
308 
Early-onset preeclampsia General requirements of preeclampsia plus 
• Diagnosis prior to 34 completed weeks of 
gestation 
277 
Preeclampsia with early 
delivery 
General requirements of preeclampsia plus 
• Delivery prior to 34 completed weeks of gestation 132 
Preeclampsia with small-for-
gestational-age 
General requirements of preeclampsia plus 
• Infant born <10th percentile weight for gestational 
ageb 
349 
a Cases with a validated diagnosis of eclampsia in the Medical Birth Registry of Norway were included in 
the preeclampsia and severe preeclampsia phenotypes. 
b Population percentiles derived from Norwegian distribution, eSnurra Norway 
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Specific Aim 2 Statistical Analysis 
For aim 2, we extended the log-linear Poisson regression models used in aim 1 to 
include interactions between genotype and smoking. Smoking was reported at several time 
points during pregnancy in the early and late pregnancy questionnaires and descriptive statistics 
were examined at each time point. Missing smoking values were analyzed for associations with 
the exposure and outcome to inform the likelihood of bias to missingness. Bivariate associations 
of smoking with each SNP and smoking with preeclampsia were analyzed. The primary goal of 
aim 2 was to determine if maternal smoking modified the relationship between SNP and 
preeclampsia. In aim 2, we extended the model in aim 1 to include two maternal and two child 
genetic risk parameters to saturate for codominant genetic main effects, and an interaction term 
was included to assess genotype by environment interactions as follows: ln : ;<=>E = ?<= + @A + F4E + GA4E + 23A4<63 + 27A4<67 + 83A4=63 + 87A4=67 + HA4E×J 
Where E (Nmcde) is the expected value of the counts of families with each of maternal genotypes, 
child genotypes, case or control status, and smoking status; d is case or control status where A = 1 for a case and A = 0 for a control; I(e=1) is an indicator for maternal smoking; and G is the 
number of copies of the variant allele that the mother carries (when assessing maternal 
interaction) or that the child carries (when assessing child interaction). The ?<= parameters 
allow flexibility of the control-mother distribution (avoiding the need to assume Hardy-Weinberg 
for the source population) and ensure that the parental genotype distribution is only constrained 
by the family relationships.  
DAG analysis was used to determine inclusions of any covariates (Figure 13).  
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Figure 13. Directed Acyclic Graph for Aim 2 
 
 DAGs are not well-equipped to fully demonstrate effect measure modification, however, 
one can show covariates that may independently confound the relationship between the 
environmental factor and outcome (smoking and preeclampsia) and the relationship between 
the genetic factor and outcome. Maternal age, maternal education, maternal BMI, income, and 
parity may all confound the relationship between maternal smoking and preeclampsia. Ancestry 
may confound both the relationship between SNP and preeclampsia and smoking and 
preeclampsia. There is a potential concern that a gene could affect a woman’s propensity to 
smoke, thus making smoking a mediator in the gene-outcome relationship, so this should be 
considered. 
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LEM software236 was used to fit these models. The expectation maximization algorithm 
was used to incorporate dyads with missing genotypes. Likelihood ratio tests comparing 
reduced models without the interaction term with the saturated model were performed to 
determine p-values for interaction for both maternal-genotype interaction and child-genotype 
interaction, each adjusted for the other genotype.  
Point estimates and 95% confidence intervals for relative risks were calculated for both 
maternal and child genotype-smoking interaction for each of the following: 
1) The risk of preeclampsia for maternal smoking compared to non-smokers stratified by 
maternal or child genotype 
2) The risk of preeclampsia for those with 1 copy or 2 copies of the variant allele 
compared to 0 copies stratified by maternal smoking  
3) The risk of preeclampsia of maternal smoking and having 1 or 2 copies of variant 
allele compared to a common referent group of non-smokers with 0 copies of the variant 
allele. 
 
Multiple Comparisons 
Because of the large number of SNPs being examined in this study, multiple hypothesis 
testing is a concern because some associations would be expected due to chance alone. This 
number increases as the number of hypotheses tested increases.  
The Bonferroni correction is frequently used to correct for multiple comparisons. The 
correction divides alpha by the total number of statistical tests to obtain a corrected “family-wise” 
Type I error rate. The Bonferroni correction, however, may be overly conservative, as it does not 
take into account the potential of correlation between tests. Therefore, to account for multiple 
comparisons, we calculated the false discovery rate (FDR), which is the expected proportion of 
type 1 errors (false positives) among all positive tests.239 We used an FDR of <0.05 (reported as 
Q-values) as our threshold for considering a finding noteworthy.  
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Interaction tests generally have low power to reject homogeneity,240 thus, in aim 2 we 
employed a more generous cutpoint that also acknowledges issues of multiple testing (P < 
0.001). We calculated both Bonferroni corrected p-values and false discovery rate239 but they 
may be overly conservative for this hypothesis-driven, yet exploratory analysis. 
 
Sensitivity Analyses 
We conducted several sensitivity analyses. As discussed, the top 3 principal 
components were plotted with 1000 Genomes reference populations. Cases and controls were 
plotted along ancestral axes to examine differential case and control status by ancestry. A 
sensitivity analysis was performed excluding outliers for the top principal component >0.01 and 
>0.04.  
Sensitivity analysis were also conducted among nulliparous women only, and among 
overweight/obese women only. 
 
Replication Methods 
Top hits for each phenotype and one additional SNP in LD for each top hit were sent to 
the InterPregGen consortium for replication analysis.241 InterPregGen samples from mother-
child pairs from the United Kingdom were used for replication analysis. Cases came from the 
UK Genetics of Pre-eclampsia (GOPEC) consortium. The same standard definition of 
preeclampsia was used. Population controls came from the Wellcome Trust Case-Control 
Consortium 1. Maternal samples (1875 cases, 5088 controls) and child samples (1004 cases, 
5286 controls) were analyzed separately for SNP associations with preeclampsia using logistic 
regression assuming an additive model. Samples from the GOPEC population included 
phenotype information for early preeclampsia, so were also analyzed as a subtype for 
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preeclampsia with severe features (505 maternal cases, 5051 maternal controls, 276 child 
cases, 5297 child controls). 
GOPEC contains DNA samples from mother-baby pairs of preeclampsia recruited at 
diagnosis between 1992 and 2009 for genetic studies of preeclampsia in the United 
Kingdom.241,242 Data for controls in GOPEC come from the WTCCC2 genome-wide analysis of 
UK 1958 Birth Cohort and UK National Blood Services.  
Case samples were assayed on the Illumina OmniExpress chip. Standard quality control 
procedures were conducted with PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/) 
and SMARTPCA (EIGENSOFT). Samples were excluded if individual call-rate was < 95%, 
heterozygosity was >3 standard deviations from the mean, any of the first 3 HapMap (based on 
CEU, YRI, CHB, JPT and GIH) principal axes of variation were >4 standard deviations from the 
mean, and recorded and DNA sex were discrepant.  Related individuals (IBD>0.1) with the 
lowest call-rate were preferentially removed. Variants were excluded if call-rate was <95%, they 
had deviations from Hardy-Weinberg equilibrium P<1 x 10-6, minor allele frequency (MAF) was 
<1%, and non-random missingness of uncalled genotypes was Bonferroni corrected P < 0.05.  
We used WTCCC1 population controls from the National Blood Donors Cohort and UK 1958 
Birth Cohort. These samples were genotyped on the Illumina 1.2M chip and the standard QC 
described above was then applied. SNPs that were not genotyped in the control dataset were 
imputed using IMPUTE2 (impute_v2.3.0) and SHAPEIT2 using the pre-phasing workflow 
against the 1000 Genomes Phase 1 reference panel.  
 
Power 
Power calculations were conducted by assuming Hardy Weinberg Equilibrium to find 
expected cell counts for controls. The additive log-linear model was then used to estimate 
expected cell counts for the cases. The chi-square noncentrality statistic was compared for the 
null model versus the saturated model to find the study power.  A sample size of 1064 case and 
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984 control dyads was used. The case-mother/control-mother model contains four relative risk 
parameters, as described in the methods. Tables 7 and 8 show power for two scenarios. For 
reference, a Bonferroni correction for 1,500 tests would be 3.3 x 10-5. 
 
Table 7. Study power for the association of genetic variants and preeclampsia (n=1064 cases, 
984 controls) with relative risk parameters R1=1.1, R2=1.2, S1=1.25, S2=1.5 at varying alpha 
levels and minor allele frequencies. 
Type I Error 
MAF 10-2 10-3 10-4 10-5 
0.10 0.55 0.28 0.12 0.05 
0.20 0.82 0.59 0.36 0.19 
0.30 0.90 0.72 0.50 0.30 
0.40 0.92 0.75 0.54 0.34 
 
Table 8. Study power for the association of genetic variants and preeclampsia (n=1064 cases, 
984 controls) with relative risk parameters R1=1.25, R2=1.5, S1=1.5, S2=2.0 at varying alpha 
levels and minor allele frequencies. 
Type I Error 
MAF 10-2 10-3 10-4 10-5 
0.10 >0.99 0.99 0.96 0.90 
0.20 >0.99 >0.99 >0.99 >0.99 
0.30 >0.99 >0.99 >0.99 >0.99 
0.40 >0.99 >0.99 >0.99 >0.99 
 
For power calculations of gene by smoking interactions, we assumed an exposure 
prevalence of 10%, based on a recent analysis of smoking by trimester in the MoBa cohort.75 
Smoking prevalence among MoBa mothers was 23% in the first trimester and 9% in the third 
trimester. Table 9 presents power calculations for a gene by smoking scenario in which I 
assumed relative risk parameters the same as above in the unexposed, and a doubling of effect 
in exposed mothers.  
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Table 9. Study power for the interaction of genetic variants and smoking and preeclampsia 
(n=1064 cases, 984 controls) with relative risk parameters R1=1.1, R2=1.2, S1=1.25, S2=1.5, 
RE1=1.1, RE2=1.2, SE1=1.5, SE2=2.0, and an environmental effect of 0.8 at varying alpha levels 
and minor allele frequencies. 
Type I Error 
MAF 10-2 10-3 10-4 10-5 
0.10 0.50 0.24 0.10 0.04 
0.20 0.79 0.55 0.32 0.17 
0.30 0.88 0.69 0.46 0.28 
0.40 0.90 0.72 0.51 0.32 
 
As expected, power to detect interactions is much lower, and analysis of all SNPs are 
considered exploratory. Since this is the first study to investigate gene by smoking interactions 
with preeclampsia, the exploratory investigation is warranted, despite low power. A much less 
conservative scenario (R1=1.25, R2=1.5, S1=1.5, S2=2.0, RE1=1.25, RE2=1.5, SE1=3.0, SE2=4.0, 
and environmental effect=0.8) has power of >90% at each minor allele frequency and 
demonstrates there is reasonable power to larger effects, which is plausible given that we are 
predicating on a strong environmental effect. 
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CHAPTER IV. A FAMILY-BASED STUDY OF CARBON MONOXIDE AND NITRIC 
OXIDE SIGNALING GENES AND PREECLAMPSIA 
 
Summary Paper 1 
Preeclampsia is thought to originate during placentation, with incomplete remodeling and 
perfusion of the spiral arteries leading to reduced placental vascular capacity. Nitric oxide (NO) 
and carbon monoxide (CO) are powerful vasodilators that play a role in the placental vascular 
system. Although family clustering of preeclampsia has been observed, the existing genetic 
literature is limited by a failure to consider both mother and child.  
We conducted a nested case-control study within the Norwegian Mother and Child Birth 
Cohort of 1,545 case-pairs and 995 control-pairs from 2,540 validated dyads (2,011 complete 
pairs, 529 missing mother or child genotype). We selected 1,518 single nucleotide 
polymorphisms (SNPs) with minor allele frequency >5% in NO and CO signaling pathways. We 
used log-linear Poisson regression models and likelihood ratio tests to assess maternal and 
child effects.  
One SNP met criteria for a false discovery rate Q-value <0.05. The child variant, 
rs12547243 in adenylate cyclase 8 (ADCY8), was associated with an increased risk (RR=1.42 
[95% CI: 1.20, 1.69] for AG vs GG, RR=2.14 [1.47, 3.11] for AA vs GG, Q=0.03). The maternal 
variant, rs30593 in PDE1C was associated with a decreased risk for the subtype of 
preeclampsia accompanied by early delivery (RR=0.45 [0.27, 0.75] TC vs CC; Q=0.02). Some 
evidence for association was seen for preeclampsia accompanied by small for gestational age 
for the child SNP, rs30562, of PDE1C (Q=0.06).    
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This study uses a novel approach to disentangle maternal and child genotypic effects of 
NO and CO signaling genes on preeclampsia.  
 
Introduction 
Preeclampsia is a common pregnancy complication, affecting approximately 2-7% of 
pregnant women, and typically characterized by new-onset gestational hypertension and 
proteinuria after 20 weeks’ gestation.2 The only definitive treatment is delivery, and it is a large 
contributor to medically-indicated preterm birth.4 Preeclampsia is associated with serious 
maternal and fetal morbidity and mortality.2 In the mother, preeclampsia may progress to 
eclampsia, and is also associated with placental abruption, thrombocytopenia, hepatic 
dysfunction including subcapsular liver hematoma, renal insufficiency, pulmonary edema, 
cerebrovascular accident, and death.2,27,32–34 Fetuses are at risk for intrauterine growth 
restriction, oligohydramnios, and intrauterine fetal demise.243 Preterm neonates incur additional 
risks associated with immaturity at birth and are at risk for perinatal death.2,42,43 Currently, low-
dose aspirin is the only therapy shown to reduce the risk of preeclampsia in high-risk 
individuals, but unfortunately this is only modestly effective (RR=0.87; 95% CI [0.79, 0.96]).25,244   
Though incompletely understood, preeclampsia is hypothesized to originate during 
placentation.2,4 Thus, both maternal and fetal components may contribute to the condition. 
During normal placentation, the fetal cytotrophoblast invades the maternal decidua and 
penetrates the walls of adjacent maternal spiral arteries. The arteries lose smooth muscle in 
order to increase vascular dilation. It is hypothesized that some individuals have incomplete 
remodeling and perfusion of the spiral arteries, leading to reduced vascular capacity5 and 
placental ischemia and hypoxia,55,57,245 leading to maternal endothelial dysfunction and the 
subsequent clinical symptoms of preeclampsia.245 
Nitric oxide (NO) and carbon monoxide (CO) are powerful vasodilators7,8 that may play 
important roles in the etiology of preeclampsia by increasing vascular capacity during spiral 
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artery remodeling. NO and CO are produced by combustion such as in cigarette smoke or 
vehicle exhaust,9,10 but are also produced endogenously in the body.11–16 The well-known 
inverse relationship of maternal smoking with preeclampsia71 may in part be attributable to the 
vasodilatory effects of NO and CO. There is evidence that combustion products may be 
required, as a large Swedish study found increased risk in users of smokeless tobacco.246 NO 
and CO are associated with smooth muscle relaxation and blood pressure regulation12,14 and 
there is evidence of their role specifically in the placental vascular system.15,77  
Genomic studies can help identify etiologically relevant underlying biologic pathways. 
Although the reason for the inverse association between maternal smoking and preeclampsia is 
unknown, assessing variants in genes that influence the endogenous production of CO and NO, 
which are components of cigarette smoke, may provide evidence for a potential mechanism of 
action. There is evidence for genetic susceptibility for preeclampsia. Numerous studies have 
suggested a familial predisposition for preeclampsia risk in first-degree relatives of women with 
preeclampsia123 and studies of familial aggregation of preeclampsia have estimated heritability 
to be as much as 50%.124–126 Although these estimates have been supported by both large-
scale registry-based epidemiologic studies127,128 and studies of transgenic mice,123,129 findings 
from human genetic studies have been inconsistent, and few genetic associations have been 
found. Both maternal and child genetics may contribute to risk of preeclampsia. 
Our objective was to determine if maternal or child single nucleotide polymorphisms 
(SNPs) in NO and CO signaling pathways were associated with preeclampsia using a mother-
child dyad design, nested within the Norwegian Mother and Child cohort (MoBa). We examined 
SNPs within three canonical pathways important for both CO and NO activity. Exploring both 
maternal and child genotype and identifying variants that may play a role in both endogenous 
and exogenous NO and CO may help establish potential therapeutic targets for this serious and 
life-threatening condition.  
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Methods 
Study population 
This study is a nested case-control study within the Norwegian Mother and Child Cohort 
Study (MoBa), conducted by the Norwegian Institute of Public Health.222 MoBa is a large 
prospective birth cohort of pregnant women and their offspring, recruited throughout Norway 
from 1999 to 2008 (N=112,908 pregnancies). All pregnant women living in Norway who gave 
birth at a hospital or maternity unit with more than 100 births annually and who could speak 
Norwegian were eligible; MoBa investigators applied no other exclusion criteria. Pregnant 
women were recruited by mail prior to their routine ultrasound appointment at 17 to 20 weeks’ of 
gestation. Of all women invited to participate, 41% enrolled in the study.222 Participants 
completed two prenatal questionnaires about their health and environment. Survey completion 
rate was 91% for the early pregnancy questionnaire (administered between weeks 13 and 17) 
and 83% for the late pregnancy questionnaire (administered at week 30).222 Maternal blood was 
collected at the first ultrasound appointment and cord blood was collected at birth. Maternal 
blood was received from 89% of participants and child (cord) blood from 81% of children in the 
cohort.222 DNA was extracted at the time of collection and then stored at the MoBa Biobank. 
Birth outcome information was obtained from the Medical Birth Registry of Norway.247 
For the purposes of this analysis, we included women with a singleton pregnancy who 
conceived spontaneously, were verified cases or controls, returned both the early and late 
pregnancy questionnaires, and had no history of chronic hypertension. Preeclampsia 
case/control status was verified using antenatal records and hospital discharge codes, as 
previously described.223 Preeclampsia was defined using American College of Obstetrics and 
Gynecologists (ACOG) criteria (see below for additional details).27 All observations registered as 
preeclampsia cases and a random sample of 2000 pregnancies registered as being unaffected 
by preeclampsia were selected from MoBa to be verified. Of the 3500 registered preeclampsia 
cases and 1840 registered to be unaffected by preeclampsia for which records were received, 
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2936 pregnancies identified as preeclampsia cases from the MBRN were verified to have been 
affected by preeclampsia, and 1745 pregnancies identified as unaffected by preeclampsia were 
found to be negative for preeclampsia. In total, 2682 preeclampsia case samples (2236 samples 
from 1118 mother/child pairs and 446 unpaired maternal samples) and 1967 non-preeclampsia 
control samples (1936 samples from 968 mother/child pairs and 31 unpaired maternal samples) 
met inclusion criteria and were genotyped. There were no unpaired offspring. (Figure 7).   
 
Outcome Assessment 
Details of the validation study for preeclampsia have been previously described223, and 
information relevant to the current investigation is included in Supporting Information Methods. 
In brief, “preeclampsia” was as defined by the American College of Obstetrics and 
Gynecologists (ACOG),27 which specifies that both of the following be present:  
4) Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure of ≥ 90 mm Hg 
occurring after 20 weeks’ gestation in a woman whose blood pressure has been 
previously normal, and 
5) Proteinuria, with excretion of ≥ 0.3 g of protein in a 24-hour urine specimen or as 
measured by 1+ on urine dipstick. 
A 2013 revision of this definition also included clinical symptoms, however, we used the criteria 
in use at the time of validation, i.e. the above two conditions. We also considered as “true 
cases” any case with an ICD-10 code of severe PE (O14.1) or HELLP syndrome (O14.2) with 
delivery < 37 weeks, or ICD-10 code of eclampsia (O15), which are routinely validated by the 
MBRN. Criteria for preeclampsia subtypes are presented in Table 6. 
 
Gene and SNP Selection 
For this study, 66 genes (Table S1) involved in CO and NO activity were identified from 
three canonical pathways, which included: 1) endothelial nitric oxide synthase (eNOS) signaling 
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pathway, which accomplishes the synthesis of NO from L-arginine, 2) heme degradation, which 
accomplishes the breakdown of hemoglobin into CO and bilirubin and 3) hypoxia-inducible 
factor 1-alpha (HIF1A), which regulates oxygen homeostasis and response to hypoxia.  A total 
of 1,518 SNPs were selected and analyzed for this study using a 10kb upstream and 
downstream margin around the transcription start and end sites for each gene. 
 
DNA Genotyping and Quality Control 
SNPs were genotyped by the UNC Mammalian Genotyping Core using the 
HumanCoreExome+ array from Illumina (Illumina, Inc., San Diego, CA). Samples and SNPs 
were examined using PLINK 1.07 (http://pngu.mgh.harvard.edu/purcell/plink) for quality control. 
SNPs were excluded if the missing rate exceeded 5% or there was substantial deviation from 
Hardy-Weinberg Equilibrium (p < 1x10-3) using PLINK. We also excluded SNPs with a minor 
allele frequency <5%. Samples with known genotype (n = 84) and DNA replicates (n = 51) were 
included on each plate and generally exhibited high accuracy; however, one pair of discordant 
duplicate samples was excluded. All other quality control samples on the implicated plates were 
found to be perfectly concordant. All subject-specific call rates were acceptable (minimum 
97.2%).  Sex-specific markers were inspected and 3 samples with sex discrepancies were 
excluded. Parent-child relatedness and inbreeding within the cohort was confirmed by identity 
by descent. Thirteen mother-child pairs were dropped because relatedness could not be 
confirmed (expected pi-hat = 0.5, observed pi-hat<0.128). Additionally, 16 pairs of siblings or 
cousins among the mothers were flagged as related (pi-hat>0.125). For each such pair of 
related mothers, we preferentially included the parent-child pair with the most complete genetic 
data, or in the case of equivalence, randomly sampled between them.  
Quantile-quantile plots and calculation of genomic control lambda226 indicated no 
systematic test statistic inflation, suggesting that population stratification was negligible (Figure 
9). However, the top 3 principal components of genetic variation were plotted for the MoBa data 
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together with the 1000 Genomes reference populations and visually inspected to assess 
evidence of admixture (Figure 10). A sensitivity analysis excluding varying levels of population 
outliers was performed and did not substantially influence results. (Table S11). The final 
analysis sample (n=4551 total samples) included dyads with both mother and child genotype 
data as well as incomplete dyads with only mother or child genotype data (n=2621 
preeclampsia case samples [1076 mother/child pairs, 459 mother only, 10 child only], n=1930 
control samples [935 mother/child pairs, 46 mother only, 14 child only]). Supporting Information 
Figure 7 describes the sample selection and quality control process.  
 
Statistical Analysis 
 To simultaneously account for maternal and child genotype, we used the case-mother 
control-mother log-linear modeling approach proposed by Shi et al.213 This method uses 
Poisson regression to model expected counts of each possible genetic mating type combination 
under the assumption of Mendelian inheritance. This method allows one to account for the 
correlation between maternal and child genotype and improves power compared to a logistic 
model.212,213,248 Two maternal and two child genetic risk parameters were included in the model 
to saturate for codominant genetic main effects, as follows: ln : ;<=> = ?<= + @A + 23A4<63 + 27A4<67 + 83A4=63 + 87A4=67 
Where E (Nmcd) is the expected value of the counts of families with each of maternal genotypes, 
child genotypes, and case or control status; d is case or control status where A = 1 for a case 
and A = 0 for a control; and I(m=j) and I(c=i) are indicators for whether a mother or child has j (= 
one or two) copies of the variant allele. The ?<= parameters allow flexibility of the control-mother 
distribution (avoiding the need to assume Hardy-Weinberg for the source population) and 
ensure that the parental genotype distribution is only constrained by the family relationships.  
LEM software236 was used to fit these models. The expectation maximization algorithm 
was used to incorporate dyads with missing genotypes. Likelihood ratio tests comparing 
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reduced models with maternal genotype or child genotype with the saturated model were 
performed to determine p-values for both maternal and child genetic effects, each adjusted for 
the other genotype. A 4 degree-of-freedom likelihood ratio test was used to determine joint p-
values for simultaneous tests of maternal/child genetic effects. Point estimates and 95% 
confidence intervals for relative risks were calculated for each SNP for both maternal and child 
genotype. 
In genetic studies that employ logistic regression, eigenstrata are generally included as 
covariates to reduce population stratification bias, however, the use of log-linear Poisson 
regression with a mating type parameter in the model should reduce the need for adjustment 
with eigenstrata. Nevertheless, because of concern that missingness may depend on 
membership in subpopulations, samples that fell outside of the European ancestral population 
were excluded in sensitivity analyses, as described above. 
 To account for multiple comparisons, we calculated the false discovery rate (FDR), 
which is the expected proportion of type 1 errors (false positives) among all positive tests.239 We 
used an FDR of <0.05 (reported as Q-values) as our threshold for considering a finding 
noteworthy.  
 To visually inspect results across the whole genome, we generated quantile-quantile 
plots of the observed versus expected -log10(p-values) for each SNP from the dyad models 
(Figure 14). We also calculated the genomic inflation factor, lambda226, for maternal and child 
genetic effects, which is based on comparing the median chi-squared value with its expectation 
under the null. Separate plots were generated for maternal and child effects. 
 
Replication Methods 
All SNPs with Q-values < 0.2 for both preeclampsia overall and preeclampsia sub-
phenotypes were sent to the InterPregGen consortium for attempted replication analysis.241 
Within InterPregGen, cases came from the UK Genetics of Pre-eclampsia (GOPEC) 
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consortium. The same standard definition of preeclampsia defined cases. Population controls 
came from the Wellcome Trust Case-Control Consortium 1. Maternal samples (1875 cases, 
5088 controls) and child samples (1004 cases, 5286 controls) were analyzed separately for 
SNP associations with preeclampsia using logistic regression, assuming a logit-additive model. 
A subset of preeclampsia cases included phenotype information for early preeclampsia, so were 
also analyzed as a proxy for the subtypes of preeclampsia with additional complications (505 
maternal cases, 5051 maternal controls, 276 child cases, 5297 child controls). Complete 
methods for recruitment, genotyping, and quality control of the replication sample are described 
Chapter III. 
 
Results 
 The final analysis sample consisted of 4,551 individual samples for 2,011 complete 
mother-child dyads, 505 samples with only maternal genotype data (459 cases), and 24 children 
with only child genotype data (10 cases) (n=2,540 pregnancies) (Table 10). Mean maternal age 
was 29.6 years (SD 4.7) and most had a university degree (55.3%). As expected, a greater 
proportion of women with preeclamptic pregnancies were nulliparous and of high body mass 
index (overweight or obese) compared to those without preeclampsia (66% and 46% compared 
to 41% and 28%, respectively). Babies born to women with preeclampsia were more often 
preterm (21.5% compared to 3.3%) and small-for-gestational-age (SGA) (22.6% compared to 
7.7%) than controls. Severe preeclampsia (including eclampsia) was present in 20% of women 
with preeclampsia.  
 Results of tests for maternal genotypic associations controlling for child genotype are 
summarized in Figure 14a and for child genotypic associations controlling for maternal genotype 
are summarized in Figure 14b. In the joint 4-degree of freedom test, we found one SNP to be 
significant (Q £ 0.05), however, this SNP was only individually significant in the child and not in 
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the mother. We found a child association of increasing risk in the variant allele of this SNP 
(rs12547243, MAF = 0.29), a synonymous substitution in a coding region of ADCY8 on 
chromosome 8.  The estimated relative risk (RR) and 95% confidence interval (CI) was 1.42 
[1.20, 1.69] for 1 copy of the minor allele and 2.14 [1.47, 3.11] for 2 copies, Q=0.04) (Table 11). 
Although no maternal genotypic associations met our FDR threshold, there were a number of 
suggestive maternal genotypic associations for SNPs in ESR1, PDE1C, PIK3C2G, and 
GUCY1A3. Generally, the ESR1 and PDE1C SNPs were associated with a reduced risk of 
preeclampsia and the PIK3C2G and GUCY1A3 SNPs were associated with an increased risk of 
preeclampsia, however, few showed a dose-response pattern and risk ratios were mostly null 
for the homozygous genotype. Table 11 shows both mother and child effect estimates, and the 
joint test results, for all top SNPs with FDR Q-values £0.20.  
Results of a sensitivity analysis excluding population outliers along axes of ancestral 
variation are presented for all SNPs with FDR Q £0.20, although only 5 are significant at 0.05. 
Supporting Information Table S11a provides risk ratios and test results for exclusion of 17 pairs 
of observations with first principal component >0.04 (See Figure 12) and Table S11b provides 
these estimates for exclusion of 47 pairs of observations with first principal component >0.01. 
Exclusion of these observations did not substantially influence results; effect estimates were 
similar and the p-values were stable. 
 Because preeclampsia is a heterogeneous condition for which underlying etiologies may 
differ, we also repeated the analysis within preeclampsia subtypes. Results for all associations 
for each subtype with Q £ 0.2 are presented in Table 4. Within subtypes, we found associations 
for two SNPs within PDE1C. We found a maternal association of rs30593 (MAF=0.35) for 
preeclampsia accompanied by delivery before 34 weeks’ gestation (RR=0.45 [0.27, 0.75] for 1 
copy; RR=1.44 [0.63, 3.30] for 2 copies; Q=0.02). We also found a suggestive child association 
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of rs30562 (MAF=0.35) for preeclampsia accompanied by SGA (RR=0.50 [0.35, 0.71] for 1 
copy; RR=1.00 [0.60, 1.67] for 2 copies; Q=0.06).  
 We provided the SNPs with Q-values < 0.2 overall and within subtypes to the 
InterPregGen Consortium for analysis. Because we found different lead SNPs among the 
general preeclampsia phenotype and preeclampsia subtypes, in the replication sample we 
assessed these SNPs for both associations with general preeclampsia (Table S12a) and early 
preeclampsia (Table S12b), the only sub-phenotype for which we had replication data. Our lead 
SNP for preeclampsia with early delivery, a maternal association of rs30593 in PDE1C, was 
nominally associated with preeclampsia, but in the UK GWAS child population (uncorrected 
p=0.05). As with this SNP in the MoBa study, we saw a similar reduced risk of preeclampsia 
(RR=0.90; 95% CI [0.82, 1.00]) in the replication study. Complete replication results are 
reported in Table S12. 
 
Discussion 
In this large, case-control study of maternal and child genetic variants in CO and NO 
pathways and validated preeclampsia, we report potential genetic associations of interest within 
both the mother and the child. In the child, we found a novel association of rs12547243 in 
ADCY8, a SNP with no previously reported associations. We found increasing risk of 
preeclampsia with the AG and AA genotypes compared with the GG genotype. Although we 
found no maternal genotypic associations that met our FDR threshold, we did find some 
suggestive maternal genotypic associations (Q < 0.1) for SNPs in ESR1, PDE1C, PIK3C2G, 
and GUCY1A3. Among preeclampsia subtypes, we found a decreased risk associated with the 
TC maternal genotype compared to CC genotype of rs30593 in PDE1C for preeclampsia 
accompanied by early delivery and a suggestive association of reduced risk associated with the 
child TC genotype compared to CC for rs30562 in PDE1C for preeclampsia accompanied by 
small for gestational age. 
  
 
93 
 Of the lead SNPs that were sent for replication analysis, only rs30593 in PDE1C was 
nominally associated with preeclampsia in the replication sample (p=0.05), however, none of 
the replication SNPs were significant after adjustment for multiple comparisons. It is plausible 
that some of our associations failed to replicate due to both different analytic methods and a 
somewhat different outcome assessment in our primary analysis and replication datasets. While 
both populations used the same definition of preeclampsia, our MoBa analysis used only 
validated cases and non-cases, whereas the InterPregGen Consortium used validated cases 
but population controls that may or may not be pregnant women. Additionally, in our analysis, 
we included both mother and child genotypes and both were modeled codominantly with a 
genetic mating type parameter to account for mother-child family structure; by contrast, the 
replication analysis independently modeled mother and child genotype logit-additively. To 
investigate how a similar type of analysis might alter our results, we analyzed our maternal and 
child samples using standard logistic regression analysis modeled additively in PLINK. Our 
associations with rs12547243 in the child were stronger, but other associations were attenuated 
(data not shown). 
Although not replicated, we did find some interesting associations that have been 
supported by animal studies and warrant further study. Several SNPs of interest are located in 
the genes ADCY8, GUCY1A2, and PDE1C. ADCY8 encodes adenylate cyclase 8 which 
catalyzes the conversion of adenosine-5’-triphosphate (ATP) to 3’, 5’-adenosine 
monophosphate (cAMP).249 GUCY1A2 encodes the guanylate cyclase 1 alpha 2 subunit, which 
acts similarly to ADCY8 in that it catalyzes the conversion of guanosine triphosphate (GTP) to 
3’, 5’-adenosine monophosphate (cGMP).250 PDE1C encodes calcium/calmodulin-dependent 
3’,5’-cyclic nucleotide phosphodiesterase 1C and catalyzes conversion of cAMP and cGMP to 
their 5-prime-monophosphates (AMP and GMP).251 All of these genes are part of the canonical 
pathway for cellular effects of sildenafil (“Viagra”), a phosphodiesterase inhibitor that operates 
through nitric oxide signaling to increase vasodilation by inhibiting conversion of cGMP to 
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GMP.252 Mouse studies have demonstrated resolution of the preeclampsia phenotype with the 
administration of sildenafil.253,254 and clinical trials are now underway for its investigation for 
treatment of preeclampsia and fetal growth restriction.255–257  
Our study is one of the largest genetic studies of preeclampsia to date, with 1,076 case 
pairs (2,152 samples) and 935 control pairs (1,870 samples), which allowed us to address both 
mother and child genotype. In contrast to some small prior studies in ethnically diverse 
populations22–24, we did not identify any associations within SNPs in NOS2 or NOS3, two of the 
most widely-studied candidate genes for preeclampsia in the CO and NO pathways. SNPs were 
selected using a 10kb upstream and downstream margin around the transcription start and end 
sites for each gene. Although we selected these margins to ensure that we captured the entire 
coding region of the gene and proximate regulatory regions, recent studies of suggest that distal 
intergenic variants can alter gene expression through their role within the regulatory regions.258 
Candidate gene studies have frequently been inconsistent and unreplicated. This study aimed 
to improve upon prior candidate gene studies by including more SNPs while continuing to apply 
a hypothesis-driven approach to maintain statistical power. 
Given the suspected pathophysiology underlying preeclampsia, it is biologically plausible 
that both maternal and child genotypes contribute to this pregnancy complication. Our dyad 
analysis accounted for family structure and included both mother and child DNA, each adjusting 
for the other. This method has been implemented for other child phenotypes in which both 
maternal and child genotype may play a role259, but has not as well explored for pregnancy 
conditions. Although a few other genetic studies of preeclampsia have addressed child 
genotype124,194,260, to our knowledge, none have simultaneously modeled both mother and child 
genotype.  
While addressing limitations of previous studies by accounting for both maternal and 
child genetic components, this study also took on the challenge of heterogeneity of the 
preeclampsia phenotype. Preeclampsia was verified by antenatal medical records and hospital 
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diagnostic codes through medical record validation.223 All cases of preeclampsia in our study 
were verified as having preeclampsia and all controls were verified as being free of 
preeclampsia. We were also able to classify cases into preeclampsia subtypes that may have 
differing underlying etiologies. 
Although our analytic method allowed us to control for paired genotypes, which is likely 
the biggest confounder, a limitation of this study design is the inability to control for external 
confounders, such as by using principal components to adjust for population admixture. We 
addressed this limitation by assessing population stratification in the quality control process to 
determine if ancestral homogeneity was a plausible assumption within this Norwegian 
population. Comparing our population with the 1000 Genomes reference populations, we 
identified a handful of MoBa participants who clustered with Chinese, Amerindian, and Nigerian 
ancestral populations. Excluding such observations in a sensitivity analysis, however, did not 
substantially change our results, indicating that population stratification bias is not a serious 
issue. However, our results are most generalizable to populations of European descent. 
Additionally, despite being the largest study, we are still underpowered to look at preeclampsia 
subtypes. Although we do see some interesting trends and suggested associations, larger 
studies are needed to study these associations in greater detail.   
Our results underscore the importance of addressing the contribution of both maternal 
and child genotype. Among our top hits, we found either maternal or child associations, but not 
both (e.g. a positive maternal association but null child association). Additionally, although they 
did not meet our significance threshold, there were instances in which we saw trends of positive 
associations for either the mother or child and negative associations in the other.  We also 
found differing patterns among mothers and offspring in our subtype analyses. For example, all 
associations of interest for preeclampsia with early delivery were maternal, while all 
associations of interest for preeclampsia associated with small for gestational age were in the 
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child. Failure to acknowledge both maternal and child genotype may result in missing important 
associations in which mother and child genotype may operate differently.  
In conclusion, this study uses a novel study design to disentangle maternal and child 
genotypic effects of NO and CO signaling genes on preeclampsia. We provide further evidence 
of a plausible biologic pathway and the role of NO signaling in the development of preeclampsia 
and support for the continuation of trials of sildenafil as a potential therapeutic treatment. Future 
research of genetics and preeclampsia should continue to incorporate maternal and child 
genetic components and expand to explore maternal-child genotypic interactions as well as 
interactions with exogenous sources of CO and NO. 
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Tables 
Table 10. Demographic characteristics of pregnancies in the final study sample for Aim 1 
(n=2540 pregnancies, 4551 samples) 
 Total (N = 2540) 
Preeclampsia 
Cases 
(N = 1545) 
Controls 
(N = 995) 
    
Maternal Age (mean(SD), years) 29.6 (4.7) 29.3 (4.9) 30.1 (4.4) 
    
 No. % No. % No. % 
Maternal Education       
     < High School 205 8.1 132 8.5 73 7.3 
     High School Graduate 703 27.7 439 28.4 264 26.5 
     University Degree 1405 55.3 831 53.8 574 57.7 
     Missing 227 8.9 143 9.3 84 8.4 
       
Body Mass Index (kg/m2)       
     Underweight (<18.5) 57 2.2 25 1.6 32 3.2 
     Normal weight (18.5-24.9) 1341 52.8 712 46.1 629 63.2 
     Overweight (25.0-29.9) 630 24.8 444 28.7 186 18.7 
     Obese (30.0+) 359 14.1 264 17.1 95 9.6 
     Missing 153 6.0 100 6.5 53 5.3 
       
Maternal Smoking       
     Smoking in weeks 11-20 215 8.5 120 7.8 95 9.6 
     Missing 127 5.0 83 5.4 44 4.4 
       
     Smoking in third trimester 135 5.3 71 4.6 64 6.4 
     Missing 245 9.7 159 10.3 86 8.6 
       
Nulliparous 1419 55.9 1012 65.5 407 40.9 
Preterm (< 37 weeks) 365 14.4 332 21.5 33 3.3 
Small for gestational age (SGA) (< 10th 
percentile)a 426 16.8 349 22.6 77 7.7 
       
Preeclampsia subtypes       
     Severe 308 12.1  19.9   
     Onset <34 weeks 277 10.9  17.9   
     Delivery <34 weeks 132 5.2  8.5   
     Accompanied by SGAa 349 13.7  22.6   
a Population percentiles derived from Norwegian distribution, eSnurra Norway 
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Figures 
 
Figure 14a. 
 
 
Figure 14b.  
 
Figure 14. Quantile-quantile plots for maternal and child genotypic effects. Test results 
(observed -log10p values) are plotted against the expected -log10p values for each of 1,518 
SNPs across 66 loci in the sample. Figure 14a. Q-Q plot of maternal genotypic effects, adjusting 
for child genotype. Genomic inflation factor, lambda=1.18. Figure 14b. Q-Q plot of child 
genotypic effects, adjusting for maternal genotype. Genomic inflation factor, lambda=1.09. 
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CHAPTER V. INVESTIGATION OF THE INVERSE SMOKING-PREECLAMPSIA 
RELATIONSHIP THROUGH THE EXPLORATION OF GENE BY SMOKING 
INTERACTIONS 
 
Summary Paper 2 
One of the most well-established associations with preeclampsia is the enigmatic 
inverse association of maternal smoking and preeclampsia. The reason for this association 
remains unknown. A plausible biological explanation for this relationship is through response to 
cigarette smoke components, either through action of vasodilators or activation of smoking 
detoxification pathways. Examining genes involved in these processes and their modification 
could provide support for a genetic or related biological mechanism. 
We conducted a nested case-control study within the Norwegian Mother and Child Birth 
Cohort of 1,533 case-pairs and 982 control-pairs from 2,596 mother-child dyads (1,988 
complete pairs, 538 missing mother or child genotype). We selected 1,915 SNPs in pathways 
involved in nitric oxide and carbon monoxide signaling or smoking detoxification and established 
smoking status from maternal questionnaire during gestational weeks 11 to 20. We used log-
linear Poisson regression models with a SNP by smoking interaction term and likelihood ratio 
tests to assess genotype-smoking interactions.  
We found limited evidence for multiplicative SNP by smoking interaction after correction 
for multiple comparisons. When examining effect measure modification by smoking, among our 
three most noteworthy SNPs (p-interaction <0.001), we saw a null association among non-
smokers and a reduced risk among smokers with the variant allele for rs3765692 (TP73) and 
rs1077343 (PIK3C2G) and an increased risk among smokers for rs2278361 (APAF1). 
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Our findings to not provide support that the inverse smoking-preeclampsia relationship is due to 
a genetic effect. Dyad methods and gene-environment interaction analysis may be useful for the 
study of pregnancy outcomes, particularly preeclampsia. 
 
Introduction 
Preeclampsia is a common pregnancy complication, affecting approximately 2-7% of 
pregnant women, and is typically characterized by new-onset gestational hypertension and 
proteinuria after 20 weeks’ gestation.2 Preeclampsia is associated with serious maternal and 
fetal morbidity and mortality2 and there are limited options for treatment other than delivery of 
the baby.4  
Few risk factors for preeclampsia have been consistently identified across studies,2 but 
one of the most consistent associations is the paradoxical and poorly understood inverse 
relationship between maternal smoking and preeclampsia. Maternal smoking is associated with 
as much as a 50% reduced risk of preeclampsia despite increasing risk of other poor pregnancy 
outcomes, such as preterm birth and fetal growth restriction which often co-occur with 
preeclampsia.71–73 The reason for this association remains unknown; both biological causes6,111 
and methodological261 reasons (e.g. survival bias) have been suggested. 
One plausible biological explanation for the reduced risk of preeclampsia in women who 
smoke during pregnancy is the response to components of cigarettes and could reflect several 
mechanisms, including: 1) increased vasodilation of the spiral arteries during placentation, or 2) 
activation of receptors involved in detoxification that reduce endothelial dysfunction and 
increase angiogenesis. Both nitric oxide and carbon monoxide are components of cigarette 
smoke that are also produced endogenously in the body. CO and NO have been shown to be 
associated with smooth muscle relaxation and blood pressure regulation12,14, and there is 
evidence of their role specifically in the placental vascular system.15,77 Exposure to exogenous 
CO and NO may reduce risk of preeclampsia by increasing vascular dilation at a critical time 
  
 
104 
during placentation when the fetal trophoblasts are penetrating and spiral arteries are 
remodeling. Nicotine and polycyclic aromatic hydrocarbons are both components of cigarette 
smoke that activate receptors involved in smoking detoxification. Nicotine stimulates the 
nicotinic acetylcholine receptor and restores proangiogenic functions to endothelial cells harmed 
by soluble fms-like tyrosine kinase (s-flt1) and soluble endoglin (sEng) while stimulating 
placental growth factor (PlGF)94 in vitro; these factors (s-flt1, sEng, PlGF) are hypothesized to 
be involved in the development of preeclampsia.95,59,61 The aryl hydrocarbon receptor (AhR) 
mediates xenobiotic metabolism, dioxin and polycyclic aromatic hydrocarbon toxicity, and 
vascular development,109 and AhR expression is elevated in preeclamptic pregnancy 
placentas.111   
It is difficult to study each of these cigarette smoke components as independent 
exposures, as they are typically found as mixtures produced through combustion. Investigating 
gene by smoking interactions may provide some insight into the inverse smoking and 
preeclampsia relationship. We aim to assess multiplicative interactions between maternal 
smoking and genetic variants in pathways involved in response to cigarette smoke components 
on risk of preeclampsia. Observing differential associations between smoking and preeclampsia 
by genotype could provide evidence for why some individuals experience a protective effect of 
smoking and potentially identify mechanistic targets for future research.  
 
Methods 
We performed a nested case-control study within the Norwegian Mother and Child 
Cohort Study (MoBa),222 a large prospective birth cohort of pregnant women and their offspring 
recruited throughout Norway from 1999 to 2008 (N=112,908 pregnancies), which has been 
previously described elsewhere.222 Participants completed two prenatal questionnaires about 
their health and environment. Survey completion rate was 91% for the early pregnancy 
questionnaire and 83% for the late pregnancy questionnaire.222 Maternal blood was collected at 
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the first ultrasound appointment and cord (child) blood was collected at birth. Maternal blood 
was received from 89% of participants and child blood from 81% of children in the cohort.222 
DNA was extracted at the time of collection before being stored at the MoBa Biobank. 
Women provided informed consent prior to participation in MoBa and the study was 
approved by the Institutional Review Board of the Norwegian Institute of Public Health. The 
current study was approved by the Institutional Review Boards of the Norwegian Institute for 
Public Health and the University of North Carolina at Chapel Hill. 
 
Outcome Assessment 
Preeclampsia was defined by the American College of Obstetrics and Gynecologists  
(ACOG),27 which specifies that both the following be present:  
6) Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure of ≥ 90 mm Hg 
occurring after 20 weeks’ gestation in a woman whose blood pressure has been 
previously normal, and 
7) Proteinuria, with excretion of ≥ 0.3 g of protein in a 24-hour urine specimen or as 
measured by 1+ on urine dipstick. 
 
Preeclampsia information from MoBa was obtained through linkage with the Medical 
Birth Registry of Norway (MBRN).247 All registered preeclampsia cases (n=3500) and a random 
sample of 2000 pregnancies registered as being unaffected by preeclampsia were selected 
from the MoBa cohort to be verified by antenatal records through an independent validation 
study.223 A 2013 revision of the ACOG definition also included clinical symptoms, however, we 
used the above criteria, current at the time of the validation study. We also considered as “true 
cases” any case with an ICD-10 code of severe PE (O14.1) or HELLP syndrome (O14.2) and 
delivery < 37 weeks, or ICD-10 code of eclampsia (O15), which are routinely validated by the 
MBRN.  
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For the current study, we included all women from the validation study with a singleton 
pregnancy who conceived spontaneously, were verified cases or controls, returned both the 
early and late pregnancy questionnaires, and had no history of chronic hypertension. In total, 
2682 preeclampsia case samples (1564 maternal and 1118 fetal blood samples) and 1967 non-
preeclampsia control samples (999 maternal and 968 fetal samples) met inclusion criteria and 
were genotyped. 
 
Maternal Smoking 
We created a dichotomous smoking variable to indicate self-report of any smoking in 
gestational weeks 11 through 20. We selected this time period to specifically capture smoking 
during the window in which maternal blood flow perfusion into the intervillous space occurs and 
trophoblasts move to an invasive state completing spiral artery remodeling.228 Women were 
surveyed twice during pregnancy about smoking habits. In the early survey (13-17 weeks’), 
women were asked whether they had smoked prior to pregnancy, whether they currently 
smoked, and if so, how many cigarettes per day or week. If they were not current smokers, they 
were also asked if they had stopped smoking after becoming pregnant, and if so, at what 
gestational age. In the late questionnaire (~30 weeks’), women were asked whether they 
currently smoked and if so, how much. They were also asked if they had quit smoking during 
pregnancy, and if so, at what gestational age they stopped. 
 For our primary smoking variable during the window of 11 to 20 weeks’ gestation, we 
used smoking information from the early pregnancy questionnaire unless it was missing or 
ambiguous, in which case we supplemented with information from the late pregnancy 
questionnaire. A woman was considered to be a non-smoker if she indicated she had never 
smoked or that she did not currently smoke, and we had no other evidence of smoking after 10 
weeks of gestation. A woman was considered a smoker in weeks 11 to 20 if she indicated that 
she currently smoked or quit after 10 weeks’ gestation on either survey. To determine the week 
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in which a woman quit smoking, we obtained the latest quit week reported on either the early or 
late pregnancy questionnaire. If a woman was missing smoking information on the early 
questionnaire and indicated being a daily smoker on the late questionnaire, we assumed she 
had also been smoking in weeks 11 to 20. To determine smoking quantity, we categorized 
smoking quantity as number of cigarettes reported daily or weekly. In a sensitivity analysis, we 
separately considered women who smoked during the entire 11-20 week window, and women 
who quit during the 11-20 week window.  
 
SNP Selection 
For this study, 124 genes involved in response to cigarette smoke components were 
identified from 8 canonical pathways (Table S2), which included: 1) endothelial nitric oxide 
synthase (eNOS) signaling pathway, 2) heme degradation, 3) hypoxia-inducible factor 1-alpha 
(HIF1A), 4) xenobiotic metabolism, 5) aryl hydrocarbon receptor signaling, 6) glutathione-
mediated detoxification, 7) nicotine degradation II, and 8) nicotine degradation III. A total of 
1,915 SNPs (MAF ³ 10%) were selected and analyzed for this study, using a 10kb upstream 
and downstream margin around the transcription start and end sites of each gene. 
 
Genotyping and Quality Control 
SNPs were genotyped by the UNC Mammalian Genotyping Core using the 
HumanCoreExome+ array from Illumina (Illumina, Inc., San Diego, CA). Samples and SNPs 
were examined using PLINK 1.07 (http://pngu.mgh.harvard.edu/purcell/plink) for quality control. 
SNPs were excluded if the missing rate exceeded 5%, there was substantial deviation from 
Hardy-Weinberg Equilibrium (p < 1x10-3) or minor allele frequency was <10%. Known genotype 
and DNA replicates were included on each plate and exhibited high genotyping quality. All 
subject-specific call rates were acceptable (minimum 97.2%).  Sex-specific markers were 
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inspected and parent-child relatedness and inbreeding within the cohort was assessed by 
identity by descent.  
Quantile-quantile plots and calculation of genomic control lambda226 (lambda mom=1.01, 
lambda child=1.03) indicated no systematic test statistic inflation, unidentified relationships, or 
cryptic admixture. Outliers for each of the first three principal components >3 standard 
deviations from the mean were excluded. The final analysis sample (n=4514 total samples) 
included dyads with both mother and child genotype data as well as incomplete dyads with only 
mother or child genotype data (n=2596 preeclampsia case samples [1063 mother/child pairs, 
450 mother only, 20 child only], n=1918 control samples [925 mother/child pairs, 45 mother 
only, 23 child only]). 
 
Statistical Analysis 
 The inverse relationship between smoking and preeclampsia in the MoBa cohort has 
been reported elsewhere (OR=0.60, 95% CI 0.48 – 0.75 for second-trimester active smoking).75 
The primary goal of this analysis was to evaluate whether genetic variants in pathways involved 
in response to cigarette smoke components modify the maternal smoking-preeclampsia 
relationship. 
 To address this goal, we extended the case-mother control-mother log-linear modeling 
approach proposed by Shi et al.,213 which simultaneously accommodates maternal and fetal 
genotypes, as well as maternal smoking, covariates, and maternal smoking-genotype 
interaction (both mother and child).  This method uses Poisson regression to model expected 
counts of each possible genetic mating type combination (the set of genotypes in the parents) 
under the assumption of Mendelian inheritance as follows:  ln # $%&'( = *%& + ,- + ./( + 0-/( + 12-/%32 + 14-/%34 + 52-/&32 + 54-/&34 + 6-/(×8 
Where E (Nmcde) is the expected value of the counts of families with each of maternal genotypes, 
child genotypes, case or control status, and smoking status; d is case or control status where 
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- = 1 for a case and - = 0 for a control; I(e=1) is an indicator for maternal smoking; and G is the 
number of copies of the variant allele that the mother carries (when assessing maternal 
interaction) or that the child carries (when assessing child interaction). The *%& parameters 
allow flexibility of the control-mother distribution (avoiding the need to assume Hardy-Weinberg 
for the source population) and ensure that the parental genotype distribution is only constrained 
by the family relationships.  
LEM software236 was used to fit these models. The expectation maximization algorithm 
was used to incorporate dyads with missing genotypes. The proportion of missing smoking data 
was low (<5%), so observations missing smoking data were excluded from analysis. Likelihood 
ratio tests comparing reduced models without the interaction term with the model including an 
interaction term were performed to determine p-values for interaction for both maternal-
genotype interaction and child-genotype interaction, each adjusted for the other genotype.  
Point estimates and 95% confidence intervals for relative risks were calculated for risk of 
preeclampsia for maternal smokers compared to non-smokers during the window of 11 to 20 
weeks of gestation, stratified by both maternal genotype and child genotype. 
We calculated Bonferroni corrected p-values to account for multiple comparisons (P < 
2.6 x 10-5). Interaction tests generally have low power to reject homogeneity,240 thus, we also 
report results for a relatively generous cutpoint that less completely acknowledges issues of 
multiple testing (P < 0.001).  
Due to the potential for exposure-related population stratification bias within family-
based studies, as reported by Shi et al.,262 we also performed a sensitivity analysis in which we 
extended the model to include smoking by mating type interaction parameters to allow exposure 
status to vary by mating type. This model is as follows:  ln # $%&'( = *%& + *%&/( + ,- + ./( + 0-/( + 12-/%32 + 14-/%34 + 52-/&32 + 54-/&34+ 6-/(×8 
in which *%&/( is now a correction to the mating type parameters where the mother smoked. 
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Results 
The final analysis sample consisted of 4,288 individual samples for 1,888 complete 
mother-child dyads, 471 dyads with only maternal genotype data (429 cases), and 41 dyads 
with only child genotype data (19 cases) (n=2,400 pregnancies) (Table 13). Of the 2,526 
pregnancies for which we had genotype information, 126 (5.0%) were missing information on 
smoking status during gestational weeks 11 to 20. Distribution of covariates did not differ 
between all pregnancies and those missing smoking data (data not shown). Of the 2,400 
pregnancies for which we had smoking information, 214 (8.9%) smoked during weeks 11 to 20. 
Fewer women with preeclampsia smoked during weeks 11 to 20 than those without (8.2% vs 
10.0%). Smoking was light overall in this population. More women with preeclampsia quit 
smoking during the 11 to 20 week window than those without preeclampsia (33% vs 25%). 
Women with preeclampsia were more often nulliparous than those without (66% vs 41%) and 
tended to have higher body mass index. Infants born to women with preeclampsia were more 
often preterm (21% vs 3%) or small for gestational age (23% vs 8%).  
 In analyses of interactions, none of our SNPs met our Bonferroni-corrected threshold (P 
< 2.6 x 10-5). We present maternal interaction results for the three SNPs with p-values for 
interaction <0.001 (Table 14). We found no SNPs meeting this threshold for child genotype 
interaction. Risk ratios for the association between smoking and preeclampsia are stratified by 
genotype (Table 14).  
 Among women who had the C allele of rs3765692 (TP73), risk of preeclampsia was 
lower for smokers compared to non-smokers (RR among CT: 0.53, 95% CI 0.36 – 0.79; RR 
among CC: 0.28, 95% CI 0.14, 0.58) compared to a null association among those with 0 copies 
of the variant allele (RR among TT: 1.00, 95% CI 0.74 – 1.36). The pattern was similar for 
rs10770343 (PIK3C2G), where among women with the C allele, smokers had a reduced risk of 
preeclampsia (RR among CA: 0.63, 95% CI 0.45 – 0.88; RR among CC: 0.37, 95% CI 0.21 – 
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0.65) compared to a null association among those without the variant allele (RR among AA: 
1.07 95% CI 0.78, 1.48). The pattern was opposite for rs2278361 (APAF1), in which smokers 
had an increasing risk of preeclampsia with increasing number of variant alleles. For rs2278361, 
a null association of smoking and preeclampsia was found among heterozygotes (RR for CT: 
1.04, 95% CI 0.76 – 1.41), while associations among the TT and CC genotypes straddled each 
side of the null (RR among TT: 0.62, 95% CI 0.44 – 0.86; RR among CC: 1.74, 95% CI 1.05 – 
2.88). Results are presented graphically in Figure 15.   
Results of the sensitivity analysis allowing for exposure-related population stratification 
are similar, although given how rare smoking is, we had a number of mating types for which 
there were no smokers, and thus we could not fully evaluate the extent to which population-
stratification by exposure may influence our findings. Nonetheless, although estimates were less 
precise, the same set of SNPs had the lowest p-values for smoking-SNP interactions in 
mothers, and risk ratios were similar in magnitude and direction for those SNPs (Table S13a). 
Two additional smoking-SNP interactions in children emerged as potentially noteworthy, but 
estimates were unstable due to sparse data (Table S13b). Results of our sensitivity analysis of 
smoking cessation revealed some differences among groups. Table S14 compares risk ratios 
and p-values for interaction for groups in which smokers consisted of 1) only those who quit 
during weeks 11-20, 2) only those who did not quit during weeks 11-20, and 3) all smokers 
during weeks 11-20 (our primary analysis). Risk ratios are presented per-minor allele to more 
easily compare the differences in associations among groups. As in the primary analysis of the 
group consisting of all smokers, the direction of the associations remained the same. Risk of 
preeclampsia for smokers compared to non-smokers decreased with each additional minor 
allele for rs3765692 (TP73) and rs10770343 (PIK3C2G), and increased for rs2278361 (APAF1). 
Although the direction of association was the same for all groups, associations were further from 
the null for the group containing smokers that did not quit smoking during the 11 to 20 week 
window.  
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Discussion 
The inverse relationship between smoking and preeclampsia is well established, though 
the reason for this association is still unknown.6 This study employed a novel approach in an 
effort to determine if there are genetic subgroups in which there are differences in the 
association between smoking and preeclampsia is due to variation in genes involved in 
smoking-related pathways. We assessed possible gene-by-maternal-smoking interaction for 
1915 candidate SNPs representing 8 canonical pathways related to biologic responses to the 
tobacco combustion products. 
We found little evidence for interaction between maternal smoking during the time of 
spiral artery remodeling and genetic variants in pathways related to biologic responses to 
cigarette smoke components. While not statistically significant, for our most noteworthy SNPs 
(p-int < 0.001), rs3765692 in TP73, rs1077343 in PIK3C2G, and rs2278361 in APAF1 we 
showed a differential effect of smoking on preeclampsia by genotype. The patterns for these 
SNPs suggest a biological mechanism related to effects of the exposure that are mediated 
through that gene may partially explain the association. 
These SNPs should be investigated for more targeted epidemiologic and mechanistic 
research as their function is currently unknown but each has some emerging evidence for 
biological plausibility. The P3IK pathway (in which PIK3C2G is included) has recently been 
reported to affect placental maternal-fetal resource allocation. 263,264 Aryl hydrocarbon receptor 
activation represses TP73 and APAF1, resulting in pro-proliferative, anti-apoptotic effects.265 
Both have biologic plausibility in the pathogenesis of preeclampsia. 
Studies of gene (TNFα, CYP1A1, GSTT1) by smoking interactions have focused on 
other reproductive outcomes such as preterm birth215 and orofacial clefts, 191214 while the 
epidemiologic study of gene by environment interaction for preeclampsia has been limited to the 
study of the MTHFR gene and folate.191 We selected a comprehensive list of SNPs from genes 
in pathways involved in response to cigarette smoke components based on biological 
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plausibility111,266,92,93 and prior interactions with smoking in other conditions such CYP1A1, 
CYP1B1, GSTM1, and GSTT1 with lung,267 head and neck,268,269 and colorectal270 cancer.266  
 In addition to approaching the question of how smoking affects preeclampsia in a new 
way by assessing gene by environment interactions, this study aimed to address several 
common methodological problems in the study of preeclampsia. Misclassification due to 
misdiagnosis and reporting is often a problem with preeclampsia.271 Preeclampsia was verified 
by antenatal medical records and hospital diagnostic codes through medical record validation.223 
All cases of preeclampsia in our study were verified as having preeclampsia and all controls 
were verified as being free of preeclampsia. The time window for maternal smoking exposure 
may be an important determinant of risk, and classification of smoking by time period has been 
a challenge in studies of preeclampsia.  Biologically, smoking during early pregnancy may 
influence outcomes differently than in late pregnancy because of differences in the placenta, 
mother, and fetus. Because of the negative effects that smoking can have on the fetus and the 
associated cultural pressures, many women stop or reduce their smoking when they find out 
they are pregnant. We had two different prenatal surveys, and both asked about weeks of 
smoking, so we were able to classify by several different time points during pregnancy. We 
selected one specific interval (gestational weeks 11 to 20) as the most biologically relevant 
exposure time for our primary analyses.  
We took several approaches to improve our study power, which is a common difficulty in 
gene by environment studies. Use of a case-mother control-mother design incorporating the 
expectation maximization algorithm to account for missing data improved power by allowing 
dyads where only one member was genotyped to contribute fully. We modeled the gene by 
environment interaction as a log-additive interaction term to improve power, although that may 
not be the most appropriate model fit. Additionally, we chose to limit our analysis to SNPs with 
both a plausible biological relationship with effects of smoking or known interaction with 
smoking, and also limited to minor allele frequencies greater than 10%. We also selected SNPs 
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using a relatively small 10kb upstream and downstream margin around the transcription start 
and end sites for each gene to ensure that we captured both the entire coding region of the 
gene and proximate regulatory regions, while constraining the number of SNPs we were 
studying to preserve our study power. This may have limited our ability to detect distal intergenic 
variants that may alter gene expression through their role within the regulatory regions.258 
Despite these strategies, we are still underpowered to assess gene by smoking interactions for 
the number of SNPs in our study. 
Our method accounted for family structure and included both mother and child DNA, 
each adjusting for the other. Given the suspected pathophysiology underlying preeclampsia, it is 
biologically plausible that both maternal and child genotypes contribute to this pregnancy 
complication. A few other genetic studies of preeclampsia have addressed child 
genotype260,124,194 but have not simultaneously modeled both mother and child genotype while 
addressing gene by smoking interactions. 
  Although we were able to account for confounding by both maternal and child genotype 
in our study, we may have inadequately addressed other types of confounding in our analysis. 
Maternal age and parity are associated with both smoking and preeclampsia in our cohort, and 
may both be potential confounding variables in the smoking-preeclampsia association. The 
mating type parameter makes inclusion of other covariates challenging due to non-positivity 
within mating types and maternal age and parity were not included in our model. Our model may 
also be vulnerable to exposure-related population stratification, which has been shown to bias 
results if both smoking exposure rates and mating type frequencies differ among 
subpopulations.262 We controlled for exposure-related population stratification bias in an 
sensitivity analysis by including additional family-based exposure parameters (Table S13), and 
results were substantially unchanged, but the small number of smokers in our dataset limits our 
ability to make inferences from models that include these additional parameters. 
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 It is a challenge to ascertain smoking exposure. Our study used self-reported smoking 
status from maternal questionnaires. Smoking status may be underreported due to social 
stigma, particularly among pregnant women where the relationship between smoking and poor 
birth outcomes is known.272 A recent validation study of self-reported smoking and plasma 
cotinine indicated that reported smoking on the MoBa questionnaire is a reasonably valid 
marker of tobacco exposure (Sensitivity=82%, Specificity=99%),227 however, even this degree of 
measurement error may have biased our results. Differential false reporting of smoking status 
may vary by preeclampsia case status, which could have influenced our ability to detect any 
effect measure modification, however, in most cases, ascertainment of smoking status came 
before preeclampsia diagnosis so this is unlikely an issue. 
Additionally, pregnancy is a time period in which many women quit smoking after 
learning they are pregnant or are actively trying to quit smoking throughout pregnancy. In our 
study 19.5% of women reported smoking in the first trimester and 5.9% in the third trimester. 
When assessing SNP by smoking interaction by time period, estimates were similar, but 
attenuated toward the null in the first trimester (data not shown). Although we selected a 
specific, biologically relevant time period for smoking, 63 of 214 (29%) of women who smoked 
during weeks’ 11-20 reported quitting in a week during that period. To address whether quitting 
specifically influenced our results, we conducted a sensitivity analysis to see if people who 
reported quitting were different than those who continued smoking.  The direction of association 
was the same for all groups, but associations were stronger and more significant for the group 
of smokers who did not quit during weeks’ 11-20 compared to those who reported that they did 
quit, indicating there may be a dose-response effect which should be investigated further (Table 
S14).   
Although smoking quantity may be important, we measured smoking dichotomously as 
any smoking during the time period compared to no smoking. Although we did have information 
on the average number of cigarettes smoked per day/week, overall smoking intensity was light 
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in this population, and stratification, along with the infrequency of smoking overall, presented 
sparse cells when stratified by case and mating type parameters. This low dose of smoking may 
have also influenced our ability to identify relevant gene-smoking interactions.    
 Overall, we found little evidence of multiplicative interaction between SNPs in smoking 
response pathways and maternal smoking during spiral artery remodeling. The case-mother 
control-mother design as well as environmental interaction analysis may be useful methods to 
include in the toolkit for the genetic study of pregnancy outcomes, particularly preeclampsia. 
However, very large studies will be needed in order to be adequately powered to examine 
exposures by mating type, genotype, case-status and dose. 
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Tables 
Table 13. Characteristics of participants by case and control status (n=2,400 pregnancies) 
 Preeclampsia Cases (N = 1451) 
Controls 
(N = 949) 
 No. % No. % 
Maternal Agea     
     £ 20 years 45 3.1 14 1.5 
     21 – 30 years 834 57.5 462 48.7 
     31 – 40 years 551 38.0 468 49.3 
     ³ 41 years 20 1.4 5 0.5 
     
Maternal Educationa     
     < High School 127 9.3 69 7.8 
     High School Graduate 431 31.6 255 28.7 
     University Degree 804 59.0 565 63.6 
     
Body Mass Index (kg/m2)a     
     Underweight (<18.5) 23 1.6 32 3.5 
     Normal weight (18.5-24.9) 686 48.8 612 66.6 
     Overweight (25.0-29.9) 437 31.1 181 19.7 
     Obese (30.0+) 259 18.4 94 10.2 
     
Any Maternal Smoking (11-20 weeks) 119 8.2 95 10.0 
     Smokers who quit during 11-20 wksb 39 32.8 24 25.3 
Smoking Intensitya, b     
     0-2 cigarettes/day 34 36.5 37 46.3 
     3-5 cigarettes/day 30 31.3 19 23.8 
     6-10 cigarettes/day 28 29.2 19 23.8 
     >10 cigarettes/day 3 6.3 5 3.1 
     
Nulliparousa 954 65.8 392 41.3 
Preterm (< 37 weeks)a 305 21.2 28 3.0 
Small for gestational age (SGA)  
(< 10th percentile)a, c 323 22.5 74 7.8 
Severe preeclampsia 285 19.7 -- -- 
Birthweight (mean grams (SD))a 3173.4 (820.3) 3676.74 (512.4) 
aMissing observations for each covariate: maternal age (1), maternal education (149), body mass index 
(76), smoking intensity (39), parity (1), preterm birth (11), small for gestational age (16), birthweight (1). 
b Percentage calculated as proportion of women who smoked during 11-20 week window. 
c Population percentiles derived from Norwegian distribution, eSnurra Norway. 
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Figures 
 
 
Figure 15. Risk ratios for the association of smoking on preeclampsia stratified by genotype for 
the top three SNP-maternal genotype interactions. 
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Additional Results 
Models were run for aim 2 (as in aim 1) for the association of SNP and preeclampsia for 
the additional 397 smoking detoxification SNPs. There were no additional significant findings. 
Analyses were run separately restricting to 1) nulliparous women, and 2) overweight women 
with preeclampsia diagnosed after 34 weeks’ gestation. Results were not substantially different 
than in the full cohort. 
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CHAPTER VI. DISCUSSION 
 
A. Summary of Findings 
This study was motivated by the well-established inverse relationship between smoking 
and preeclampsia, the reasons for which remain unknown.6 Although methodological reasons 
for this inverse association have been suggested,261 this study aimed to investigate potential 
biological reasons for the association.   
The first aim was to determine if variants in carbon monoxide and nitric oxide signaling 
genes are associated with preeclampsia, both overall, and among preeclampsia subtypes. This 
aim investigated genes that may mimic smoking as a proxy for exposure. For example, it is 
difficult to measure nitric oxide in the placental tissue and uterine arteries, however, we can 
measure genotype within the nitric oxide synthase gene, which has a direct effect on synthesis 
of nitric oxide in the body. This genetic pathway is of interest because there are 
pharmaceuticals that directly operate through the action of nitric oxide that could potentially be 
used as a therapeutic treatment for preeclampsia. An association between a gene in these 
pathways and preeclampsia could provide support for specific ways in which components of 
cigarette smoke influence the development of preeclampsia.  
In our aim 1 analysis, assessing associations of SNPs within carbon monoxide and nitric 
oxide signaling pathways with preeclampsia, we found one SNP meeting our criterion of Q-
value <0.05, a child variant, rs12547243 in adenylate cyclase 8 (ADCY8). We also saw some 
suggestive maternal associations of SNPs in PDE1C for preeclampsia accompanied by early 
delivery and preeclampsia accompanied by small for gestational age.  
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Biologically, these associations are interesting and relevant. ADCY8 encodes adenylate 
cyclase 8 which catalyzes the conversion of adenosine-5’-triphosphate (ATP) to 3’, 5’-adenosine 
monophosphate (cAMP).249 PDE1C encodes calcium/calmodulin-dependent 3’,5’-cyclic 
nucleotide phosphodiesterase 1C and catalyzes conversion of cAMP and cGMP to their 5-
prime-monophosphates (AMP and GMP).251 Both are part of the canonical pathway for cellular 
effects of sildenafil (“Viagra”), a phosphodiesterase inhibitor that operates through nitric oxide 
signaling to increase vasodilation,252 and mouse studies have demonstrated resolution of the 
preeclampsia phenotype with the administration of sildenafil.253,254 
The second aim was to determine if genetic variants in carbon monoxide and nitric oxide 
signaling genes, as well as smoking detoxification genes modify the effect of smoking on 
preeclampsia. Our hypothesis was that the smoking-preeclampsia relationship could be affected 
by detoxification of components of cigarette smoke (e.g. nicotine, aryl hydrocarbons) or through 
the additional endogenous production of byproducts (NO/CO). Although there is a strong 
inverse association between smoking and preeclampsia, there is individual variation in those 
who experience a reduced risk of preeclampsia in the presence of smoking; many women who 
smoke still get preeclampsia. Biologically, it is possible that smoking activates a gene that 
induces a response that reduces susceptibility to preeclampsia. For example, there are genes 
that are activated by smoking such as the aryl hydrocarbon receptor gene (AHR) and members 
of the GST and CYP families of genes. The encoded proteins are hypothesized to protect the 
body against the harmful effects of smoking, however, may also have more general protective 
properties such as reducing oxidative stress and inflammation and increasing angiogenesis. 
Although the specific gene may not directly affect preeclampsia, activation in the presence of 
smoking may induce a response. Given the strong effect of smoking on preeclampsia, genes 
that are affected by smoking may modify the overall association between smoking and 
preeclampsia. Observing differential associations between smoking and preeclampsia by 
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genotype could provide evidence for why some individuals experience a protective effect of 
smoking and potentially identify mechanistic targets for future research. 
In aim 2, we found limited evidence for multiplicative SNP by smoking interaction after 
correction for multiple testing but saw a few potentially interesting findings.  We saw decreasing 
risk of smoking on preeclampsia with increasing number of maternal variant alleles for 
rs3765692 (TP73) and rs10770343 (PIK3C2G) and an increasing risk of smoking on 
preeclampsia with increasing number of maternal variant alleles for rs2278361 (APAF1). 
The P3IK pathway (in which PIK3C2G is included) has recently been determined to 
affect placental maternal-fetal resource allocation. 263,264 And the aryl hydrocarbon receptor 
activation represses TP73 and APAF1, resulting in pro-proliferative, anti-apoptotic function,265 all 
of which may play a role in preeclampsia. One could argue, however, that all of these genes 
were selected for their biological relevance to preeclampsia, and thus, we might expect to see 
some interesting biological patterns among our results.  
 
B. Strengths and Limitations 
Strengths 
This study is innovative in that it is one of the few to tackle the potential reasons for the 
inverse smoking-preeclampsia association and explore potential biological mechanisms using 
epidemiologic data. In particular, there are very few studies of gene by environment interactions 
that have been conducted for preeclampsia and reproductive outcomes in general, and to our 
knowledge, this is the first of gene by smoking interaction with preeclampsia.  
A major advantage of this study is that it is nested within a cohort whose target 
population is all pregnant women in Norway. Selection from a well-defined cohort improves both 
internal and external validity. Because of the structure of healthcare in Norway, limited access to 
prenatal care does not impede recruitment as it would in other studies in which women are 
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recruited through prenatal care providers. This can increase generalizability to a broader 
population, potentially making the study population more comparable to the target population. 
Prior genetic studies of preeclampsia have been limited by power. Our study is one of 
the largest genetic studies of preeclampsia to date, which allowed us to address both mother 
and child genotype. Our study design takes advantage of family-based constraints and uses the 
expectation maximization algorithm to account for missing data and improve power. Although 
there are serious criticisms of candidate genes studies,273 this study, though not whole-genome 
scale, aimed to improve upon prior candidate gene studies by including more genes and SNPs 
while continuing to apply a hypothesis-driven approach to maintain statistical power. 
Given the suspected pathophysiology underlying preeclampsia, it is biologically plausible 
that both maternal and child genotypes contribute to this pregnancy complication. Our dyad 
analysis accounted for family structure by including both mother and child DNA, each adjusting 
for the other by characterizing associations with mating types. Few other genetic studies of 
preeclampsia have addressed child genotype124,194,260, and even fewer have simultaneously 
modeled both mother and child genotype.274 
While addressing limitations of previous studies by accounting for both maternal and 
child genetic components, this study also took on the challenges of misclassification and 
heterogeneity of the preeclampsia phenotype. Preeclampsia was verified by antenatal medical 
records and hospital diagnostic codes through medical record validation.223 All cases of 
preeclampsia in our study were verified as having preeclampsia and all controls were verified as 
being free of preeclampsia. Using this information, we were also able to classify cases into 
preeclampsia subtypes that may have differing underlying etiologies an aspect of preeclampsia 
that has not been well-explored in genetic studies. 
In addition to addressing some of the challenges of defining the preeclampsia outcome, 
we also addressed challenges of defining maternal smoking exposure. We did so by selecting a 
specific etiologic window during which aberrant placentation may affect development of 
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preeclampsia. For our primary analysis, we combined information from multiple questions about 
smoking timing and behavior to define smoking as any smoking during gestational weeks’ 11 to 
20. We selected this time period to specifically capture smoking during the period in which 
maternal blood flow perfusion into the intervillous space increases and trophoblasts move to an 
invasive state completing spiral artery remodeling.228 
 
Limitations 
Candidate gene studies have had limited success in identifying causal variants in the 
past,275 and this study is no exception. Although we use prior evidence of biological significance 
to inform this hypothesis-driven study, genome wide association studies are typically a more 
efficient and thorough way of identifying potential associations. Prior GWA studies of 
preeclampsia, however, have suffered from insufficient sample size and heterogeneity of 
ancestry. Our study used a hybrid, hypothesis-driven approach to examine SNPs in whole 
pathways while still reducing the number of statistical tests compared to a GWAS.  
Our gene by environment analysis was limited by statistical power. In the gene by 
environment analysis, we chose to limit our analysis to SNPs with plausible biological 
significance for their relationship with smoking, and with minor allele frequencies greater than 
10%. However, despite doing so, we are still underpowered to assess gene by smoking 
interactions for the number of SNPs in our study, particularly when mating types were allowed to 
differ by exposure status, and when smoking was considered by continuity across the exposure 
window. 
Our study assessed multiplicative SNP by smoking interactions. However, additive 
interactions may deliver a more easily translatable public health message insofar as they 
describe the absolute risk difference among subgroups.152 We were only able to estimate 
multiplicative interactions, but it is possible that important additive interaction exists. 
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Development of good methods for assessing additive interactions based on a case-
parent/control-parent approach is a matter for future work. 
We attempted to replicate our findings within UK data from the InterPregGen 
Consortium, a consortium of studies of genetics of preeclampsia. Although our ability to include 
mother-child pairs is innovative, most available preeclampsia data sources do not include paired 
mother-child dyads. Our replication approach analyzed both mother and child genetic data, but 
the data were unpaired, and thus, may not be comparable. 
Although our analytic method is innovative, improves power, and allows us to account 
for mother and child genetic contributions, this study may be subject to several types of 
confounding, misclassification, and selection biases.  
 
Confounding 
This study controlled for paired mother-child genotypes, which is likely the biggest 
confounder However, a limitation of this study design is the challenge of controlling for external 
confounders. After accounting for maternal and child genotype, in the SNP-preeclampsia 
relationship, there is little confounding since there is little that directly affects genotype. 
However, ancestry does affect genotype and given that inference under this design relies on 
comparison of case-mother pairs with control-mother pairs, there is still room for bias due to 
population stratification. Moreover, because we are potentially interested in the joint effect of 
both SNP (or related biological mechanisms) and maternal smoking, we would want to control 
for confounding in the relationship of the factor defining the subgroups (smoking) as well.276 
Maternal age and parity are associated with both smoking and preeclampsia in our cohort, and 
both are potential confounding variables in the smoking-preeclampsia association. Maternal age 
and parity were not included in the model, however, age is not associated with preeclampsia 
after adjusting for nulliparity or related to allele frequency of the SNPs in our study so 
confounding due to these variables is unlikely an issue. 
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Population stratification bias, resulting from systematic differences in allele frequencies 
by population substructure may lead to spurious associations. In a typical logistic regression 
analysis, principal components are included as covariates in the model to adjust for population 
substructure; as with other covariates, ability to include eigenstrata is limited as well. We 
addressed this limitation by assessing population stratification in the quality control process to 
determine if ancestral homogeneity was a plausible assumption within this Norwegian 
population. We compared our population with the 1000 Genomes reference populations and 
excluded outlier observations in a sensitivity analysis. 
Our model may also be vulnerable to exposure-related population stratification, which 
has been shown to bias results if both smoking exposure and mating type frequencies differ 
among subpopulations.262 We controlled for exposure-related population stratification bias in a 
sensitivity analysis by including additional family-based exposure parameters (Table S13), and 
results were substantially unchanged. 
 
Classification of Smoking 
Our study used self-reported smoking status from maternal questionnaire. Use of self-
reported data, as well as the changing smoking behaviors of women throughout the course of 
pregnancy may result in misclassification bias. Smoking status may be underreported due to 
social stigma, particularly among pregnant women where the relationship between smoking and 
poor birth outcomes are known.272 A recent validation study of self-reported smoking and 
plasma cotinine indicated that reported smoking on the MoBa questionnaire is a fairly valid 
marker of tobacco exposure (Sensitivity=82%, Specificity=99%).227 However, this degree of 
measurement error may have biased our results.  
Additionally, pregnancy is a time period in which many women quit smoking after 
learning they are pregnant or are actively trying to quit smoking throughout pregnancy. In our 
study 19.5% of women reported smoking in the first trimester and 5.9% in the third trimester. 
  
 
128 
When assessing SNP by smoking interaction by time period, estimates were similar, but 
attenuated toward the null in the first trimester (Fig S1). Although we selected a specific, 
biologically relevant time period for smoking, 63 of 214 (29%) of women who smoked during 
weeks’ 11-20 reported quitting in a week during that period. To address whether quitting may 
have influenced our results, we conducted a sensitivity analysis to see if people who reported 
quitting were different than those who continued smoking. The direction of association was the 
same for all groups, but associations were stronger and more significant for the group of 
smokers who did not report quitting during weeks’ 11-20 compared to those who did quit, 
indicating there may be a dose-response effect that should be investigated further (Table S14).   
Although smoking quantity may be important, we analyzed smoking dichotomously (ever 
versus never in that period). Although we did have information on smoking intensity of number 
of cigarettes smoked we were unable to assess smoking dose, as our data were already sparse 
before stratifying by smoking. Table S15 shows the data table for one of our lead SNPs 
demonstrating that cell counts are already sparse without further stratifying by smoking 
intensity. Additionally, this is a population of relatively light smokers; even the heaviest smokers 
were smoking only approximately half a pack of cigarettes a day. 
 
Selection Factors 
This study is also open to several forms of selection bias. Possible selection bias may 
occur due to refusal to participate. MoBa is a long-term prospective cohort study, and the 
criteria to participate are somewhat stringent; participants must agree that MoBa can access 
health registries for purposes within the broad aim of the study and they agree to give 
biospecimens from themselves and their infant. The participation rate is low, at approximately 
45%.221 When MoBa study participants were compared with the population of all births in 
Norway during the same time period, prevalence of preeclampsia was similar, but women in 
MoBa were less likely to be young (<25 years), live alone, smoke, and have more than two 
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births.277 When associations between covariates and birth outcomes in the two populations were 
compared, however, there were few differences (e.g. the ratio of adjusted odds ratios between 
smoking and low birthweight and between parity and preeclampsia were approximately 1.0).277 
A consistent problem in the study of preeclampsia is the problem of left truncation, which 
may result in another form of selection bias. Lisonkova and Joseph posit that left truncation bias 
due to differential rates of early pregnancy loss among smokers is a plausible explanation for 
the inverse relationship between smoking and preeclampsia.261 They make the following 
assumptions in their simulation model: 1) abnormal placentation leads to preeclampsia, 2) 
similar rates of abnormal placentation occur in smokers and non-smokers, 3) higher rates of 
early pregnancy loss occur among smokers versus non-smokers, 4) higher rates of early 
pregnancy loss occur among women with abnormal placentation than without, and 5) the 
highest rates of early pregnancy loss occur among smokers with abnormal placentation. By 
varying rate ratios of early pregnancy loss due to smoking and early pregnancy loss due to 
abnormal placentation, they illustrate that the inverse association with smoking may be a result 
of bias due to left truncation.  
Because women enrolled in MoBa between 13 and 17 weeks’ gestation, we were unable 
to capture early pregnancy losses and whether there is differential loss by smoking status. 
Therefore, we are unable to exclude left truncation as a potential mechanism for the smoking-
preeclampsia relationship. However, Kinlaw and colleagues278 recently re-examined the 
assumptions of Lisonkova and Joseph, and the impact of varying these assumptions on the 
inverse association of smoking. Lisonkova assumed: 1) all fetuses surviving past 20 weeks of 
pregnancy with abnormal placentation progress to preeclampsia, 2) no fetuses surviving past 20 
weeks of pregnancy without abnormal placentation progress to preeclampsia, and 3) maternal 
smoking has no effect on abnormal placentation.278 Kinlaw and colleagues present scenarios in 
which there is much less bias due to differential early pregnancy loss when more realistic 
assumptions about the contributions of abnormal placentation on preeclampsia are applied.277 
  
 
130 
Though we did not find any evidence of gene by smoking interaction of SNPs within any 
of the GST genes in our study, there is evidence that the glutathione S-transferase P1b-1b 
genotype is found more often in women with early pregnancy loss, and particularly among those 
who smoked cigarettes279 demonstrating a factor that might influence differential early loss by 
smoking and also affect placentation. It is possible that the inverse association between 
maternal smoking and preeclampsia is due to some combination of a biological effect of 
smoking on preeclampsia, some bias due to differential early pregnancy loss (or competing risk 
by preterm birth), and some additional unknown mechanism(s). Our results contribute to the 
growing literature of biologically interesting findings of the relationship between smoking and 
preeclampsia. 
 
C. Directions for Future Research 
The estimated heritability of preeclampsia is approximately 55%,280 and thus it is 
surprising that this study and previous studies have not found any strong and replicated genetic 
signals. Because of evidence that there are genetic contributors to preeclampsia, questions of 
genetic influences on preeclampsia should continue to be investigated, but may require novel 
methods to address. 
In our study, SNPs were selected using a 10kb upstream and downstream margin 
around the transcription start and end sites for each gene. Although we selected these margins 
to ensure that we captured the entire coding region of the gene and proximate regulatory 
regions, recent studies suggest that distal intergenic variants can alter gene expression through 
their role within the regulatory regions.258 Although there were no previously found genome-wide 
associations found for any of our SNPs, a search with HaploReg281 revealed that several of 
them (rs12547243, rs30593, and rs10770343) were found to alter the regulatory motifs of 
proteins encoded by genes not included in the present study (NF-kappaB, TATA, and NRSF, 
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respectively). GWAS can capture these intergenic variants by looking across the whole genome 
but will require large sample sizes to be adequately powered.  
The pathophysiology of preeclampsia, and likely involvement of the placenta in its 
etiology, may be another reason that previous genetic studies of preeclampsia have not found 
any significant genetic signal. Our most noteworthy results are for child-genotype associations 
with preeclampsia. A few other genetic studies of preeclampsia have addressed child 
genotype,124,194,260 but most have focused on the maternal component. While our analytic 
method begins to address some of the complexity of correlated mother and child genotype, it 
does not assess their interaction, which may be important and is a future area of interest to our 
study. It is plausible that there is a maternal genetic factor that affects a physiological response 
in the mother and a different fetal genetic factor that influences fetal programming and both 
must occur simultaneously during pregnancy to support optimal growth of the placenta and 
fetus. Likewise, maternal-fetal incompatibility can contribute to development of disease, such as 
that that is experienced with hemolytic disease of the newborn with mother and child having 
different Rhesus factor.282 Our current analytic methods cannot handle inclusion of mother-child 
genetic interactions because it would over-parameterize our model, but future studies could 
incorporate mother-child interactions through the extension of our design with the use of 
methods like the maternal-fetal incompatibility test developed by Sinsheimer and colleagues, 
which allow one to estimate direct effects of both maternal and child variant alleles, as well as 
their interactions through determination of whether maternal and fetal alleles are the same or 
different at each locus.283 These methods are just beginning to be applied on a genome-wide 
scale.284 
Additionally, there is some evidence that paternally-inherited imprinted genes and 
partner-genotype discordance may be important in the placenta and in the development of 
preeclampsia in particular. 285,286 A fetal contribution to preeclampsia may, in part, occur through 
paternal genes. Skjærven and colleagues found that men born after a pregnancy complicated 
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by preeclampsia had an increased risk of fathering a preeclamptic pregnancy (OR=1.5, 95% CI: 
1.3, 1.7)287 and Lie and colleagues found that risk for preeclampsia is increased for women in 
which the pregnancy was fathered by a man who has previously fathered a preeclamptic 
pregnancy in a different woman (OR=1.8, 95% CI: 1.2, 2.6).127 Although our mother-child dyad 
design will account for paternal contributions through inclusion of child genotype, other family-
based approaches are necessary to detect contributions of paternal imprinting or paternal 
genetic discordance. Future analyses of preeclampsia should consider using information from 
the father where available, and new studies should consider inclusion of fathers at study 
development. Although they have their limitations, family-based studies are useful in the toolkit 
to study reproductive outcomes and can be expanded to incorporate paternal genotype and 
imprinting, a relevant area of study for preeclampsia. The triad approach also is fully protective 
against bias due to population stratification. 
Heterogeneity of the preeclampsia phenotype can limit the ability to detect genetic 
effects. This heterogeneity may be due to both how preeclampsia is defined and classified, and 
those changing definitions over time, as well as differences among the underlying etiologies of 
different types of preeclampsia. Our study was one of the few that had a validated measure of 
the preeclampsia phenotype and assessed subtypes, but further refinement of the phenotype in 
future studies could improve our ability to detect associations and investigate biological 
mechanisms. Use of other methods such as growth mixture models that investigate blood 
pressure and proteinuria repeatedly over time could enable one to identify trajectories over time 
and provide insight into other ways of classifying preeclampsia that may have different etiology. 
These analyses could incorporate smoking and other environmental information; for example, 
Macdonald-Willis and colleagues did a latent class analysis of proteinuria and found that 
smoking was weakly associated with odds of proteinuria after 37 weeks’ gestation.288 
Examination of other early pregnancy physiological factors instead of just a preeclampsia 
diagnosis could also provide insight into genetic contributions. Preeclampsia is diagnosed after 
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20 weeks’ gestation, which is after the hypothesized mechanisms contributing to preeclampsia 
have already occurred. There are methods in development to detect precursors to 
preeclampsia, such as mapping of the placenta vasculature. 289,290 Use of such methods in 
future studies could provide a more refined phenotype that may reveal different associations 
than diagnosed preeclampsia. 
 The lack of replication in the literature is likely principally due to low power, and our 
study of gene by smoking interactions was particularly underpowered. Although it would provide 
less specific information and allow less flexibility in the model, we could improve our study 
power by using a 2 degree of freedom test that is a joint significance test for SNP and SNP by 
exposure.291 However, a preferred approach is to pool across several large European birth 
cohorts, which would increase the availability of paired mother-child dyad data and increase 
statistical power. There are multi-study consortia forming with the objective of studying genetics 
of preeclampsia.241 These collaborative efforts may provide the necessary power to more 
thoroughly address this perplexing condition. 
Finally, it is plausible that any genetic effects of preeclampsia may not be purely a single 
SNP association but rather epigenetic or polygenic. There are already studies underway that 
are using some of these novel methods for the study of preeclampsia161,292 and future studies 
should continue to explore potential genetic mechanisms beyond single SNP-outcome 
associations 
 
D. Public Health Significance 
Preeclampsia is a well-studied condition, though one in which there are still many 
unknowns about underlying mechanisms and etiology. We have known of the inverse 
association with maternal smoking for decades, yet the reason for this relationship is still 
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elusive. This study contributes to the small existing literature exploring the smoking-
preeclampsia relationship and the growing literature on genetics and preeclampsia. 
There are currently few options for effective treatment of preeclampsia or interventions 
for prevention. Study of genetic variants involved in carbon monoxide and nitric oxide signaling 
can provide additional support for clinical trials that are currently underway investigating 
potential treatments that operate upon these pathways, such as sildenafil and L-arginine. 
Pharmacogenomic analysis of data from those clinical trials will likely provide additional insights 
into mechanisms of effect. 
Our study underscores the importance of addressing the contribution of both maternal 
and fetal components to the condition of preeclampsia. The fetal genotypic contribution to 
preeclampsia has been widely understudied despite the probable placental contribution to the 
condition; indeed, our primary finding was for a fetal SNP. Methods that incorporate maternal 
and fetal genetics may be relevant to a diverse set of reproductive and perinatal conditions that 
may have a dyadic nature (e.g. congenital anomalies, preterm birth, breastfeeding problems, 
postpartum depression) most of which have predominantly been explored as solely fetal or 
solely maternal. Failure to acknowledge both maternal and child genotype may result in missing 
important associations in which mother and child genotype may operate differently. 
This study contributes to the growing area of genetic perinatal epidemiology. Perinatal 
epidemiology is an area in which there are unique methodological challenges due to 
unobserved data in early pregnancy, limited ability to collect biomarkers of a fetus, changing 
maternal behaviors throughout the course of pregnancy, and simultaneous maternal and child 
contributions. This study brings attention to the importance of considering these issues as 
genetic epidemiology in the area of perinatal health continues to expand. 
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APPENDIX: SUPPLEMENTARY TABLES AND FIGURES 
 
Table S1. Genes and pathways for Aim 1 
Gene Symbol Chr Primary Canonical Pathway 
CASP9 1 eNOS Signaling  
ADCY3 2 eNOS Signaling  
CASP8 2 eNOS Signaling  
CASP3 4 eNOS Signaling  
CCNA2 4 eNOS Signaling  
GUCY1A3 4 eNOS Signaling  
GUCY1B3 4 eNOS Signaling  
ESR1 6 eNOS Signaling  
CAV1 7 eNOS Signaling  
ADCY8 8 eNOS Signaling  
GUCY1A2 11 eNOS Signaling  
CHRNA3 15 eNOS Signaling  
CHRNA5 15 eNOS Signaling  
EPAS1 2 eNOS Signaling Related Gene 
STAT1 2 eNOS Signaling Related Gene 
PDE1C 7 eNOS Signaling Related Gene 
PDGFA 7 eNOS Signaling Related Gene 
PON1 7 eNOS Signaling Related Gene 
ENG 9 eNOS Signaling Related Gene 
TLR4 9 eNOS Signaling Related Gene 
GUCY2C 12 eNOS Signaling Related Gene 
MPO 17 eNOS Signaling Related Gene 
PRKCA 17 eNOS Signaling Related Gene 
PDGFB 22 eNOS Signaling Related Gene 
PDGFC 4 eNOS Signaling/HIF1α Signaling  
NOS3 7 eNOS Signaling/HIF1α Signaling  
PIK3C2G 12 eNOS Signaling/HIF1α Signaling  
AKT1 14 eNOS Signaling/HIF1α Signaling  
FIGF X eNOS Signaling/HIF1α Signaling  
MAPK10 4 NOS Signaling/HIF1α Signaling 
MAPK9 5 NOS Signaling/HIF1α Signaling 
MAPK13 6 NOS Signaling/HIF1α Signaling 
MAPK14 6 NOS Signaling/HIF1α Signaling 
MAPK8 10 NOS Signaling/HIF1α Signaling 
MAPK3 16 NOS Signaling/HIF1α Signaling 
MAPK1 22 NOS Signaling/HIF1α Signaling 
MAPK11 22 NOS Signaling/HIF1α Signaling 
MAPK12 22 NOS Signaling/HIF1α Signaling 
NOS1 12 NOS Signaling/HIF1α Signaling  
NOS2 17 NOS signaling/HIF1α Signaling  
ARNT 1 HIF1α Signaling  
NCOA1 2 HIF1α Signaling  
EDN1 6 HIF1α Signaling  
EPO 7 HIF1α Signaling  
MAPK15 8 HIF1α Signaling  
MMP1 11 HIF1α Signaling  
MMP12 11 HIF1α Signaling  
MMP3 11 HIF1α Signaling  
MDM2 12 HIF1α Signaling  
APEX1 14 HIF1α Signaling  
HIF1A 14 HIF1α Signaling  
MAPK6 15 HIF1α Signaling  
MMP2 16 HIF1α Signaling  
MAPK7 17 HIF1α Signaling  
MAPK4 18 HIF1α Signaling  
EGLN2 19 HIF1α Signaling  
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Gene Symbol Chr Primary Canonical Pathway 
MMP9 20 HIF1α Signaling  
HBB 11 Heme Degradation 
HBA1 16 Heme Degradation 
HBA2 16 Heme Degradation 
HMOX2 16 Heme Degradation  
HMOX1 22 Heme Degradation  
CA9 9 Heme Degradation Related Gene 
NGB 14 Heme Degradation Related Gene 
HP 16 Heme Degradation Related Gene 
MB 22 Heme Degradation Related Gene 
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Table S2. Genes and pathways for Aim 2 
Pathway Description Genes* 
Endothelial nitric oxide 
synthase signaling 
Describes the synthesis of nitric oxide from 
L-arginine. Endothelial nitric oxide 
synthase plays a crucial role in the state of 
blood vessel vasodilation and blood 
pressure regulation. 
CASP9, ADCY3, CASP8, CASP3, 
CCNA2, GUCY1A3, GUCY1B3, 
ESR1, CAV1, ADCY8, GUCY1A2, 
CHRNA3, CHRNA5, EPAS1, 
STAT1, PDE1C, PDGFA, PON1, 
ENG, TLR4, GUCY2C, MPO, 
PRKCA, PDGFB, PDGFC, NOS3, 
PIK3C2G, AKT1, FIGF, MAPK10, 
MAPK9, MAPK13, MAPK14, 
MAPK8, MAPK3, MAPK1, MAPK11, 
MAPK12, NOS1, NOS2 
Heme degradation Describes the breakdown of hemoglobin 
into carbon monoxide, biliverdin, iron, and 
bilirubin. 
HBB, HBA1, HBA2, HMOX2, 
HMOX1, CA9, NGB, HP, MB 
Hypoxia-inducible 
factor 1-alpha 
signaling 
Describes regulation of oxygen 
homeostasis and response to hypoxia. 
Activates transcription of nitric oxide 
synthase. Also involved in the xenobiotic 
response via aryl hydrocarbon receptor 
nuclear translocator. 
PDGFC, NOS3, PIK3C2G, AKT1, 
FIGF, MAPK10, MAPK9, MAPK13, 
MAPK14, MAPK8, MAPK3, MAPK1, 
MAPK11, MAPK12, NOS1, NOS2, 
ARNT, NCOA1, EDN1, EPO, 
MAPK15, MMP12, MMP3, MDM2, 
APEX1, HIF1A, MAPK6, MMP2, 
MAPK7, MAPK4, EGLN2, MMP9 
Xenobiotic metabolism Describes the three groups of enzymes 
that metabolize, eliminate, and detoxify 
harmful substances. Phase I: introduces 
polar moiety, Phase II: conjugates toxins to 
small hydrophilic molecules, Phase III: 
transporters that export toxins. 
IL1A, MAPK1, HS2ST1, CYP3A7, 
MAPK13, IL6, NFKB1, MAPK11, 
PTGES3, ARNT, HMOX1, GSTT1, 
MAOB, CYP1A2, ALDH1A1, 
MAPK3, NOS2, AHR, GSTK1, 
PRKCA, ATM, GSTA3, ABCB1, 
GSTM1, CYP1A1, GSTM3, GSTA4, 
NQO1, MAPK8, PIK3C2G, MAPK9, 
NFKB2, MAPK12, GSTO1, 
CYP1B1, AIP, MAPK14, SULT1A1, 
NCOA1, IL1B, CYP2B6, MAPK7, 
GSTO2, TNF, UGT1A9, GSTP1, 
MAOA 
Aryl hydrocarbon 
receptor signaling 
Describes mediation of halogenated and 
polycyclic aromatic hydrocarbons by the 
aryl hydrocarbon receptor. Activates 
xenobiotic metabolizing enzymes and 
other growth factors and proteins involved 
in cell cycle progression and apoptosis. 
CDKN2A, MAPK1, TP73, IL6, 
CCND1, ARNT, MYC, RB1, 
ALDH1A1, CYP1A2, CCND3, 
TGFB1, MAPK3, AHR, FASLG, 
GSTK1, ATM, TP53, CCNE2, 
GSTM3, CDK6, NFKB2, CCND2, 
E2F1, TGFB3, ESR1, TNF, GSTP1, 
CDK2, IL1A, CDK4, NFKB1, 
PTGES3, FAS. CCNA2, GSTT1, 
TGFB2, CHEK2, GSTA3, GSTM1, 
CYP1A1, GSTA4, NQO1, APAF1, 
MAPK8, MDM2, BAX, CYP1B1, 
GSTO1, AIP, CCNE1, CDKN1A, 
IL1B, ATR, CDKN1B GSTO2 
Glutathione-mediated 
detoxification 
Describes detoxification in which the first 
step is catalyzed by glutathione 
transferases. 
GSTA3, GSTM1, GSTT1, GSTM3, 
GSTA4, GSTO2, GSTP1, GSTO1, 
GSTK1 
Nicotine degradation II 
and III 
Describes degradation of nicotine primarily 
through the metabolic action of cytochrome 
P450. 
CYP2D6, ADH7, CYP1A1, CYP1A2, 
CYP2E1, CYP2A7, CYP3A7, 
CYP2A6, CYP2B6, UGT1A9, 
CYP1B1 
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Table S3. Number of duplicates on each plate 
Plate Duplicate Pairs 
NPE003 1 
NPE005 1 
NPE009 1 
NPE010 1 
NPE011 1 
NPE012 1 
NPE013 1 
NPE014 1 
NPE015 1 
NPE016 1 
NPE017 1 
NPE018 1 
NPE019 1 
NPE020 1 
NPE021 1 
NPE022 1 
NPE023 1 
NPE024 1 
NPE025 1 
NPE027 1 
NPE028 1 
NPE029 1 
NPE030 1 
NPE601 1 
NPE602 1 
NPE603 1 
NPE604 1 
NPE605 1 
NPE606 1 
NPE607 1 
NPE608 1 
NPE609 1 
NPE610 1 
NPE611 1 
NPE612 1 
NPE613 1 
NPE614 1 
NPE615 1 
NPE616 1 
NPE618 1 
NPE619 2 
NPE620 1 
NPE621 1 
NPE623 1 
NPE702 1 
NPE703 1 
NPE704 1 
NPE705 1 
617/617r 1 
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Table S4. Study duplicate pairs 
Sample ID Plate Well Duplicate ID Plate Well Relationship 
92096 3 H03 91567 3 H08 Child 
92098 5 F02 91767 5 H09 Child 
91282 9 B01 89205 9 A04 Mother 
91283 10 F07 89352 10 E10 Child 
89405 11 D05 91284 11 F11 Mother 
89493 12 E04 91285 12 B05 Mother 
89597 13 A06 91286 13 A01 Mother 
91287 14 D02 89660 14 H01 Child 
91288 15 G10 89791 15 F06 Mother 
91289 16 C06 89878 16 F05 Child 
91290 17 C05 90013 17 A11 Mother 
91291 18 D10 90100 18 H09 Child 
91292 19 H03 90179 19 C08 Mother 
91293 20 D01 90222 20 G01 Child 
90379 21 G09 91294 21 F02 Mother 
91295 22 B09 90498 22 H12 Child 
91296 23 F06 90539 23 B06 Mother 
90599 24 G01 91297 24 D04 Mother 
91298 25 E12 90769 25 D11 Mother 
91300 27 F03 90890 27 A03 Child 
91301 28 C03 91028 28 E08 Child 
91119 29 C08 91302 29 B07 Mother 
91303 30 E04 91162 30 F01 Child 
96109 601 H03 98671 601 F07 Mother 
98672 602 E03 96196 602 H02 Child 
98673 603 D06 96358 603 F11 Child 
98674 604 C01 96408 604 A06 Child 
98675 605 D09 96495 605 A05 Mother 
98676 606 F03 96648 606 F12 Child 
96653 607 C01 98677 607 B07 Mother 
98679 608 F07 96788 608 E06 Child 
98680 609 E02 96924 609 G11 Child 
98681 610 F08 96938 610 F01 Child 
98682 611 D03 97118 611 F12 Child 
98683 612 D02 97136 612 B03 Child 
98684 613 G03 97257 613 E06 Mother 
98685 614 B12 97365 614 B08 Mother 
98686 615 F05 97407 615 E01 Mother 
97501 616 E01 98687 616 B09 Mother 
98689 618 C03 97687 618 C01 Mother 
97845 619 E09 98690 619 A06 Mother 
98382* 619 H05 102247* 619 B07 Mother 
98691 620 D01 97943 620 A10 Mother 
98692 621 B10 98022 621 H07 Child 
98694 623 H05 98181 623 D04 Mother 
102243 702 E09 98282 702 D09 Mother 
98437 703 B03 102242 701 C03 Mother 
102244 703 F02 98558 703 E02 Mother 
102245 704 A03 98346 704 A02 Mother 
102246 705 H04 98245 705 G04 Mother 
98688 617/617r E02 97620 617 G04 Child 
*Duplicate pair 98382/102247 excluded for discordance 
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Table S5. Identification of trio members from 5 CEPH Utah families 
Family ID Child ID Gender Paternal ID Maternal ID 
1341 6991 Female 6993 6985 
1347 10859 Female 11881 11882 
1362-A* 10860 Male 11992 11993 
1362-B* 10861 Female 11994 11995 
1408 10831 Female 12155 12156 
CEPH Pedigree information can be found at: 
https://catalog.coriell.org/0/sections/collections/nigms/CEPHFamilies.aspx?PgId=49&coll=GM 
* 1362-A and 1362-B are two branches of the same pedigree. 1362-A is the father and paternal 
grandparents while 1362-B is mother and maternal grandparents, therefore, branches are unrelated. 
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Table S6. Number of Centre d’Etude du Polymorphisme Humain (CEPH) known family trios 
genotyped on each plate 
Plate Samples 
NPE001 2 
NPE002 1 
NPE003 1 
NPE004 1 
NPE005 5 
NPE006 7 
NPE007 3 
NPE008 2 
NPE009 1 
NPE010 1 
NPE011 1 
NPE012 1 
NPE013 1 
NPE014 1 
NPE015 1 
NPE016 1 
NPE017 1 
NPE018 1 
NPE019 1 
NPE020 1 
NPE021 1 
NPE022 1 
NPE023 1 
NPE024 1 
NPE025 1 
NPE026 1 
NPE027 1 
NPE028 1 
NPE029 1 
NPE030 1 
NPE601 1 
NPE602 1 
NPE603 2 
NPE604 2 
NPE605 1 
NPE606 1 
NPE607 2 
NPE608 1 
NPE609 1 
NPE610 1 
NPE611 1 
NPE612 1 
NPE613 1 
NPE614 1 
NPE615 1 
NPE616 1 
NPE617 1 
NPE618 2 
NPE619 3 
NPE620 1 
NPE621 1 
NPE622 1 
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Plate Samples 
NPE623 2 
NPE701 2 
NPE702 2 
NPE703 2 
NPE704 3 
NPE705 1 
Total 84 
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Table S7. CEPH Samples and Plates 
Sample ID Study ID Plate Well Pedigree 
NA_06985_06B08 06985 6 B08 1341 
NA_06985_06D04 06985 6 D04 1341 
NA_06985_27B02 06985 27 B02 1341 
NA_06985_28G11 06985 28 G11 1341 
NA_06985_601C01 06985 601 C01 1341 
NA_06985_618D06 06985 618 D06 1341 
NA_06985_619F04 06985 619 F04 1341 
NA_06991_05D03 06991 5 D03 1341 
NA_06991_25B02 06991 25 B02 1341 
NA_06991_602F09 06991 602 F09 1341 
NA_06991_603H08 06991 603 H08 1341 
NA_06991_619C06 06991 619 C06 1341 
NA_06993_05D05 06993 5 D05 1341 
NA_06993_26G11 06993 26 G11 1341 
NA_06993_603E04 06993 603 E04 1341 
NA_06993_618C04 06993 618 C04 1341 
NA_10831_04G11 10831 4 G11 1408 
NA_10831_05B04 10831 5 B04 1408 
NA_10831_23B02 10831 23 B02 1408 
NA_10831_24G11 10831 24 G11 1408 
NA_10831_615C06 10831 615 C06 1408 
NA_10831_617A06 10831 617 A06 1408 
NA_10831_703F11 10831 703 F11 1408 
NA_10859_06G01 10859 6 G01 1347 
NA_10859_06G12 10859 6 G12 1347 
NA_10859_08G11 10859 8 G11 1347 
NA_10859_15B02 10859 15 B02 1347 
NA_10859_16G11 10859 16 G11 1347 
NA_10859_604B05 10859 604 B05 1347 
NA_10859_606B11 10859 606 B11 1347 
NA_10859_621D08 10859 621 D08 1347 
NA_10859_622E01 10859 622 E01 1347 
NA_10860_07E06 10860 7 E06 1362A 
NA_10860_09B02 10860 9 B02 1362A 
NA_10860_607F01 10860 607 F01 1362A 
NA_10860_701A07 10860 701 A07 1362A 
NA_10861_02G11 10861 2 G11 1362B 
NA_10861_17B02 10861 17 B02 1362B 
NA_10861_30G11 10861 30 G11 1362B 
NA_10861_610H02 10861 610 H02 1362B 
NA_10861_704C06 10861 704 C06 1362B 
NA_11881_06D12 11881 6 D12 1347 
NA_11881_14G11 11881 14 G11 1347 
NA_11881_604H09 11881 604 H09 1347 
NA_11881_620D09 11881 620 D09 1347 
NA_11882_06G11 11882 6 G11 1347 
NA_11882_08G04 11882 8 G04 1347 
NA_11882_13B02 11882 13 B02 1347 
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Sample ID Study ID Plate Well Pedigree 
NA_11882_605C06 11882 605 C06 1347 
NA_11882_619H03 11882 619 H03 1347 
NA_11992_06H05 11992 6 H05 1362A 
NA_11992_11B02 11992 11 B02 1362A 
NA_11992_12G11 11992 12 G11 1362A 
NA_11992_607C04 11992 607 C04 1362A 
NA_11992_609F12 11992 609 F12 1362A 
NA_11992_701F09 11992 701 F09 1362A 
NA_11993_07B02 11993 7 B02 1362A 
NA_11993_07H03 11993 7 H03 1362A 
NA_11993_10G11 11993 10 G11 1362A 
NA_11993_608E05 11993 608 E05 1362A 
NA_11993_702D04 11993 702 D04 1362A 
NA_11993_702G05 11993 702 G05 1362A 
NA_11994_01F12 11994 1 F12 1362B 
NA_11994_03B02 11994 3 B02 1362B 
NA_11994_19B02 11994 19 B02 1362B 
NA_11994_20G11 11994 20 G11 1362B 
NA_11994_29B02 11994 29 B02 1362B 
NA_11994_612F01 11994 612 F01 1362B 
NA_11994_623D06 11994 623 D06 1362B 
NA_11995_01B02 11995 1 B02 1362B 
NA_11995_18G11 11995 18 G11 1362B 
NA_11995_611A06 11995 611 A06 1362B 
NA_11995_613B02 11995 613 B02 1362B 
NA_11995_623G03 11995 623 G03 1362B 
NA_11995_705B02 11995 705 B02 1362B 
NA_12155_05B02 12155 5 B02 1408 
NA_12155_21B02 12155 21 B02 1408 
NA_12155_614G02 12155 614 G02 1408 
NA_12155_703B08 12155 703 B08 1408 
NA_12155_704B02 12155 704 B02 1408 
NA_12156_05B01 12156 5 B01 1408 
NA_12156_22G11 12156 22 G11 1408 
NA_12156_616B02 12156 616 B02 1408 
NA_12156_704A10 12156 704 A10 1408 
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Table S8. Discordant CEPH duplicates 
  Discordant SNPs 
Sample 1 Sample 2 Chr SNP 
06911 05 D03 06911 619 C06 5 rs7718740 
  22 rs4820872 
06911 25 B02 06911 619 C06 5 rs7718740 
  22 rs4820872 
06911 602 F09 06911 619 C06 5 rs7718740 
  22 rs4820872 
All duplicate problems were due to sample 6991 in plate 619 well C06 
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Table S9. All sample exclusions 
FID IID Reason for Exclusion 
11169 89205 QC Duplicate 
11083 91284 QC Duplicate 
10265 91285 QC Duplicate 
10137 91286 QC Duplicate 
11694 89791 QC Duplicate 
12659 90013 QC Duplicate 
10982 90179 QC Duplicate 
11859 91294 QC Duplicate 
10022 90539 QC Duplicate 
11396 91297 QC Duplicate 
11908 90769 QC Duplicate 
10763 91302 QC Duplicate 
11269 98671 QC Duplicate 
10771 96495 QC Duplicate 
11964 98677 QC Duplicate 
12361 97257 QC Duplicate 
11765 97365 QC Duplicate 
11878 97407 QC Duplicate 
11757 98687 QC Duplicate 
11727 97687 QC Duplicate 
12737 98690 QC Duplicate 
10143 102247 QC Duplicate 
10842 97943 QC Duplicate 
10255 98181 QC Duplicate 
11501 102242 QC Duplicate 
11901 98282 QC Duplicate 
10689 98558 QC Duplicate 
12621 98346 QC Duplicate 
11787 98245 QC Duplicate 
10832 96189 Sex Problem - Coded as female genotype male 
12072 97549 Sex Problem - Coded as female genotype male 
11887 98636 Sex Problem - Coded as female genotype male 
11337 90324 Potential sample swap; labeled baby but duplicate of another mom 
10471 89191 Fugitive relatedness - related to baby 96774 
12293 89193 Fugitive relatedness - related to mom 89745 
12245 96349 Fugitive relatedness - related to mom 89225 
12005 97516 Fugitive relatedness - related to mom 89203 
10553 89340 Fugitive relatedness - related to mom 90631 
10296 89359 Fugitive relatedness - related to mom 96871 and baby 96872 
10296 89360 Fugitive relatedness - related to mom 96871 and baby 96872 
10403 98231 Fugitive relatedness - related to mom 89329 
10115 89369 Fugitive relatedness - related to mom 96557 and baby 96558 
10115 89370 Fugitive relatedness - related to mom 96557 
10488 96605 Fugitive relatedness - related to mom 89433 
12723 89489 Fugitive relatedness - related to baby 96872 
11246 91133 Fugitive relatedness - related to mom 89549 and baby 89550 
11246 91134 Fugitive relatedness - related to mom 89549 
11782 97593 Fugitive relatedness - related to mom 89635 and baby 89636 
11782 97594 Fugitive relatedness - related to mom 89635 
11481 89797 Fugitive relatedness - related to mom 97753 and baby 97754 
11481 89798 Fugitive relatedness - related to mom 97753 
11519 89799 Fugitive relatedness - related to baby 97554 
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FID IID Reason for Exclusion 
11646 98410 Fugitive relatedness - related to mom 90021 
10627 90009 Fugitive relatedness - related to baby 97690 
10441 89971 Fugitive relatedness - related to mom 90717 and baby 90718 
10441 89972 Fugitive relatedness - related to mom 90717 and baby 90718 
12167 98631 Fugitive relatedness - related to mom 90219 and baby 90220 
11892 97454 Fugitive relatedness - related to baby 91293 and mom 90221 
12203 90284 Fugitive relatedness - related to baby 90650 
12521 97277 Fugitive relatedness - related to mom 90505 
10760 98224 Fugitive relatedness - related to mom 90741 
11864 97659 Fugitive relatedness - related to baby 90814 
11864 97660 Fugitive relatedness - related to baby 90814 
12037 91165 Fugitive relatedness - related to mom 91229 
10490 91236 Fugitive relatedness - related to mom 97723 
10490 91235 Fugitive relatedness - related to mom 97723 and baby 97724 
12685 98363 Fugitive relatedness - related to mom 91201 
10225 96783 Fugitive relatedness - related to baby 96108 
10998 96242 Fugitive relatedness - related to mom 97167 
11781 97461 Fugitive relatedness - related to mom 96639 
11845 97031 Fugitive relatedness - related to baby 96916 
11845 97032 Fugitive relatedness - related to baby 96916 
12062 98653 Fugitive relatedness - related to baby 97426 
10355 97918 Fugitive relatedness - related to baby 97912 
11083 89405 Shown as unrelated for FID 11083 
11083 89406 Shown as unrelated for FID 11083 
11723 89437 Shown as unrelated for FID 11723 
11723 89438 Shown as unrelated for FID 11723 
11528 89651 Shown as unrelated for FID 11528 
11528 89652 Shown as unrelated for FID 11528 
12309 90335 Shown as unrelated for FID 12309 
12309 90336 Shown as unrelated for FID 12309 
10344 91299 Shown as unrelated for FID 10344 
10344 90809 Shown as unrelated for FID 10344 
10837 93526 Shown as unrelated for FID 10837 
10837 93527 Shown as unrelated for FID 10837 
12037 91166 Shown as unrelated for FID 12037 
11822 96757 Shown as unrelated for FID 11822 
11822 96758 Shown as unrelated for FID 11822 
10143 98382 Duplicate with high levels of discordance (duplicate of 10143, 102247) 
11757 97501 Duplicate with high levels of discordance (duplicate of 11757, 98687) 
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Table S10. SNPs missing genotype information for all individuals 
SNP Chr Freq Missing 
UNC_Eclampsia_chr1:11745321 1 1 
UNC_Eclampsia_chr1:11860798 1 1 
exm17102 1 1 
exm19516 1 1 
exm2253585 1 1 
exm75804 1 1 
exm81979 1 1 
exm90310 1 1 
exm90327 1 1 
exm101774 1 1 
exm136342 1 1 
rs2689154 1 1 
indel.11236 1 1 
newrs11339452 1 1 
rs17015608 2 1 
exm243367 2 1 
rs892515 2 1 
UNC_Eclampsia_chr3:12256739 3 1 
exm332686 3 1 
exm2238321 3 1 
exm342498 3 1 
UNC_Eclampsia_rs1840961 3 1 
UNC_Eclampsia_rs1823227 3 1 
exm371798 3 1 
exm384902 4 1 
exm402024 4 1 
UNC_Eclampsia_rs4693753 4 1 
UNC_Eclampsia_rs2250724 4 1 
exm427425 4 1 
exm476743 5 1 
exm522796 6 1 
UNC_Eclampsia_rs404655 6 1 
UNC_Eclampsia_rs2735096 6 1 
rs2571391 6 1 
exm-rs3129813 6 1 
exm528518 6 1 
exm-rs3130970 6 1 
exm-rs1265095 6 1 
UNC_Eclampsia_rs2770 6 1 
exm-rs10046127 6 1 
exm535710 6 1 
exm535831 6 1 
UNC_Eclampsia_rs34951355 6 1 
exm536131 6 1 
exm-rs2144014 6 1 
exm-rs6900824 6 1 
exm540227 6 1 
exm546933 6 1 
exm548257 6 1 
exm555771 6 1 
exm561835 6 1 
exm588851 6 1 
exm612435 7 1 
UNC_Eclampsia_chr7:71788534 7 1 
exm636185 7 1 
exm637995 7 1 
exm644742 7 1 
exm658486 7 1 
exm2258137 7 1 
exm684450 8 1 
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SNP Chr Freq Missing 
exm695749 8 1 
UNC_Eclampsia_rs16891561 8 1 
exm700589 8 1 
rs12265 8 1 
exm713312 8 1 
exm730833 8 1 
exm742955 9 1 
rs2383246 9 1 
exm790118 9 1 
exm790686 9 1 
UNC_Eclampsia_chr9:135034420 9 1 
exm820363 10 1 
UNC_Eclampsia_rs250706 10 1 
exm854205 10 1 
UNC_Eclampsia_rs1706879 11 1 
exm2219045 11 1 
exm966579 11 1 
var_11_125864230 11 1 
exm982429 12 1 
rs4763494 12 1 
indel.24166 12 1 
exm1018827 12 1 
rs373767 13 1 
rs577487 13 1 
exm1085830 14 1 
exm2251753 14 1 
variant.31710 14 1 
UNC_Eclampsia_rs181478 14 1 
exm1113017 14 1 
exm1129029 14 1 
exm1134125 14 1 
exm1166050 15 1 
exm1178847 15 1 
exm1325307 17 1 
exm1912211 18 1 
exm1420231 19 1 
exm1422205 19 1 
UNC_Eclampsia_chr19:19402787 19 1 
indel.54461 19 1 
var_19_22272062 19 1 
UNC_Eclampsia_rs12461383 19 1 
variant.56280 19 1 
exm1477565 19 1 
exm1478264 19 1 
exm1504396 19 1 
exm1504410 19 1 
exm1506322 19 1 
exm-IND19-60217915 19 1 
newrs143207252 19 1 
exm1518874 20 1 
exm1536190 20 1 
UNC_Eclampsia_rs495064 22 1 
exm1632722 23 1 
indel.108572 23 1 
exm1653205 23 1 
newrs237520 23 1 
UNC_Eclampsia_mt3796 26 1 
exm2263340 26 1 
200610-25 26 1 
2010-08-MT-158 26 1 
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SNP Chr Freq Missing 
MitoT13966C 26 1 
exm2263330 26 1 
UNC_Eclampsia_mt14769 26 1 
exm2216494 26 0.09315 
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Table S12. Replication Results 
Table S12a. Replication results for replication cohort of preeclampsia 
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Table S12b. Replication results for replication cohort of early preeclampsia 
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Table S15. Data table for rs3765692 (TP73) 
Phenotype Smoking Mom Alleles Child Alleles Count 
Control No 0 0 503 
Control No 0 1 75 
Control No 1 0 99 
Control No 1 1 98 
Control No 1 2 13 
Control No 2 1 11 
Control No 2 2 1 
Case No 0 0 575 
Case No 0 1 81 
Case No 1 0 103 
Case No 1 1 125 
Case No 1 2 15 
Case No 2 1 17 
Case No 2 2 3 
Control Yes 0 0 47 
Control Yes 0 1 12 
Control Yes 1 0 11 
Control Yes 1 1 13 
Control Yes 1 2 1 
Control Yes 2 1 1 
Control Yes 2 2 0 
Case Yes 0 0 62 
Case Yes 0 1 7 
Case Yes 1 0 7 
Case Yes 1 1 6 
Case Yes 1 2 2 
Case Yes 2 1 0 
Case Yes 2 2 0 
Control No 0 Unknown 23 
Control No 1 Unknown 9 
Control No 2 Unknown 2 
Case No 0 Unknown 292 
Case No 1 Unknown 92 
Case No 2 Unknown 10 
Control Yes 0 Unknown 6 
Control Yes 1 Unknown 3 
Control Yes 2 Unknown 0 
Case Yes 0 Unknown 31 
Case Yes 1 Unknown 4 
Case Yes 2 Unknown 0 
Control No Unknown 0 14 
Control No Unknown 1 6 
Control No Unknown 2 0 
Case No Unknown 0 13 
Case No Unknown 1 5 
Case No Unknown 2 1 
Control Yes Unknown 0 0 
Control Yes Unknown 1 1 
Control Yes Unknown 2 0 
Case Yes Unknown 0 0 
Case Yes Unknown 1 0 
Case Yes Unknown 2 0 
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Figure S1. Risk ratios of the association of preeclampsia in smokers compared to non-smokers, 
stratified by maternal genotype for rs1077343 (PIK3C2G) at three time points: 1) first trimester, 
2) gestational weeks 11 to 20 (primary analysis), and 3) third trimester. 
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